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eEF1A is a molecule which plays a significant role in a process used by cells to make 
new proteins, which are important for them to survive. This molecule occurs in slightly 
different forms in many animals, for example, in mice and human, there are two forms 
called eEF1A1 and eEF1A2. Every cell contains only one form of eEF1A. eEF1A2 is 
present only in the nerve, heart and muscle cells, while eEF1A1 can be found in the 
rest of the other cells types. Mice that have no eEF1A2 show abnormal characteristics 
such as loss of nerve and muscle cells, deteriorate rapidly and die at 28 days old. 
Recently, eEF1A2 has been shown to cause epilepsy, autism and intellectual disability 
in humans. Our research focuses on providing better understanding of the role of 
eEF1A2 in these neurological disorders. Our approach involves the use of different 
models, as insights from them can lead to better treatment strategies. 
One model that is increasingly becoming popular is the zebrafish. Zebrafish has many 
advantages, one in particular is the ease to use them for drug testing experiments. The 
main aim of my PhD was to try and generate a zebrafish model of these neurological 
disorders caused by eEF1A2. Zebrafish have four forms of eEF1A genes: eef1a1l1, 
eef1a1a, eef1a1b and eef1a2.  As we do not know much about eef1a in zebrafish, I 
looked at different early stages and adult tissues for the different eef1a forms using 
some molecular techniques. My results showed eef1a1l1 is seen first, followed by 
eef1a1a and eef1a1b and much later during development, eef1a2. To understand the 
role of eef1a2 in zebrafish, I generated and characterised zebrafish with two mutant 
copies of eef1a2. These fish were healthy and did not show any neurological 
abnormality, and unlike the process seen in mice, they survive to adulthood. We think 
the fish remain healthy because of the presence of the other eef1as and so any 
deleterious effect that may have occurred by the loss of eef1a2 is prevented. However, 
a pilot study suggests that loss of eef1a2 might make zebrafish vulnerable to induced 
seizures similar to cases we have observed in mice.   
In all, this study has provided us with valuable information of how eEF1A works in 





Eukaryotic elongation factor (eEF1A) plays a vital role in protein synthesis. It recruits 
amino-acylated tRNAs and delivers them to the ribosome during protein translation. 
eEF1A is conserved throughout evolution and exists as independently encoded 
isoforms in many species. In mammals, there are two isoforms: eEF1A1 and eEF1A2. 
Unlike eEF1A1 which is widely expressed, expression of eEF1A2 is restricted to the 
brain, heart and skeletal muscle and is upregulated during development. In mice, 
homozygote deletion in Eef1a2 gene resulting in the complete loss of function of 
eEF1A2 causes severe neurodegeneration, loss of muscle bulk and death by 28 days. 
Recently, de novo heterozygous missense mutation in EEF1A2 has been identified in 
humans which cause epilepsy, autism and intellectual disability. The main aim of this 
project was to investigate the use of zebrafish as a model to better understand the role 
of eEF1A2 in neurological disorders. In addition to its many advantages, the zebrafish 
has been shown to be an excellent tool for in vivo drug screening. This is an attractive 
attribute for our studies as regards developing treatment strategies for these disorders. 
Zebrafish possess four eef1a genes: eef1a1l1, eef1a1a, eef1a1b and eef1a2 which 
encodes separate highly similar proteins: eEF1A1L1, eEF1A1A, eEF1A1B and 
eEF1A2 respectively. The zebrafish eEF1A2 shares a 94% sequence identity with the 
mouse and human eEF1A2 at the amino acid level. In this work, characterisation of 
zebrafish eEF1A genes was first carried out, as there is currently little information 
available. Using conventional reverse transcriptase polymerase chain reaction (RT-
PCR) and real time quantitative PCR (qPCR), I analysed the expression pattern of 
eef1a genes at different embryonic stages and adult tissues. These genes were 
differentially expressed with only eef1a1l1 detected at earlier developmental stages, 
followed by eef1a1a and eef1a1b. Similar to mammals, eef1a2 is detected much later 
(48 hpf) during development. Co-expression of eef1a mRNA was observed in the adult 
tissues analysed except in liver where eef1a2 was not detected. An attempt to knock-
in one of the epilepsy causing variant, G70S into the zebrafish genome using 
CRISPR/Cas9 technology was unsuccessful. However, I established two null eef1a2 
mutant lines using this technology. Homozygotes from these null lines showed no 
obvious phenotype and in contrast to null Eef1a2 mice, they are fertile and viable 
through adulthood. No evidence of neurodegeneration was observed. These results 
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suggest the possibility of compensatory mechanisms activated by the other eef1a genes 
to buffer the loss of eef1a2 in the mutants. However, preliminary findings suggest that 
eef1a null mutation might cause zebrafish to be susceptible to PTZ-induced seizures.  
Results from this work has provided vital information on functional redundancy of 
eef1a genes in zebrafish and a foundation for further validation of the zebrafish as a 
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Chapter 1: Introduction 
1.0 Protein synthesis 
Protein synthesis is one of the essential biological processes employed by cells to 
survive. During protein synthesis, cells use the information contained in the DNA to 
make specific proteins that help in the proper functioning of the cell. An important part 
of this process is translation, which is the actual stage where the protein is synthesised 
using mRNA as a template. Protein synthesis is divided into three phases; initiation, 
elongation and termination. During initiation, the initiation complex is formed by the 
binding of the ribosomal small unit and the initiator methionine-tRNA to the start 
codon (AUG) on the mRNA. Subsequently, the large ribosomal subunit binds to the 
initiator complex. The second phase, elongation, involves the assembling of amino 
acids which are carried by tRNAs to the growing polypeptide chain following the 
sequence contained in the mRNA. This phase is repeated and involves the same 
mechanism until any of the three stop codons, UAA, UAG and UGA, is reached in the 
mRNA and signals the start of the last phase, termination. At this phase, the newly 
synthesised protein is released from the ribosome which is then recycled and made 
available for another translation process. Each of these phases is coordinated by 
several protein factors to ensure the precise spatial and temporal levels of protein are 
synthesised for normal physiological functions (Livingstone et al., 2010). 
1.1 Eukaryotic elongation factor 1 alpha (eEF1A)  
Eukaryotic elongation factor 1 alpha (eEF1A), formerly referred to as EF1α, is a 
member of the G protein family and the second most abundant protein after actin, 
making up about 1-2% of the total protein in normal growing cells (Condeelis, 1995). 
Delivery of aminoacylated-tRNAs to the A-site of the ribosome during the elongation 
step of translation is catalysed by this protein. This process is GTP-dependent and is 
mediated by the guanine exchange factor, eEF1B. Once the anticodon region of the 
recruited aminoacylated-tRNA correctly matches the codon of the mRNA at the A-site 
of the ribosome, the GTP bound to eEF1A is hydrolysed. The inactive eEF1A-GDP 
complex is then reactivated by eEF1B which exchanges the GDP for GTP, to bind 




   
Figure 1.1. Schematic of eEF1A participation in protein translation. During elongation, the eEF1A 
in its active state (bound to GTP) recruits aminoacylated tRNA to the A site of the ribosome. 
Recognition of the anticodon region of the aminoacylated tRNA by the codon of the mRNA triggers the 
hydrolysis of GTP to GDP, releasing eEF1A-GDP from the ribosome to be recycled. To reactivate itself, 
eEF1A exchanges the bound GDP for GTP with the guanine exchange factor, eEF1B. The multi-unit 
eEF1B protein consists of three subunits: eEF1B is shown in orange, eEF1G in green, and eEF1D in 
purple. Taken from (Li et al., 2013). 
1.1.1 eEF1A exists as different isoforms that show reciprocal 
expression patterns 
The presence of multiple eEF1A genes which are usually located on separate 
chromosomes has been described in different eukaryotic species. For example, two 
sequence-redundant eEF1A genes TEF1 and TEF2 are present in the yeast, 
Saccharomyces cerevisiae (Nagata et al., 1984; Nagashima, Nagata and Kaziro, 1986). 
In Drosophila melanogaster, two genes, F1 and F2, have been described (Hovemann 
et al., 1988) while in Xenopus laevis, four eEF1A genes, EF-1αO, EF-1αS, 42Sp50 
and eEF1A2, have been reported so far (Djé et al., 1990; Newbery et al., 2011). In 
mammalian species, two eEF1A genes have been shown to be actively expressed (Ann 
et al., 1992; Knudsen et al., 1993; Chambers, Peters and Abbott, 1998; Kahns et al., 
1998; Svobodová et al., 2015). In vertebrates, these genes encode different eEF1A 
proteins, eEF1A1 and eEF1A2, with amino acid sequences that are highly conserved. 
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Interestingly, eEF1A variants are more identical between species than they are when 
compared within the same species. For example, human eEF1A1 show a 99.8% 
sequence identity with its mouse orthologue but is only 92.4% identical to the human 
eEF1A2 isoform. This suggests that these duplicated eEF1A genes might have 
acquired some other functional differences which are biologically important, hence 
they were positively selected and retained in the genomes.      
Another common feature of eEF1A genes is that they show a developmental and 
tissue-specific pattern of expression. In mammalian species where this has been 
extensively studied, eEF1A1 is widely expressed during development but is then 
down-regulated in the brain, heart and skeletal muscle postnatally and replaced with 
eEF1A2 in these tissues (Knudsen et al., 1993; Lee, Wolfraim and Wang, 1993; 
Chambers, Peters and Abbott, 1998; Svobodová et al., 2015). While a complete switch 
of eEF1A variants is observed in adult muscle tissues, eEF1A1 remains expressed in 
the glial cells, some small neuronal cells (most neurons show eEF1A2 expression) and 
white matter of the spinal cord in mice (Khalyfa et al., 2001; Newbery et al., 2007). In 
human and mice, eEF1A2 expression was also observed in the pancreatic islet cells, 
enteroendocrine cells in colon crypts and specific cells in the lungs using 
immunohistochemistry. A consistent expression pattern, except in the lungs, was 
observed between the two species suggesting the possible functional importance of 
eEF1A2 in these cells (Newbery et al., 2007). 
1.1.2 Isoform switching is conserved through evolution 
Although it is still not clear why there are two eEF1A isoforms with very high 
sequence identity in vertebrates, it is quite intriguing they show differential expression 
pattern and are developmentally regulated. The regulation of eEF1A variants was 
initially observed by different studies in mammalian species and was shown to occur 
at the mRNA level. Subsequent analysis in our laboratory using Xenopus confirmed 
the presence of eEF1A2 in non-mammalian vertebrates (Newbery et al., 2011). 
Analysis of a range of adult tissues showed overlapping expression of eEF1A1 and 
eEF1A2 mRNA in the brain, heart and muscle tissues (Figure 1.2A). However, when 
the expression of eEF1A isoforms were investigated at the protein level, eEF1A1 was 
absent in the muscle and optic ganglion while eEF1A2 expression was observed in 
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these tissues (Figure 1.2B). The absence of eEF1A1 and the presence of eEF1A2 in 
the muscle at the protein level, with both mRNA present was also observed in Xenopus 
tropicalis in this study. Interestingly, translational regulation of eEF1A had been 
previously suggested to occur in Xenopus laevis during embryogenesis and in serum-
deprived cultured Xenopus cell line (Loreni, Francesconi and Amaldi, 1993). Cell-
specific expression data obtained using immunohistochemistry showed eEF1A2 to 
have widespread expression in cardiac muscle but was restricted to large neurons in 
the brain and spinal cord of Xenopus laevis (Figure 1.2C). This same expression 
pattern was also seen for eEF1A2 in mammals (Newbery et al., 2007).  
    
Figure 1.2: Expression pattern of eEF1A isoforms in adult Xenopus laevis. A. RT-PCR of eEF1A1 
(top) and eEF1A2 (bottom) mRNA from Liver (Li), Lung (Lu), Spleen (S), oocytes (O), gall bladder 
(G), brain (B), heart (H) and muscle (M) B. Expression analysis using protein lysates from Og-optic 
ganglion, Brain (B), spinal cord (Sc), Muscle (M), Liver (Li), gall bladder (G), Lung (Lu), Kidney (K) 
and Spleen (S) for western blot for eEF1A1 (top) and eEF1A2 (bottom). The molecular weight of both 
protein is ~50kDa. C. Immunohistochemistry for eEF1A2 in the spinal cord (top panel) and cardiac 
muscle (bottom panel). In the spinal cord, eEF1A2 expression is restricted to the neuronal cells but is 




The observation that the tissue-specific expression of eEF1A2 and the down-regulation 
of eEF1A1, most notably in the muscle (where eEF1A2 replaces it), is conserved in 
vertebrates provides strong evidence to suggest this to have biologically important 
consequences. What the functional significance is, remains unclear. A plausible 
hypothesis is that these two isoforms might have other functional differences even 
though they share the same major role in translation. This is an attractive notion when 
the architecture of cells that express eEF1A2 only is considered. These cells are 
terminally differentiated and are more stable, therefore it is likely that some other 
functional roles of eEF1A1 in these cells might interfere with their overall structure. 
For this reason, eEF1A1 is replaced with eEF1A2 to avoid or modify these functions 
but at the same time ensure translational activities are maintained in the cells (Newbery 
et al. 2007). Interestingly, Khalyfa et al., 2003 showed a dramatic upregulation of 
eEF1A1 in rats muscle after about one month of being subjected to permanent 
denervation. The level of the eEF1A1 remained high even after two years and could 
possibly stem from the unstable tissue environment caused by the injury. Similarly, a 
165-fold increase of eEF1A1 mRNA was observed in the muscle tissues of trauma 
patients that were in catabolic conditions than in muscle samples obtained from age-
matched healthy controls (Bosutti et al., 2007). These studies further stress the 
possibility that the non-canonical functions of eEF1A1 might be needed at only a 
certain point in the development of these cell types that express only eEF1A2 in adults.        
 1.1.3 Non-canonical roles of eEF1A 
In addition to its central role in translation, there is growing evidence that shows 
eEF1A is a multifunctional protein with a role in a wide variety of biological processes 
( reviewed in Ejiri, 2002; Mateyak and Kinzy, 2010). Some non-canonical roles of 
eEF1A include cytoskeleton interaction and remodelling, proteolysis, apoptosis, 
nuclear transport and heat shock response. It is still unclear if some of these non-
canonical functions, except for heat shock which is eEF1A1 specific (see section 
1.1.3.2), are shared by both eEF1A isoforms and how they perform these roles. 
Understanding this could provide insights into the biological significance of isoform 
switching in certain cell types. Unfortunately, detangling these ‘moonlighting’ 
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functional relationship between eEF1A1 and eEF1A2 has been technically challenging 
mostly because of the high similarities in their amino sequence.   
1.1.3.1 Cytoskeleton interaction and remodelling 
The association of eEF1A with the cytoskeleton is the most established non-canonical 
function of eEF1A as it has been demonstrated by numerous studies across species. 
The first direct evidence that showed eEF1A interaction with actin, an important 
protein of the cell cytoskeletal system, was demonstrated in Dictyostelium 
discoideum(Demma et al., 1990; Yang et al., 1990). Demma et al, 1990 showed 
eEF1A (formerly known as ABP-50) isolated from Dictyostelium discoideum to have 
strong actin binding and bundling properties in vitro. Actin-binding activities of 
eEF1A, unlike its translational function, are not GTP-dependent but are modulated by 
pH changes (Edmonds, Murray and Condeelis, 1995). Although there is an obvious 
link between protein synthesis machinery and the cytoskeleton, the binding of 
aminoacylated-tRNA and the actin by eEF1A are biochemically separate events. 
Increasing the pH (from 6.5 to 7.0) favoured the binding of eEF1A to aminoacylated-
tRNA and reduced its affinity for F-actin (Liu et al., 1996). However, changes in pH 
did not affect the binding affinity of eEF1A for aminoacylated-tRNA. Interaction of 
eEF1A with actin was then demonstrated in vivo in the yeast, Saccharomyces 
cerevisiae. Using site-directed mutagenesis, different mutations were identified that 
reduced actin bundling and disorganisation induced by the overexpression of eEF1A 
(Gross and Kinzy, 2005, 2007). Some of the mutant strains showed normal elongation 
activities, while two mutations resulted in reduced translation rate in the yeast. 
However, aberrant protein synthesis observed in these mutants was due to a translation 
initiation defect (Gross and Kinzy, 2007). Their finding is consistent with the report of 
Liu et al, 1996 that these two functions of eEF1A are distinct processes. 
Although eEF1A2 has been less studied in terms of actin-related activities, it has been 
shown to have a role in actin remodelling through its interaction with the 
phosphatidylinositol-4 kinase III β (PI4IIIKβ). Activation of PI4IIIKβ by eEF1A2 
stimulates the formation of filopodia (slender projections that contain bundles of cross-
linked actin filaments) in vitro (Jeganathan et al., 2008). More efforts are now being 
made to better understand the actin activities of this variant especially as this can 
provide more insights into its implication in other processes in particular 
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transformation (further discussed in section 1.2.3). Recent studies by Novosylna et al., 
2017 demonstrated the actin-bundling activity of eEF1A2 in vitro. Interestingly, 
eEF1A1 and eEF1A2 generate actin bundles with different morphology (Figure 1.3), 
with eEF1A2 producing short, thick and splinter-like actin bundles (Novosylna et al., 
2017). The authors implicated the compact dimeric structure of eEF1A2 which was 
described by Timchenko et al., 2013 as a possible explanation for their observation 
since it is most likely that eEF1A performs its actin bundling activities as a dimer 
(Vlasenko et al., 2015). Interestingly, in silico analysis of the human eEF1A variants 
showed that almost all of the amino acid residues that differ between the two proteins 
were located on one side of the modelled structures away from the binding site of 
eEF1Bα (Soares et al., 2009). They also demonstrated that the residues were arranged 
in two clusters; a circular band of 12 residues within domain I and a swathe of 14 
residues across domain II and III on the variable face of the 3D structures. The 
identification of eight residues that impact on actin binding properties from the yeast 
mutagenesis studies (Gross and Kinzy, 2005, 2007) which are also found within 
domain II and III together with the findings of Novosylna et al., 2017 could suggest 
that eEF1A1 and eEF1A2 may differ in their actin-related functions.          
    
Figure 1.3: eEF1A isoforms generate F-actin bundles with different morphology. A. Atomic force 
microscopy (AFM) image showing phalloidin-stabilised F-actin only (Left panel), F-actin bundled with 
eEF1A1 (centre panel) and F-actin bundled with eEF1A2 (right panel). B. Confocal microscope images 
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showing only F-actin stabilised with phalloidin (bottom left panel), F-actin bundled with eEF1A1 
(bottom centre panel) and F-actin bundled with eEF1A2 (bottom right panel). Taken from Novosylna 
et al 2017   
In addition to actin, eEF1A has been shown to interact with other components of the 
cytoskeleton. For example, eEF1A has been reported to have both microtubule 
bundling and severing abilities. The microtubule bundling activity of eEF1A was 
demonstrated in vitro using eEF1A isolated from carrots (Durso and Cyr, 1994), while 
eEF1A was purified from Xenopus eggs as a rapid microtubule severing protein 
(Shiina et al., 1994). This study also demonstrated that human eEF1A displays quick 
microtubule severing function in vitro and by microinjecting the recombinant form of 
the protein into rat fibroblasts. The functional importance or regulation of these 
microtubule-related activities of eEF1A remains unclear.              
1.1.3.2 Temperature induced stress  
In response to cold stress, enzymatic elongation factor activities were significantly 
enhanced in the liver, kidney, spleen, gill, white muscles of rainbow trout with the 
activity rate varying in these organs except in the red muscle where no compensatory 
enhancement was observed (Simon, 1987). Although no particular elongation factor 
was identified in this study, using hybrid protein synthetic systems from fish and rat, 
eEF1A from Antarctic fish was identified as a major component that was sufficient 
alone to protect the rat system from the effect of temperature breaks (Haschemeyer, 
1985). Similarly, eEF1A was differentially expressed in maize under cold stress, with 
its mRNA level upregulated in the leaves and transiently reduced in the roots 
(Berberich et al., 1995).  
In response to environmental stresses such as thermal stress, low oxygen and 
starvation, cells activate genes that encode the heat shock proteins (HSPs). This is 
known as the heat shock response and has been found to occur in every organism 
studied so far. Although some characteristics may vary, all organism share many of 
the features of this response which include the rapid and intense production of HSPs 
(Lindquist and Craig, 1988). Induction of the heat shock response is regulated by the 
HS factors (HSFs) in eukaryotes, with numerous evidence supporting HSF1 as the 
master regulator in vertebrates (Shamovsky and Nudler, 2008). HSF1 is present in all 
cells but is only activated by environmental stress stimuli. 
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The first direct evidence of eEF1A playing a role in the heat shock response was 
demonstrated in vitro by Shamovsky et al., 2006. In this study, eEF1A was identified 
as a co-activator of HSF1 alongside a non-coding RNA, which they termed heat shock 
RNA-1 (HSR1). They suggested that the shutdown of protein synthesis and the 
collapse of the cell cytoskeletal system in response to stress stimuli might cause the 
release of adequate amounts of eEF1A which is then available to activate the heat-
shock response in cells. Although the variant of eEF1A was not indicated, the protein 
was isolated from rat liver which is known to express only eEF1A1 (Lee, Wolfraim 
and Wang, 1993). 
Subsequent work by Vera et al., 2014 provided a more detailed mechanism of the 
eEF1A heat-shock response activities. This study revealed a more multi-faceted role 
of eEF1A in coordinating the heat-shock response. In addition to activating HSF1 as 
observed in previous work, eEF1A was also responsible for the quick transcription, 
stabilisation and nuclear export of HSP70 mRNAs upon stress. Also, this study 
confirmed that eEF1A1 was the variant with heat shock function and that this is not 
shared by the eEF1A2 isoform. This was demonstrated by the use of short interfering 
RNA (siRNA) to knockdown eEF1A1 and eEF1A2. Only eEF1A1-deficient cells 
showed impaired induction of HSPs genes when stressed. This is consistent and 
provides a suitable explanation for the findings of Batulan et al., 2003, who showed 
that HSP70 was only expressed in glial cells (express only eEF1A1) but not in cultured 
motor neuron cells (express eEF1A2 only) when heat-shocked.          
1.1.3.3 Apoptosis 
Apoptosis, also referred to as programmed cell death, is a tightly controlled series of 
cellular events employed in multicellular organisms to remove unwanted or damaged 
cells. Work by Duttaroy et al., 1998 showed that the changes in the expression levels 
in eEF1A affected the rate of apoptosis in serum-deprived cultured mice fibroblasts. 
According to this study, overexpression of eEF1A favoured apoptosis while cells were 
protected from this process with reduced eEF1A levels. In contrast, Talapatra et al, 
2002 identified eEF1A from a screen of cDNA libraries to confer apoptotic resistance 
to hematopoietic cells upon growth factors withdrawal during culture. Despite this 
discrepancy, the global rate of protein synthesis in the cells were observed to remain 
unaffected in both studies, suggesting the apoptotic and translational activities of 
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eEF1A are independent functions. However studies from Ruest et al, 2002 
demonstrated that the eEF1A variants modulate apoptotic activities in different ways. 
While eEF1A1 was observed to be pro-apoptotic, eEF1A2, on the other hand, was 
anti-apoptotic increasing the survival rate of serum-deprived cultured differentiated 
myotubes. Their findings provide a reasonable explanation to the contradicting results 
described above especially as it is not clear which of the isoforms these two groups 
investigated. It is still not fully understood how these isoforms perform the opposite 
effects on apoptosis. However, it is likely they bind with different protein partners and 
exert differential regulation on genes involved in this process. For example, Chang and 
Wang, 2007 showed that eEF1A2 and not eEF1A1 interacts with peroxiredoxin 1 
(Prdx-1) in yeast two-hybrid experiments. Mouse cell line NIH 3T3 fibroblasts 
transfected with both eEF1A2 and Prdx-1 were resistant to peroxide-induced cell 
death. In addition, activation of caspases 3 and 8, key proteins in the initiation and 
execution phase of apoptosis, were significantly reduced in these cells. Instead, levels 
of Akt protein, which promotes survival, increased 5-fold with a further half-fold 
increment observed when transfected cells were treated with peroxide.     
1.1.4 Post-translational modification 
Several post-translational modifications (PTMs) have been reported in the eEF1A 
protein across species. Interestingly, unlike the amino acid sequence, these 
modifications are less conserved in eukaryotes (Merrick et al., 1990).   
In the rabbit, seven PTMs were identified in eEF1A1 isolated from reticulocytes. 
These include the addition of ethanolamine to the glutamic amino acids at position 301 
and 374, while the other five PTMs involved lysines amino acids with dimethylation 
at position 55 and 165 and trimethylation at position 36, 79 and 318 (Dever et al., 
1989). Chemical sequencing of eEF1A2 purified from rabbit skeletal muscle revealed 
the same PTMs as eEF1A1 at Glu301 and Glu374. However, Lys55 and Lys165 were 
trimethylated in this isoform and not dimethylated as observed in eEF1A1 (Kahns et 
al., 1998). 
In silico functional analysis by Soares and Abbott, 2013 identified 74 positions that 
could be post-translationally modified in human eEF1A isoforms. Similarly to the 
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rabbit eEF1A, there is evidence, as provided by several bioinformatics and 
experimental studies, that the human eEF1A isoforms may also show different PTM 
patterns. However, it is worth mentioning that most of the positions involve conserved 
residues and as such it is impossible to infer the specific isoform these peptides are 
derived from in most studies. Although most of the type of PTMs reported so far 
involves phosphorylation of serine, threonine and tyrosine residues, the addition of 
ethanolamine to Glu301 and Glu374 has been shown to occur in human eEF1A in vitro 
as seen in rabbit (Rosenberry et al., 1989). Some experimentally reported 
phosphorylation sites in human eEF1A is summarised in table 1.1.    
Table 1.1 Summary of experimentally validated phosphorylated sites in eEF1A isoforms 
Residues  Isoform  Conserved?  Techniques  Reference  
Tyr29, Tyr141 Ambiguous Y MS Rush et al., 
2005 
Tyr29, Ser163 eEF1A1 Y MS Molina et al., 
2007 
Thr432 eEF1A1 Y MS, SDM Eckhardt et al., 
2007 
Ser300 eEF1A1 Y 2D-
phosphopeptide 
mapping, SDM 
Lin et al, 2010 
Ser21 Both Y MS, SDM Sanges et al, 
2012 
Thr88 eEF1A1 Y MS, SDM Sanges et al, 
2012 
Ser205  eEF1A2 Y MS, immunoblot 
with Ab against 
S358 phospeptide 
Gandi et al, 
2013 
Ser358 eEF1A2 N MS, immunoblot 
with Ab against 
S358 phospeptide  
Gandi et al, 
2013 
  Y- Yes, N- No, MS- Mass spectrometry, SDM- Site directed mutagenesis 
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Although no functional importance has been assigned to most PTMs residues, a few 
studies have shown that these modifications are capable of regulating the human 
eEF1A isoforms affecting its translational and/or non-canonical activities. Lin et al, 
2010 showed that phosphorylation of Ser300 by type 1 TGF-β receptor (TβR-1) 
inhibited the translation activities of eEF1A1 by interfering with its binding ability 
with aminoacylated-tRNAs (Lin et al., 2010), whereas phosphorylation of Ser21 was 
shown to modulate the stability of both eEF1A isoforms as well as regulate their 
apoptotic functions. Mutation of this residue in eEF1A1 resulted in an increase of early 
apoptosis while an increase of late apoptosis in eEF1A2 mutants was observed in 
transfected H1355 cell lines (Sanges et al., 2012). Interaction of eEF1A2 with newly 
synthesised polypeptides intended for degradation was found to be enhanced when its 
Ser205 and Ser358 residues were phosphorylated by stress-activated c-Jun N-terminal 
kinase (Gandin et al., 2013).  
Another common form of PTMs that has been reported in the human eEF1A isoform 
is lysine methylation. Using mass spectrometry, two studies identified methylated 
lysine residues; 36, 55,79,165 and 318, in the human eEF1A which corresponded to 
those previously reported in the rabbit eEF1A (Cao, Arnaudo and Garcia, 2013; Guo 
et al., 2014). An additional site; K313, was found to be dimethylated in eEF1A2 (Guo 
et al., 2014). All of these residues are conserved between the two eEF1A isoforms. 
The lysine (K)-specific methyltransferase (KMTs) enzymes responsible for the 
methylation of four of these sites; K36, K79, K165 and K318 have been identified 
(Dzialo et al., 2014; Shimazu et al., 2014; Jakobsson et al., 2017; Małecki et al., 2017). 
The effect of methylation on the human eEF1A isoforms is still poorly understood but 
it is likely to be of functional importance as suggested by the conservation of the 
methylation of two of these sites; K79 and K318 over a large evolutionary distance 
from yeast eEF1A to human eEF1A isoforms and by orthologues of the same KMTs 
in yeast and human (Lipson, Webb and Clarke, 2010; Dzialo et al., 2014; Hamey et 
al., 2016). Also, investigations by Jakobsson et al., 2017 showed that methylation of 
K36 modulates mRNA translation by affecting the dynamics as well translation speed 
of distinct codons using ribosome profiling. Using the same technique, they also 
demonstrated that methylation of K165 impacted the translation of certain mRNA 
(Małecki et al., 2017). This study also revealed a difference in the methylation pattern 
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of K165 in eEF1A1 between tissues and cancer cell lines, with a significantly higher 
methylation level in human cancer cell lines compared to different rat organs and a 
variation of K165 methylation between the different organs were also noted (Małecki 
et al., 2017). It therefore possible that the structure of the eEF1A isoforms, in addition 
to their tiny differences in amino acid residues, has been further strengthened by their 
difference in PTMs making them more functionally divergent, and hence allowed them 
to be retained in the genome. 
1.2 eEF1A2 role in diseases 
1.2.1 The wasted mouse 
A deletion spanning 15.8 kilobases involving the promoter and first exon of eEF1A2 
was identified to cause a wasted (wst) phenotype in mice (Chambers, Peters and 
Abbott, 1998). This mutation which occurred spontaneously in the Jackson laboratory 
in 1972, eliminated the transcription of Eef1a2. Mice which are homozygous for this 
mutation appear normal earlier in development. However, abnormal phenotypes such 
as tremors, weight loss and uncoordinated gait become visible from around 21 days of 
age. The severity of the wasted phenotypes increases, leading to paralysis and death of 
the mouse at around 30 days of age (Shultz, L.D, Sweet, H.O, Davisson, 1982). Despite 
having low levels of eEF1A2, heterozygous mice (+/wst) show no neuromuscular 
dysfunction or spinal cord abnormalities (Griffiths et al., 2012). 
Further works from our laboratory confirmed that the eEF1A2 gene was solely 
responsible for the phenotypes observed in the wasted mice. This was demonstrated 
using transgenic experiments. Newbery et al, 2007 generated two different sets of 
transgenic mice carrying mouse bacterial artificial chromosome (BAC) with either 
intact Eef1a2 or a loss of function mutation in Eef1a2. Only the BAC transgene 
containing intact Eef1a2 was able to rescue the wasted phenotypes. The mutant Eef1a2 
containing BAC was unable to correct the wasted phenotypes even though it carried 




Prominent neurological features of the wasted mouse include vacuolar degeneration 
of motor neurons located in the anterior horn of the spinal cord and the accumulation 
of phosphorylated neurofilaments (Lutsep and Rodriguez, 1989). Detailed analysis of 
the pathology of the wasted mouse showed that neurological abnormalities occur as 
early as 17 days postnatal and start in the spinal cord (Newbery et al., 2005). Elevated 
GFAP staining, indicative of reactive gliosis, in the spinal cord and a reduction in the 
number of innervated endplates in the thoracic muscles, were first seen. This was then 
followed by axon and motor neuron degeneration and weak synaptic input from muscle 
fibres. These pathologies occur in a rostrocaudal manner starting at the cervical level 
and progressing caudally. Muscle wasting which results in significant loss of total 
body weight in wasted mice begins at about 21 days of age. When subjected to rotarod 
activity, an assay for testing motor function, wasted mice performed progressively less 
compared to their wild-type littermates from 21 days. 
The onset of the neuromuscular abnormalities in wasted mice falls within the period 
when Eef1a1 is down-regulated and is gradually replaced with Eef1a2 in the brain, 
heart and skeletal muscle (Chambers, Peters and Abbott, 1998, Khalyfa et al, 2001). 
A more dramatic effect is seen in the skeletal muscles for the wasted mouse. Since 
eEF1A2 completely replaces eEF1A1 in the muscle, homozygous wasted mice do not 
have any form of eEF1A in their muscles resulting in the total loss of protein synthesis 
activities in these tissues. However, in vivo studies from our laboratory have 
demonstrated that the characteristic muscle wasting phenotype in these null mutants 
has a neurogenic origin (Doig et al., 2013). This was shown using tissue-specific 
eEF1A2 constructs to restore expression of eEF1A2 in the neurons or muscle of wasted 
mice. Although generating transgenic wasted mice with eEF1A2 expression only in 
the neurons was unsuccessful, the presence of eEF1A2 in the muscle only and not the 
neurons was shown to be insufficient to correct the wasted phenotypes in the 
transgenic wasted mice. Their results were consistent and fit well with the findings of 
Newbery et al, 2005 where the first signs of abnormalities in these mutants are 
observed at the neurological levels.  
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1.2.2 eEF1A2 role in epilepsy, autism and intellectual disability  
The use of whole exome sequencing to investigate the underlying genetic cause of 
some neurodevelopmental disorder has identified several missense mutations in 
EEF1A2 (see table 1.2). Most of these mutations reported are de novo and occur in the 
heterozygous state. More recently, Cao et al., 2017 reported a homozygous missense 
EEF1A2 mutation (P333L) which they identified in two siblings who died in early 
childhood of dilated cardiomyopathy (DCM). Diagnosis of DCM is unique to this 
study as it was not reported in the de novo cases. Although Cao et al., 2017 postulated 
that this might be because cardiac function was not evaluated in the patients in these 
other studies, it is possible that DCM was absent because mutations identified in these 
other patients are heterozygous and/or it could manifests later in life. The DNA from 
both parents were also sequenced and are shown to be heterozygous for the mutation. 
While the mother appeared normal, the father was described to smile in an 
inappropriate manner and avoided eye contact during a medical examination session. 
He also has relatives with a history of neurodevelopmental problems such as learning 
disability, speech delay and seizure disorder (Cao et al., 2017).  
In all cases, individuals with eEF1A2 missense mutations presented with intellectual 
disability (ID) and developmental delay and in almost all cases, epilepsy or abnormal 
EEG. Many of the individuals also displayed autistic behaviours, while in some cases, 
facial dimorphic features such as tented upper lip and broad nasal bridge were noted. 
The effect of these different mutations varies ranging from extremely severe to mild 
phenotypes presented by the individuals. For example, a case described by Lam et al, 
2016 of a 9 years old patient with a heterozygous F98L mutation. She presented with 
very severe hypotonia and global developmental delay and daily seizures. She is 
nonverbal and is unable to move her head, sit or stand. A much milder case is a 10 
years old patient with a heterozygous E124K mutation who showed no sign of 
hypotonia and is capable of walking unaided. Although she shows significant delays 
in language and comprehension, she can communicate in sentences. Unlike the case 
of the patient with a F98L mutation, her seizures are well controlled with anti-epileptic 
drugs (Lam et al., 2016).   
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G70S F (22y) 
Onset at 4 months with 
myoclonic seizures, absences 
and grand mal 
SID, GDD, very limited 
speech development 
Y Y N 
Head circumference 
normal at 22 years 
old 
de Ligt et al., 
2012 
G70S M (14y) 
Onset at 10 weeks with 
myoclonic seizures, infantile 
spasms, GTC, refractory 
Severe delay,  Non-
verbal, incoordination 
and gait instability 





G70S F (3y) 
Onset at 2 months with 
myoclonic and tonic-clonic 
seizures, now absence 
seizures 
GDD NM Y Y 
No microcephaly at 9 
months, dysphagia 
Lam et al., 
2016 
E122K F (12y) 
Onset at 4 months with 
infantile spasms, controlled 
SID, Non-verbal, motor 
delay, ataxic gait 






E122K F (2y) 
Onset at 10 months with 
myoclonic seizures, atypical 
absence, uncontrolled 
SID, development 
stagnated during seizure 
episodes, non-verbal, 
cannot roll over at 2 
years 




Inui et al., 
2016 
E122K M  (2y) 
Onset at 8 months with 




delay, non-verbal and 
cannot stand unaided at 
2 years 
NM NM Y Cerebral atrophy 
Inui et al, 
2016 
E122K F (6y) 
Infantile spasm onset from 
10 weeks, controlled 
Gross motor delay, 
unsteady gait, non-
verbal but vocalizes uses 
signs 
N Y Y 
Small head 
circumference 














































































E124K F (10y) 
Onset at 3 months with 
myoclonic seizures, now 
absence seizures, controlled 
Normal but immature 
gait, verbal but 
significant delay in 
language, mild ID 
N N Y 
Normal MRI, head 
circumference at 
25th centile at 5 
years 
Lam et al, 
2016 
D252H F (8y) 






Y Y Y 
Progressive 
microcephaly, mild 
cerebral atrophy at 2 
and 4 years 
Nakajima et 
al., 2014 
A92T F (6y) Seizure onset at 1 months 
ID, Significant 
developmental delay 
Y NM NM  
Lopes et al., 
2016 
I71L M (9y) Seizures 
Severe GDD, non-verbal 
but uses signs 




Lam et al, 
2016 
D91N F (14y) 
Onset at 2y with head drops, 
eye rolling and arm extension 
seizures, uncontrolled 
GDD, non-verbal, 
unable to walk unaided 
at 14 years 




reduced bone density 
accompanied with 
fractures 
Lam et al, 
2016 
F98L F (9y) 
Onset at infant with focal 
seizures, now myoclonic, 
tonic and occasional tonic-
clonic seizures 
Severe GDD, non-
verbal, unable to sit or 
stand 
N Y Y 
Head circumference 
85th centile at 6 
months, poor bone 
density 
Lam et al, 
2016 
R423C M (5y) 
Onset at 4 months, multiple 
seizure types daily 
GDD, non-verbal, can’t 
walk at 5 years 
NM Y Y 
MRI showed mild 
hypoplasia of corpus 
callosum and mild 

















































































Onset at 7 months, febrile 
seizures, eye deviation, 
tonic-clonic, absences 
GDD, non-verbal, 
unable to walk 
NM Y Y 
FTT, progressive 
DCM leading to 
early death at 29 
months 
Cao et al, 
2017 
*P333L F 
Onset at 12 months, febrile, 
tonic-clonic 
SID, GDD NM Y Y 
Microcephaly, FTT, 
progressive DCM 
leading to early death 
at 5 years 
Cao et al, 
2017 
Y- Yes, N- No, NM- Not mentioned, DCM- Dilated cardiomyopathy, FTT- Failure to thrive, GTC- Generalised tonic-clonic, GDD- Global developmental 
delay, SID- Severe intellectual disability. * indicate mutation is homozygous recessive in patients and not de novo heterozygous as the other mutations. 
Adapted from Lam et al, 2016.   
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These missense mutations are not present in online databases including the Exome 
Aggregation Consortium (ExAC) and Genome Aggregation Database (gnomAD) 
which contain data set from 60,706 unrelated individuals and 123,136 exome 
sequences respectively (Lam et al, 2016, Cao et al, 2017). They involve residues that 
are shared between both eEF1A isoforms and are evolutionarily conserved across 
species. Mapping of these mutations on the surface of the 3-D modelled structure of 
the human eEF1A2 shows that most of them are clustered around the binding sites 
critical for protein elongation. Some of these residues which are buried in the modeled 
structure lie in close proximity to the eEF1B binding sites or located at or close to 
residues involved in domain-domain contacts (Figure 1.4).   
 
Figure 1.4. 3-D structure of human eEF1A2 showing location of missense mutations with respect 
to known binding sites mapped onto its surface. Two views rotated by 180o about the y-axis of the 
eEF1A2 structure with the equivalent location of eEF1Bα (cyan) and GTP/GDP binding site (yellow) 
from yeast eEF1A crystal structure. Variant residues between the human eEF1A1 and eEF1A2 are also 
indicated (green). Mutations are shown in red with residues with buried side-chains labelled in brown. 
A92T, M102V, T432M also lie in close proximity to the eEF1Bα binding site, while M102V, R423C 
and T432M are located at or adjacent to inter-domain contacts. Modelling and figure made by Dinesh 
Soares. 
 
 1.2.3 eEF1A2 in cancer 
Several studies have implicated eEF1A2 as an oncogene consistent with its 
overexpression in tumour cells derived from different tissues as summarised in table 
1.3 (Reviewed in (Lee and Surh, 2009; Abbas, Kumar and Herbein, 2015). Most 
importantly, functional analysis carried out by most of these studies showed that 
indeed eEF1A2 has the ability to transform cells. For example, Anand et al, 2002 
demonstrated the transformation ability of eEF1A2 in vivo by injecting nude mice with 
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EEF1A2-expressing NIH3T3 cells. These cells grew as tumours on the mice, while no 
tumour was seen in the parental mice or those injected with vector-transfected NIH3T3 
cells only. It is still not yet clear how the expression of eEF1A2 is enhanced in tumour 
cells. Working with primary ovarian tumour cells, Anand et al, 2002 showed that 
EEF1A2 amplification may elevate its expression in most, but not all, tumour cells. 
Tomlinson et al, 2007, however, demonstrated a lack of correlation between EEF1A2 
copy number and its expression in ovarian tumours. Interestingly, they found the 
highest EEF1A2 copy number in a tumour that did not express eEF1A2. Although they 
did not find any functional mutation or differential methylation modification of the 
EEF1A2 locus in normal and tumour cells, their findings suggest there are other 
alternative ways by which eEF1A2 is upregulated. The authors postulated the improper 
expression of a trans-acting factor in some tumours as a likely cause for eEF1A2 
overexpression.  
Table 1.3: Summary of some studies which showed overexpression of eEF1A2 in 
different human cancer types   
Cancer type Methods of eEF1A2 
detection 
Relevant findings Reference 
Ovarian cancer Northern blot Increased EEF1A2 
expression in ~30% 
primary ovarian tumours 
while it was detected in 
normal ovarian tissues 
Anand et al., 2002 
Ovarian cancer RT-PCR, WB, IHC ~75% of ovarian clear cell 
carcinomas showed 
overexpression of eEF1A2 
using IHC 
Tomlinson et al., 
2007 
Breast cancer RT-PCR, IHC 40 out of 63 breast tumours 
showed increased 
expression of eEF1A2 with   
more significant observed 
in ER-positive tumours 




Breast cancer DNA microarray, 
IHC 
Upregulation of eEF1A2 
found in ~30% of ductal 
and lobular carcinomas and 
tumour metastases 
Kulkarni et al., 
2007 
Lung cancer CGH Overexpression of eEF1A2 
was related to gene 
amplification and stage of 
the disease 
Li et al., 2006 
Lung cancer CGH EEF1A2 suggested as a 
strong oncogene with a 
marked upregulation of 
127.9-fold increase  
Zhu et al., 2007 
Hepatocellular 
carcinoma 
qRT-PCR Overexpression of  eEF1A2 
partially dependent on gene 
amplification  






Increased expression of 
eEF1A2 in about half HCC 
cell lines. 




qRT-PCR, WB, IHC Upregulation of eEF1A2 in 
83% of pancreatic cancer 
tissues 
Cao et al., 2009 
Prostate cancer 
(PCa)  
qRT-PCR, IHC Enhanced expression of 
eEF1A2 in 26/30 (86.7%) 
PCa tissues  
Sun et al., 2014 
 
How eEF1A2 promotes tumorigenesis is still poorly understood. Thornton et al., 2003 
suggested that increased protein synthesis as a result of eEF1A overexpression occurs 
in these cells. This, in turn, leads to the excessive production of protein which then 
promotes cell growth and proliferation. Another possibility could relate to the other 
non-canonical functions of eEF1A2, in particular, its cytoskeletal remodelling and 
anti-apoptotic role which has obvious implications for tumour progression. Different 
studies have shown that the promoting effect of eEF1A2 in the migration, invasion and 
metastasis of tumour cells occurs in an Akt and P13K (phosphatidylinositol-3-kinase) 
dependent manner (Pecorari et al., 2009; Li et al., 2010; Xu, Hu and Zhu, 2013). Using 
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both bioinformatics and experimental approaches, it has been shown that only eEF1A1 
interact with calmodulin (Kanibolotsky et al., 2008; Novosylna et al., 2017). In their 
study, Novosylna et al 2017 also demonstrated that calmodulin interfered with the 
tRNA-binding ability of eEF1A1 and also had an inhibitory effect on its actin-bundling 
activity. This made the authors suggest that eEF1A2, when present in this tissues, 
might escape eEF1A1-specific regulation. This then leads to the inappropriate 
behaviour of the cells which makes them become oncogenic. This hypothesis is 
strengthened by the fact that only eEF1A1 is normally expressed in most of the tissues.  
1.3 Zebrafish: a useful tool for modelling human diseases 
The zebrafish (Danio rerio) is a small freshwater vertebrate that is undoubtedly 
becoming a popular choice of animal model for understanding human diseases. As a 
model, the zebrafish has several advantages that make it suitable for this purpose. The 
breeding and maintenance of these animals is not only easy but also space and cost-
efficient. A single mating pair of the zebrafish produces large clutch sizes of fertilised 
eggs within a range of 200-300 in a week, with the generation time relatively rapid. 
More so, the embryos develop ex utero in a transparent chorion. This, together with 
the embryo being translucent up till early larval stages make it ideal for visualising 
different aspects of development using different techniques including conventional 
light microscopy. For example, monitoring of motor neuron axonal length and 
branching pattern, which is a marker indicating motor neuron degeneration in 
zebrafish, can be carried out in embryos as early as 24 hours post fertilisation (Kabashi, 
Brustein, et al., 2011). 
Zebrafish are genetically tractable models, a feature which is further strengthened by 
the continuous development of advanced and more precise genome-editing techniques 
such as TALEN and CRISPR-Cas9. Fortunately, the complete sequence of the 
zebrafish genome is now available and shows that approximately 70% of human genes 
have at least one clear orthologue in its genome (K. Howe et al., 2013). Another 
important and very attractive feature of the zebrafish is the ease to use them as an in 
vivo model to carry out high-throughput chemical screening for drug discovery 
researches for different human diseases such as neurological disorders and cancers 
(Reviewed in (Lieschke and Currie, 2007; Bootorabi et al., 2017). Due to their small 
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size, larvae can be placed into a 96-well plate containing water-soluble drugs, allowing 
large numbers of fish to be tested simultaneously. This benefit and others mentioned 
above not only makes zebrafish a suitable complement to rodent models but also helps 
in reducing the number of rodents used for research purposes, as unprotected (larval) 
stages can also be used in experiments, therefore, adhering to the 3Rs (replacement, 
refinement and reduction) principles.   
1.3.1 Comparison of the zebrafish and human central nervous system 
with a focus on relevant regions in modelling human neurological 
disease 
The central nervous system (CNS) is the most complex tissue in vertebrates, as such 
raising questions as to the suitability of using the zebrafish to model neurological 
disorders. Although the human CNS is much more complex and some of the structures, 
for example, the cerebral hemisphere, are bigger than that of the zebrafish, the overall 
organisation of their CNS is similar. As in other vertebrates, the CNS of the zebrafish 
is divided into forebrain, midbrain, hindbrain and spinal cord.  
The zebrafish brain shares some similarities with that of mammals. For example, the 
cerebellum which plays a key role in motor control has the typical three-cell layer 
structure; molecular layer, Purkinje cell layer and granule cell layer as seen in the 
mammalian cerebellum. Using in situ hybridisation, Bae et al., 2009 also showed 
similar expression profiles of most of the key genetic markers for GABAergic and 
glutamatergic neurons in the cell types found in these layers. As suggested by the 
authors, this could indicate that the development and functioning of the cerebellum 
may be the same in these species, as such the zebrafish could also provide insights to 
understand cerebellar development. However, the major difference between the teleost 
and the mammalian cerebellum is the presence of teleost-specific eurydendroid cells 
identified by Nieuwenhuys, Pouwels and Smulders-Kersten, 1974; these  are located 
in the Purkinje layer. These cells are homologous to the deep cerebellar nuclei (DCN) 
found in mammals which are located further away from the Purkinje layer. These two 
cell types are efferent neurons and receive inputs from the Purkinje cells and transmit 
them to other regions of the brain. As shown by Bae et al, 2009, the expression of 
VGLUT2 which also has preferential expression for DCN is conserved in the 
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eurydendroid cells. However, it is still not clear if these different cell types develop or 
perform their function in the same manner. 
Other parts such as the medulla, tectum and olfactory system of the zebrafish brain 
also show some structural similarities to the corresponding regions in the human brain. 
Deterioration of the olfactory system has been noted to correlate to the progression of 
some neurodegenerative diseases in preclinical studies suggesting it has some clinical 
importance (Aguilar Martínez et al., 2017). The sensory pathway of the olfactory 
system of the zebrafish shares homology with that of mammals (Tropepe and Sive, 
2003). For example, the olfactory nerves project through the olfactory bulb to targets 
within the telencephalon and diencephalon in teleost as well as in mammals 
(Wullimann, 1997). However, caution should be taken when interpreting data on 
homologies from the forebrain regions as the forebrain is much smaller and less 
developed in the zebrafish. In addition, unlike mammals which have an evaginated 
telencephalon, the teleost telencephalon is everted. Although, there are now various 
studies aimed at providing more insights into the structural and functional homologies 
of this region between the zebrafish and mammals. For example, tracing studies using 
neuronal tracers has identified the dorsal nucleus of the zebrafish ventral telencephalic 
area to be homologous to part of the mammalian striatum (Rink and Wullimann, 2004). 
The striatum is one of the main input regions for the basal ganglia which is also 
involved with neurodegenerative diseases in human.  
Most of the descending neural pathway originating from the brainstem down to the 
spinal cord appears to be phylogenetically conserved in teleost and mammals 
(reviewed in (Yamamoto, Nakayama and Hagio, 2017). However, an important 
difference is the lack of descending projections referred to as corticospinal tract (CST) 
in the homologous telencephalic area in teleost species. In mammals, the CST is sent 
out from the motor cortex to the spinal cord and has been suggested to play a role in 
skilled movement of the forelimbs in primates (Iwaniuk and Whishaw, 2000). This is 
an important difference to consider particularly when modelling neurodegenerative 
diseases associated with the upper motor neurons.  
Apart from the neurons, major glial cell types such as oligodendrocytes (Kirby et al., 
2006) and microglia (Peri and Nüsslein-Volhard, 2008) are present in the brain and 
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spinal cord parenchyma of the zebrafish and show similar development and function 
as in mammalian species (reviewed in (Lyons and Talbot, 2015). With the recent 
findings implicating glial cells in neurodegenerative diseases (Kurosinski, Biol and 
Götz, 2002), this also strengthens the suitability of the zebrafish as a model system. 
Although stellate-shaped astrocytes have been reported to be found in the adult 
zebrafish spinal cord (Kawai, Arata and Nakayasu, 2001) and adult rainbow trout brain 
(Alunni et al., 2005), this has not been supported by other studies. However radial 
cells, which usually transform to astrocytes during the maturation of the mammalian 
nervous system are found in abundance in the zebrafish. There are studies that provide 
evidence that the radial glial cells have the capabilities to subserve some of the roles 
which have been described for the mammalian differentiated astrocytes (Lyons and 
Talbot, 2015). One function of the astrocytes is their involvement in the maintenance 
and modulation of the blood-brain barrier (BBB) in mammals (Janzer and Raff, 1987; 
Daneman et al., 2010). Interestingly, it has recently been demonstrated that a 
functional endothelial tight junction BBB, similar to that of higher vertebrates is also 
present in the zebrafish brain (Jeong et al., 2008). As the BBB also presents a challenge 
for the efficient delivery of therapeutic compounds, this finding suggests that a better 
understanding of the BBB can also be achieved using the zebrafish. This, therefore, 
strengthens its utility as an in vivo model for chemical screening for the purpose of 
developing treatments for neurological disorders.    
Although investigations of the comparative homologies between the zebrafish and 
human CNS are still ongoing, there is enough evidence that suggests the conservation 
of the overall structure and function of the CNS in these species, thereby validating 
the use of the zebrafish model to contribute to the understanding and treatment of these 
complex neurological disorders. This is further supported by the findings of numerous 
studies that have noted phenotypes in zebrafish models of some neurological disorders 
to parallel those of rodent models. 
1.3.2 Zebrafish models for motor neuron disease 
Motor neuron disease (MND) is a collective term which is used to describe a 
heterogeneous group of neurodegenerative disorders that results in the selective death 
of motor neurons resulting in the increasing weakness and wasting of the associated 
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muscles. MND can be categorised depending on whether the disease affects the upper 
motor neurons (UMNs), which start in the motor cortex of the brain and end within the 
spinal cord and/or the lower motor neurons (LMNs) which are located from the spinal 
cord or brainstem to the skeletal muscles. There are different types of MND such as 
spinal muscular atrophy (SMA), hereditary spastic paraplegia and amyotrophic lateral 
sclerosis (ALS), which is the most common form of the disease and will be the focus 
of this review.  
ALS, which is also referred to as MND in the UK (henceforth will be used 
interchangeably with ALS), is a late-onset neurodegenerative disorder that affects both 
UMNs and the LMNs. It has been found in different populations with an incidence rate 
ranging between 0.9-2.4 per 100,000 depending on the population (Sathasivam, 2010). 
While 90% of ALS cases occur sporadically, about 5-10% of cases are inherited in a 
Mendelian fashion, although a systematic metanalysis suggests 5.1% as the accurate 
rate of familial ALS (Byrne et al., 2011). Most cases of ALS are diagnosed in people 
between the ages of 40-70, although a much rarer form known as juvenile ALS can 
occur in younger individuals below 25 years of age. A study in a combined European 
cohort by Logroscino et al., 2010 shows that the incidence of ALS rapidly increases 
after the age of 40 years and peaks at the early 70s for men and late 60s for women, 
after which it falls. The location of the onset of the disease varies, with ~70% ALS 
patients presenting with limb-onset, ~20% with bulbar-onset and ~5% with trunk and 
respiratory involvement and spread to other region of the body (Kiernan et al., 2011).  
The neuropathological hallmarks of ALS include the disappearance of the pyramidal 
and Betz cells which results in retrograde axonal degeneration, loss of the anterior horn 
cells of the spinal cord as well as the lower cranial nerve motor nuclei of the brain 
stem, accumulation of intracellular inclusions such as phosphorylated neurofilaments 
and ubiquitinated inclusions within the anterior horn cells, and gliosis (Hirano, 1996; 
Maragakis and Galvez-Jimenez, 2018). The disease rapidly progresses and 
deteriorates, leading to the death of most patients within 2-5 years of diagnosis often 
due to respiratory failure (Van Damme, Robberecht and Van Den Bosch, 2017).        
Although there is currently no cure, the growing interest in this condition has provided 
valuable insights into the aetiology of ALS which is still essentially unknown. About 
20 genes have been identified over the last decade, most of which are associated with 
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the familial form of the disease (Corcia et al., 2017). Most of these genes are involved 
in different biological pathways reflecting the multifactorial cause of this disease. The 
first causative gene implicated in ALS is the Superoxide dismutase 1 (SOD1) identified 
in 1993 (Rosen et al., 1993) with the frequency of 12-23.5%. Other most common 
genes linked to ALS are C9ORF72, TARDBP and FUS with frequencies of 39.3% 
(Familial ALS), 5% and 4.1% respectively (Al Sultan et al., 2016). Most of the ALS-
causing mutations in these genes were identified in patients with the familial form of 
ALS (see Table 1.4 below).   
Table 1.4: Most common genes linked to ALS with statistics obtained from the 
Amyotrophic lateral sclerosis online genetics database (accessed July 2018)  
Gene FALS SALS Most frequent 
mutation reported 
CORF72 60 46 HREM 
FUS 77 27 Arg521His 
SOD1 286 44 Cys6Ser 
TARDBP 58 40 Ala382Thr 
FALS- Familial Amyotrophic lateral sclerosis, SALS- Sporadic Amyotrophic lateral sclerosis, 
HREM - hexanucleotide repeat expansion mutation 
The heterogeneous clinical presentation of ALS in patients even within individuals 
from the same family and the same causative gene stresses the need to better 
understand this disease as this has implications for identifying potential therapeutic 
targets (Van Damme, Robberecht and Van Den Bosch, 2017). Different animal models 
have been generated to recapitulate the neurological abnormalities or the genetic 
aspects of the condition (reviewed in (Van Damme, Robberecht and Van Den Bosch, 
2017).  Although there is no perfect animal model displaying all the clinical features 
of the disease, they have no doubt served as a valuable tool in providing insights into 
the mechanism of motor neuron disease. An example is the wasted mouse, which is 
one of the several spontaneous mouse strains (reviewed in (Doble and Kennel, 2000) 
and a model that our laboratory has worked extensively on. In terms of neurological 
abnormalities, the wasted mouse (described in section 1.2.1) presents with clinical 
features that more closely resemble ALS in humans than the other spontaneous mice 
models. More recently, different zebrafish models for ALS have been described in 
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several studies (reviewed in (Babin, Goizet and Raldúa, 2014; Patten et al., 2014). 
However, most of the approaches used in generating these models involve the injection 
of mRNA for overexpression of ALS-related genes or morpholinos to knockdown 
these genes in the embryos. Expression of genes in these models is only transient, 
limiting the time to perform any phenotypic assay. This poses a challenge for this 
condition which has a late onset (Kabashi et al, 2011) as well as having the potential 
for off-target effects associated with the use of morpholinos, therefore results from 
these studies should be interpreted with caution. However, due to the ease and speed 
of these methods, models generated with these approaches have been used to confirm 
the usefulness of the zebrafish as a tool for understanding the pathogenesis of motor 
neuron disease as well as for screening small molecules to be used for treatment for 
the condition in combination with other animal models.  
The first ALS disease zebrafish model was generated by Lemmens et al., 2007 using 
an overexpression approach. Microinjection of embryos with three different ALS-
causing mutations of the human SOD1 mRNA induced axonal abnormalities that were 
specific to the motor neuron and were reminiscent of those seen in transgenic SOD1 
rodent models. It has been reported that the phenotype associated with the mutation of 
SOD is modified by two factors; wild-type SOD1 and the vascular endothelial growth 
factor (VEGF) gene in rodents. VEGF has been suggested to have a protective effect 
on motor neuron in humans and rodents models of ALS (Lambrechts et al., 2003; 
Storkebaum et al., 2005). Wild-type SOD1 worsens the ALS phenotype in transgenic 
SOD1 mutant mice and even cause these phenotypes to appear in mice carrying a 
mutation, SOD1A4V that has been previously shown to not induce any ALS phenotypes 
in mice even after 2 years, consistent with a toxic gain of function effect (Deng et al., 
2006). Lemmens et al, 2007 investigated the effect of VEGF and wild-type SOD1 on 
their mutant embryos and their findings were consistent with those observed in mice. 
This not only validated the zebrafish model for studying motor neurodegeneration but 
has led to the development of transient zebrafish models as well as stable transgenic 
lines carrying mutations in different genes involved in MND by different groups; these 
have been reviewed in Babin, Goizet and Raldúa, 2014. As a result of this work, the 
interactions between these genes are now being studied in the hope that this will 
provide a complete picture of the pathogenesis of MND and better inform the 
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development of effective therapeutic strategies for the different gene mutations. A 
good example is that demonstrated by Kabashi, Bercier, et al., 2011, where the 
interactions of FUS with TARDBP and SOD1 was investigated. They showed that 
human wild-type FUS was able to rescue phenotypes such as motor neuron branching 
and swimming abnormalities induced by the knockdown of zebrafish tardbp but not 
vice versa while the wild-type form of both human  FUS and TARDBP genes had no 
effect on fish injected with the human G93A mutant SOD1 mRNAs. Also, human wild-
type SOD1 had no effect on phenotypes induced by the overexpression of human 
mutant FUS and TARDBP or knockdown of the zebrafish fus and tardbp. However, a 
more severe phenotype was observed in injected embryos co-expressing human mutant 
SOD1 with either human mutant forms of FUS or TARDBP. Their findings suggested 
that FUS shares a common pathway with TARDBP, although the latter acts upstream 
and hence was unable to rescue the phenotype induced when the zebrafish fus was 
knockdown. On the other hand, SOD1 might act independently of FUS and TARDBP 
(Kabashi, Bercier, et al., 2011). Consistent with these findings, Laird et al., 2010 had 
previously shown that overexpression of human progranulin gene had a 
neuroprotective effect on the axonopathy induced by mutant TARDBP but not mutant 
SOD1 expression. Interestingly, the zebrafish models are now being used to identify 
other gene modifiers that could serve as a potential target for therapeutic interventions. 
Van Hoecke et al., 2012 identified the ephrin receptor, epha4, as a modifier of ALS 
using a morpholino-based modifier screen approach with embryos overexpressing 
human mutant SOD1. They then confirmed that this factor was also a modifier in 
rodents ALS models as well as in ALS patients, with lower EPHA4 expression 
resulting in later disease onset and reduced severity and progression of the disease. 
Pharmacological inhibition of the Epha4 signalling pathway also completely rescued 
the axonopathy induced by mutant SOD1 in zebrafish and delayed onset of the disease 
as well as increased the survival rate of ALS rat models (Van Hoecke et al, 2012).     
Despite the fact that zebrafish was only recently validated as a suitable model for 
investigating MND pathogenesis, the fish models are already being used to carry out 
chemical screenings for drug discovery purposes confirming their advantage, 
particularly as regards economic issues, over rodent models. The first in vivo chemical 
screening was performed using three compounds; lithium chloride, methylene blue 
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(MB) and riluzole which are known for their neuroprotective potential, first in 
transgenic mutant TDP-43 (mTDP-43) and mFUS Caenorhabditis elegans ALS 
models and then later with transgenic zebrafish models, referred to as mTDP-43 and 
mFUS by the authors, using only MB which showed more promise in worms (Vaccaro 
et al., 2012). In both their worm and fish models, motor neuron abnormalities induced 
by TDP-43 and FUS mutations such as paralysis in C. elegans and swimming deficits 
with shortened and unbranched axons in zebrafish were significantly improved with 
MB, with earlier rather than late administration of MB being more effective in worms. 
This study also identified the molecular mechanism of MB as the oxidative stress 
levels in mTDP-43 and mFUS zebrafish and C. elegans models were reduced using 
dihydrofluorescein diacetate (DHF) assay. In the presence of intracellular peroxide 
which is a marker of oxidative stress, DHF produces a strong fluorescent signal which 
was observed in mTDP-43 and mFUS zebrafish and C. elegans. When both mutant 
models were treated with either MB and ero-1 (ER oxidoreductin 1) RNAi, the 
intensity of the fluorescent signal was significantly reduced (Vaccaro et al., 2012, 
2013). This suggests that MB exerted a neuroprotective effect through the endoplasmic 
reticulum (ER) stress pathway that is activated in response to the accumulation of the 
unfolded mutant proteins (UPRER) which was demonstrated with only mTDP-43 
zebrafish models (Vaccaro et al., 2013). Understanding the mode of action of MB led 
to the identification of three other candidate compounds with therapeutic potential 
which were structurally similar to MB in the same study. Two of these compounds, 
salubrinal and guanabenz have previously been demonstrated to be active in the UPRER 
(Boyce et al., 2005; Tsaytler et al., 2011) while the first evidence of the 
neuroprotective ability of phenazine through this pathway was reported in the study of 
Vaccaro et al., 2013. Interestingly, salubrinal was also found to reduce disease onset 
and delay its progression through the ER stress pathway in the transgenic FALS mouse 
model expressing the human SOD1G93A mutation (Saxena, Cabuy and Caroni, 2009). 
These three compounds act through different branches within the UPRER pathway and 
proved to be more efficient when combined with MB (Vaccora et al, 2013). Validation 
of the suitability of Vaccora et al, 2013 mTDP-43 zebrafish model for drug screening 
subsequently led to a high-throughput screening for other drugs for MND which has 
now been translated to patients with ALS (Patten et al., 2017). In this recent study, 
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3,850 small molecules were first screened using mTDP-43 C. elegans models and 13 
lead compounds, all neuroleptics, were identified as positive hits. Using the mTDP-43 
zebrafish model, only 10 of these compounds were confirmed, with pimozide being 
the lead compound with neuroprotective abilities which was also observed in zebrafish 
overexpressing the mutant form of human SOD1 and FUS. Pimozide was next tested 
in mutant SOD1 mice where it was shown to restore neuromuscular synaptic 
transmission. This study also demonstrated the safety and promise of using pimozide 
in patients with SALS in a pilot randomised controlled trial (RCT), allowing a second 
RCT trial with 100 patients to be approved for further investigation (Patten et al., 
2017).  
Some other studies have also validated the use of mutant sod1 zebrafish models for 
small molecules screening. McGown et al., 2013 demonstrated the effectiveness of 
riluzole, the only approved drug for MND, in their transgenic sod1 mutant and also 
identified a new role of the drug in reducing neuronal stress in interneurons. Another 
antioxidant drug, olesoxime was also shown to protect against SOD1 neurotoxicity in 
a T701 sod1 zebrafish model generated using TILLING (targeting induced local 
lesions in genomes) by Da Coasta and colleagues, 2014. Interestingly, apomorphine 
was also found to be effective in reducing oxidative stress in the different sod1 
zebrafish mutants in both studies (McGown et al., 2013; Da Costa et al., 2014). This 
drug has also been demonstrated to reduce motor dysfunction in SOD1G93A transgenic 
mice as well as attenuate oxidative stress and increase the survival rate in fibroblasts 
derived from ALS patients subjected to oxidative insult in vitro (Mead et al., 2013). 
Apomorphine is an activator of the nuclear factor erythroid 2-related factor (NRF2), 
which drives the expression of several neuroprotective genes by interacting with the 
antioxidant response elements (ARE). Further investigation of this compound as well 
as of the NRF2-ARE pathway, which has been shown to be impaired in SOD1 mutant 
mice models and brain and spinal cord tissues from ALS patients (Sarlette et al., 2008; 
Vargas et al., 2008), can now be done using the zebrafish in combination with the other 
available animal models. This could potentially speed the translatability of research 




1.3.3 Zebrafish models of epilepsy  
Epilepsy is a complex neurological disorder marked by unprovoked and recurrent 
seizures that are caused by abnormal electrical activity in the brain. This disorder is 
common, affecting approximately 1% of the general population. Despite the wide 
range of anti-epileptic drugs (AEDs), epileptic seizures in around one-third of these 
patients cannot be controlled with the available treatment (Cunliffe, 2016). Also, some 
of these AEDs have been shown to have an adverse effect, for example, increased rate 
of congenital malformation and developmental and cognitive impairment in children 
with in utero exposure to valproate, a widely used AED, has been reported (Adab et 
al., 2004; Morrow et al., 2006). It is therefore important that new drugs with better 
efficacy for drug-resistant epilepsy and with fewer side effects are developed. 
Several factors, for example, genetic mutations or head trauma can cause epilepsy; 
however, the cause is still unknown in at least 40% of cases (Shorvon, 2011). The 
number of these cases is gradually diminishing, especially for childhood cases of 
epilepsy, with the advent of whole exome sequencing (WES). Exome sequencing of 
patient-parents trios has identified many de novo mutations in genes that have never 
previously been implicated in neurological disorders. These patients present with other 
cognitive and behavioural deficits such as autism and intellectual disability (ID) along 
with the seizures. This in itself is no surprise, as it is known that there is a strong 
association between epilepsy, ID, autism and even motor impairment in infants 
(Tuchman and Cuccaro, 2011). However, it is still not clear if these other 
neurodevelopmental disorders are as a result of the damage caused by the seizure itself, 
as implied by the term epileptic encephalopathy, or independent of the presence of 
seizures but with a common underlying cause. Most studies seem to point to the latter, 
especially in the development of autism, which will suggest that these disorders might 
share a common molecular pathway that these genes are involved in (Tuchman and 
Cuccaro, 2011). The development of animal models which recapitulate some of these 
phenotypes has been and is still extremely valuable in understanding the contribution 
of these genetic mutations to neurodevelopmental disorders especially as more new 
genes, whose causal role have to be validated, are being discovered. 
33 
 
The zebrafish has again been employed in epilepsy research and has contributed 
immensely to the growing information currently available (recently reviewed in 
Cunliffe, 2016). One of the attractive features of using the zebrafish is the ability to 
effectively model epilepsy using both larval and adult stages. While the larvae can be 
used to model early-onset epilepsy, other more complex seizure-related behaviours 
can be further investigated using the adult fish (Stewart et al., 2012). Epileptic seizures 
can be investigated in zebrafish models using pharmacological induced and/or genetic 
manipulation methods. Chemically induced seizure was first demonstrated by Baraban 
et al., 2005 using pentylenetetrazole (PTZ), a common convulsant drugs also used in 
rodent models. In this study, they found PTZ induced locomotor convulsive behaviour, 
abnormal electrical discharges in the brain and increased expression of c-fos, a 
biomarker for neuronal activity, in the brain of PTZ treated zebrafish larvae, 7 days 
post fertilization (dpf). All these changes were similar to those seen in the rodent 
seizure models and were readily suppressed using valproate and diazepam, two AEDs 
that are also known to be effective in PTZ-induced seizure in rodents. The well-
established scoring system of seizure behaviour of PTZ treated fish from this study has 
paved the way for other uses of the PTZ assay. The assay was used to perform the first 
large-scale genetic screening in N-ethyl-N-nitrosourea (ENU) mutagenized larvae 
which identified six candidate genes that conferred resistance to seizure (Baraban et 
al., 2007). Interestingly, this study showed that PTZ can also be used to induce seizures 
effectively in larvae at earlier developmental stages from 3-5 dpf which are not 
regulated (unlike 7 dpf larvae) and will not require a license to carry out these 
experiments,  an added benefit of this model. In 3dpf larvae, Teng and colleagues used 
this assay in combination with morpholinos to demonstrate that knockdown of lgi1a 
or lgi1b, both of which encodes ion channel proteins, increased the susceptibility of 
their Lgi1a and Lgi1b zebrafish morphants to PTZ-induced seizures (Teng et al., 2010, 
2011). Other convulsant drugs used in mammals have now been shown to be equally 
effective in inducing seizures in zebrafish, but PTZ still remains the most widely used 
(reviewed in Stewart et al., 2012). 
Zebrafish have been shown to be sensitive to mutations in genes shown to cause 
epilepsy in humans and rodents. An example is the sodium channel subunit scn1La 
zebrafish mutation which was identified from an ENU mutagenesis screen (Baraban, 
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Dinday and Hortopan, 2013). Heterozygous missense mutations in SCN1A, most of 
which are de novo (85%), account for the underlying cause of Dravet syndrome (DS) 
in about 70- 80% of individuals with this disorder (Rosander and Hallböök, 2015). DS 
is a severe form of epilepsy marked by prolonged frequent generalised seizures that 
may or not be caused by a fever. These seizures begin within the first year of life, 
usually around 5 months of age and are poorly controlled by the available AEDs 
(Bender et al., 2012). In addition to epilepsy, these patients also present with 
developmental delay, cognitive and behavioural problems towards the second year of 
life. Some other neurological abnormalities such as hypotonia, ataxia and gait 
abnormalities accompany these other features in some infants with DS (Dravet, 2011). 
Another example is the KCNQ3 gene which encodes for the voltage-gated potassium 
channel, kv7.3. Mutation in this gene and another of this gene family, KCNQ2, are 
associated with a range of early-onset epilepsies with varying severity from the mild 
inherited epilepsy benign familial neonatal seizures (BFNS) to the severe epileptic 
encephalopathy usually caused by de novo mutations in these genes (Charlier et al., 
1998; Singh et al., 1998; Miceli et al., 2015). Using morpholinos, knockdown of 
KCNQ3 expression in zebrafish induced seizure-like activities shown by the abnormal 
electrical discharges obtained from the brains of larval morphants using 
electrophysiology (Chege et al., 2012).   
Most of the pro and anti-convulsant drugs are water soluble and can easily be 
administered by placing in a small volume of the normal bathing medium of the fish. 
Combined with the small size and genetic amenability of the zebrafish larvae, this 
makes the larval form excellent for high-throughput screening to identify new AEDs 
drugs. This has been further strengthened with the development of devices for 
automated compound delivery with in-built software for automated behavioural 
analyses that are compatible with a 96-well plate allowing large number of larvae to 
be tested simultaneously (for example, www.noldus.com). A good example where 
these benefits have been employed is seen in the study of Baraban et al, 2013. They 
performed a relatively large screen using a chemical library made up of 320 
compounds in the scn1La zebrafish Dravet syndrome models and found that clemizole 
was effective in reducing seizure activity in 5dpf larval mutants. A larger screening of 
about 2000 small molecules has also been performed using PTZ-induced seizure wild 
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type larvae at 2dpf with similar equipment (Baxendale et al., 2012). The authors also 
demonstrated the change of c-fos expression associated with seizure activities in 
zebrafish was robust enough to be used as another in vivo criterion for assessing the 
anti-convulsant properties of compounds in high-throughput chemical screens. The 
ability to use zebrafish larvae to carry out chemical screening not only identifies the 
effective doses of potential compounds but also allows for the simultaneous evaluation 
of their toxicity in vivo to determine if they are safe to be used for treatment of epilepsy. 
Goldsmith et al, 2007 showed that GBR12909, a dopamine reuptake inhibitor, 
although having an anti-convulsant effect on zebrafish and rodent models of 
generalised epilepsy, has a cardiac side effect as it induced abnormal heart rhythms in 
zebrafish even at the effective dose concentration for treating epilepsy. Interestingly, 
this finding parallels data from two phase 1 clinical studies that suggested the potential 
QT prolongation of GBR12909 in humans (Goldsmith et al., 2007). Their study 
demonstrates that the zebrafish could be used as the first in vivo platform to assess 
safety of a drug, once it has been identified as a hit, to determine if it should be 
developed further and then tested in the mammalian system. This could help avoid a 
waste of time and resources (and welfare issues) in the development of drugs that 
might be found to have serious side effects in the long run. Taken together, these 
studies demonstrate that zebrafish larvae present an excellent platform for identifying 
new and safe AEDs drugs for pharmocoresistant seizures, as well as seizures that are 
currently controlled by AEDs shown to have major side effects in the long term e.g 
valproate. 
1.4 Local mRNAs translation in neurons  
 mRNA localisation is a highly conserved mechanism that allows for the 
spatiotemporal control of the synthesis of specific proteins in cells. Using 
differentiated neurons separated into neurites and soma fractions, Zappulo et al., 2017 
showed that mRNA localisation accounted for half of the neurite-localised proteome. 
This finding together with those from a number of studies support the idea that mRNA 
localisation underlie the establishment and maintenance of dendrites and axons which 
are functionally specialised compartments of the neuron (reviewed in (Holt and 
Schuman, 2013). The mRNAs localised to these compartments fall into diverse 
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functional categories such as translation, cytoskeleton, degradation and 
channel/receptor formation. This further reflects the ability of axons and dendrites to 
function independently as they are able to coordinate and regulate the translation of 
these mRNAs locally when needed. Interestingly, this has already been demonstrated 
in vivo in a study by Harris and Colleagues in 1987. Using time-lapse video recordings, 
they showed that axons isolated from the soma were able to grow and navigate 
correctly to the optic tectum in Xenopus embryos (Harris, Holt and Bonhoeffer, 1987).  
There is much evidence that demonstrates the role of axonal mRNA translation in axon 
growth and navigation, synapse formation as well as the survival of axons and deficits 
in this process can lead to neurodevelopmental and neurodegenerative disorders 
(reviewed in (Cioni, Koppers and Holt, 2018; Costa and Willis, 2018). Interestingly, 
there are studies that link eEF1A to local protein synthesis during synaptic formation. 
It was demonstrated that eEF1A is important for the maintenance of newly formed 
synapses using sensory neurons isolated from Aplysia (Giustetto et al., 2003). In this 
study, it was observed that applying serotonin (5-HT) increases the level of eEF1A 
protein and mRNA but its mRNA was only enriched in the axonal processes when 
applied to both the cell body and the synapse. Blocking the expression of eEF1A using 
antisense oligonucleotides or antibodies resulted in the failure of the long-term 
facilitation (LTF) induced by 5-HT to last beyond 24 hrs. LTF is the major form of 
synaptic plasticity in invertebrates and has been suggested to underlie long-term 
learning behaviour and memory in Aplysia (Frost et al., 1985).  
Long-term potentiation (LTP) and long-term depression (LDP) which describes the 
long-lasting increase or decrease in synaptic strength respectively are the most studied 
form of synaptic plasticity, which is also believed to underlie learning and memory in 
human. Similarly, these processes require de novo protein synthesis suggesting that 
local mRNA translation at the synapses is important for their maintenance. There are 
studies that show the local translation of eEF1A2 mRNA at the synapses is required 
for LTP and LDP. Using microarray, eEF1A was identified as part of a subset of 
dendritic mRNAs from rat hippocampal neurons (Zhong, Zhang and Bloch, 2006). 
Another study demonstrated that eEF1A2 binds the alpha-2 subunit of the glycine 
receptor (GlyR) in a pull-down assay using extracts from adult rat brain (Bluem et al., 
2007). Immunofluorescence microscopy also showed eEF1A to colocalise with GlyR 
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from the soma into the dendrites and at inhibitory synapses in cultured hippocampal 
and spinal cord neurons from rat. Stimulation of hippocampal LTP in dendrites that 
have been severed from the cell body led to the increased expression of eEF1A, 
suggesting its translation is locally regulated at the dendrites. This effect was absent 
when the rat hippocampal slices were then treated with rapamycin, an inhibitor of the 
mammalian target of rapamycin (mTOR) pathway, and also blocked the maintenance 
of LTP (Tsokas et al., 2005). In another study, induction of LDP in rat hippocampal 
slices resulted in the enhanced expression levels of eEF1A protein in the dendrites 
(Huang, Chotiner and Steward, 2005).  
These findings provide strong evidence for the conserved role of eEF1A in maintaining 
long-term synaptic plasticity and possible in learning and memory. Interestingly, 
expression of eEF1A protein is reduced in the hippocampus, in particular the CA1 and 
dentate, but not in the cerebellum or midfrontal gyrus in post mortem brain samples 
obtained from patients diagnosed with Alzheimer disease (AD) (Beckelman, Zhou, et 
al., 2016). AD is a neurodegenerative disorder with memory loss as one of the first 
symptom in patients. This group also showed that impaired LTP characteristic to AD 
is attenuated by the upregulation of eEF1A in hippocampal slices obtained from 
transgenic AD mice models (Beckelman, Day, et al., 2016).  Similarly, dysregulation 
of eEF1A was found to underlie the impaired synaptic elimination observed in Fragile 
X syndrome, the major form of inherited learning disability. Tsai et al., 2012 showed 
that reducing eEF1A levels which is found to be elevated in Fmr1 knockout neurons 
restore synaptic elimination in mice. FMR1 protein participates in the spatial and 
temporal control of local protein synthesis during synaptic development. This protein 
represses translation of certain neuronal mRNAs whose levels are elevated in its 
absence (Bagni et al., 2012). Although not all these mRNAs are known, a direct 
interaction between eEF1A mRNA and FMR1 protein has been demonstrated (Sung 
et al., 2003; Darnell et al., 2011) which could explain the enhanced levels in 
individuals with this disorder and Fmr knockout mice models.                           
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1.5 Previous studies of the eukaryotic elongation factor 1 
alpha in zebrafish 
Before the complete sequence of the zebrafish genome was available, the zebrafish 
was thought to have only one gene copy of eEF1A. The structure of the zebrafish 
eEF1A gene was first reported by Gao et al., 1997. They described this gene to be 
made up of 8 exons interspersed with 7 introns. The exon-intron organisation of the 
eEF1A gene was found to be identical to the human and displayed the same splice 
pattern and exon sizes with the human eEF1A gene. Differential expression levels of 
eEF1A mRNA was observed when compared in different developmental stages and 
cultured cells derived from adult fish tissue. This led to the suggestion that eEF1A was 
developmentally regulated in the zebrafish. Another study then identified this eEF1A 
gene to be important for embryonic development based on the results from a large 
insertional mutagenesis screen carried out in zebrafish (Golling et al., 2002; 
Amsterdam et al., 2004). Homozygous eef1a mutants develop abnormally with 
phenotypes becoming visible from 2 days post fertilisation (dpf). At 3 dpf, they have 
small heads and eyes and grow slowly compared to their wild type siblings. At 4 and 
5 dpf, their swim bladders fail to inflate and they then die  by day 5. In this study, this 
gene was identified as the orthologue of the human EEF1A1. On the contrary, Clark 
et al., 2011 found that homozygous eef1a mutants did not show any abnormal 
phenotype and were viable till adulthood. In their study, mutants were generated using 
a gene-break transposon mutagenesis system which resulted in the knockdown of most 
transcripts by >99%. Only the gene ID, zgc:73138 was mentioned, but it was also 
identified as the orthologue of the human EEF1A1, with a paralogue gene identified 
as zgc:110335 in the zebrafish genome. These two studies were carried out at the time 
when the zebrafish sequencing project was still in its early stage. However, with the 
complete sequence now available, it is now obvious that the zebrafish has more than 
one eEF1A gene. The reason for the discrepancy between the two studies was actually 
due to the groups identifying different eEF1A genes. While the gene reported by 
Amsterdam et al., 2004 is now known as eef1a1l1, zgc:73138 and zgc:110335 have 
been renamed eef1a1a and eef1a1b respectively (ZFIN). The zebrafish eEF1A 
isoforms are described in more details in chapter 3 of this thesis. 
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A guide to the past and current nomenclature of the zebrafish eEF1A is summarised in 
table 1.5. However, for the sake of clarity, the mammalian naming convention for 
proteins will be used when referring to eEF1A proteins from all species in this thesis. 
Table 1.5: Nomenclature of the zebrafish eEF1A isoforms 
Current gene symbol Previous gene names Protein 
eef1a1l1 ef-1 alpha, ef1 alpha, ef1a, 
EFL1-alpha,  
eEF1A1L1 
eef1a1a j64c02, wu:fj64c02, 
zgc:73138 
eEF1A1A 
eef1a1b eef1a1, wu:fj34g08, 
zgc:110335 
eEF1A1B 
eef1a2 zgc:92085 eEF1A2 
  
1.6 Project aims  
With the growing evidence that supports the utility and the contribution of the 
zebrafish in understanding different human disease pathogenesis, the main aim of this 
project was to investigate the potential of using the zebrafish as a model to understand 
the role of eEF1A2 in neurological disorders. The objectives of this project include: 
1. To characterise eEF1A isoforms in zebrafish using bioinformatics and gene 
expression analyses  
2. To recreate the G70S eEF1A2 mutation in the zebrafish to investigate the 
mechanisms by which it causes the observed human phenotype 
3. To generate and characterise eEF1A2 null zebrafish model for complementary 
use with mice models with the intention of using the zebrafish model as an in 
vivo platform for chemical screening. This would help in the identification of 
potential compounds that could ameliorate any observed phenotype(s) caused 






Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Reagents 
The recipe for the different reagents used throughout this work is listed in table 2.1 
below. 
Table 2.1: List of reagents used in this work and their recipe 
Whole mount in situ  hybridisation (WISH) experiment 
Name  Composition   
1M Lithium chloride 4µl of 10M LiCl (Fluka) diluted in 36µl 
of DEPC-treated water 
0.003% PTU (Sigma-Aldrich) 100x stock solution of 0.3% PTU (w/v) 
dissolved in distilled water was diluted 
in E3 to working concentration of 
0.003% PTU (v/v)  
4% PFA  4g of PFA (Sigma-Aldrich) dissolved in 
1x PBS 
aPBS-T 1ml of Tween 20 (Thermo Fisher 
Scientific) diluted in 1L of 1x PBS 
Hybridisation Mix (HM+) 50% Formamide, 5X SSC, 0.1% Twee 
20, 50µg/ml Heparin, 500µg/ml RNAse 
free tRNA 
Hybridisation Mix (HM-) Same as above without RNAse free 
tRNA and heparin 
10x Maleic acid buffer (MAB) 58g Maleic acid, 43.5g NaCl, 20g 
NaOH, 400ml distilled water, pH 
adjusted to 7.5 
MABT 10x MAB diluted to 1x in distilled water, 
0.1% Tween 20 
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Blocking buffer 10% stock blocking reagent powder 
(Roche) diluted to 1% in MABT 
Alkaline phosphatase buffer (NTMT) 5ml 1M Tris HCl pH 9.5 
2.5ml 1M MgCl2  
1ml 5M NaCl  
250µl 20% Tween 20  
Distilled water up to 50ml  
Staining solution 200µl of NBT/BCIP stock solution 
diluted in 10ml NTMT 
Protein detection using western blota 
RIPA lysis buffer 1.5ml 1M NaCl, 0.1ml Nonidet P-40, 
50µl 0.5% Sodium deoxycholate, 50µl 
20% SDS, 5ml 50mM Tris, pH8.0, dH2O 
up to 10ml. 1 Complete Protease 
inhibitor tablet (Roche) added prior use 
10% separating gel 8ml 1.5M Tris pH8.8, 10.4ml 30% 
acrylamide/bis (Bio-Rad), 160µl 20% 
SDS, 20µl TEMED, 80µl 25% AMPS, 
13.4ml dH2O 
4.3% stacking gel 5ml 0.5M Tris-HCl pH6.8, 2.9ml 30% 
acrylamide/bis (Bio-Rad), 100µl 20% 
SDS, 10µl TEMED, 100µl 25% AMPS, 
11.9ml dH2O 
TBS-T 1ml of Tween 20 (Thermo Fisher 
Scientific) diluted in 1L of 1x TBS 
Blocking buffer 5% dried skimmed milk (Marvel) 
dissolved in TBS-T 
Histology 
3% hydrogen peroxide 100ml 30% stock H2O2 diluted in 900ml 
distilled water 




2.1.2 Oligonucleotides for gRNAs synthesis 
Sequences of oligonucleotides used in the cloning of gRNA into the expression vector, 
pDR274 for the CRISPR/Cas9 experiments are listed in table 2.2 below. All 
oligonucleotides were purchased from Integrated DNA Technologies (IDT) with a 5’ 
phosphate modification to improve ligation efficiency. 
Table 2.2: Oligonucleotide sequences used to generate gRNAs for CRISPR/Cas9 
experiment  
Name Sequence (5’ to 3’) 
eef1a2 CR F1 [P] TAGTGATCGGCCATGTTGATTC 
eef1a2 CR R1 [P] AAACGAATCAACATGGCCGATC 
eef1a2 CR F2 [P] TAGGGCATCTCATCTACAAATG 
eef1a2 CR R2 [P] AAACCATTTGTAGATGAGATGC 
gRNA3 1 [P] TAGGATAAGTTGAAGGCTGAGA 
gRNA3 2 [P] AAACTCTCAGCCTTCAACTTAT 
gRNA5 1 [P] TAGGTTTGAGAAAGAGGCAGCTG 
gRNA5 2 [P] AAACCAGCTGCCTCTTTCTCAAA 
gRNA7 1 [P] TAGGTAAACCCTGATGCTTCCTG 
gRNA7 2 [P]  AAACCAGGAAGCATCAGGGTTTA 
 
2.1.3 Primers 
Sequences of primers used in this project are listed in Table 2.3 below together with 
the applications they were used for indicated by the subheadings. Primers were 
purchased from Sigma-Aldrich unless otherwise indicated. 
Please note that primers highlighted in grey were obtained from the Primerdesign gene 
detection kit and their sequences are copyrighted and may not be used to synthesise 





Table 2.3: Sequences of primers used in this work     
Expression analysis of eef1a during development and adult tissues 
eef1a1l1 RT-PCR F ACCTACCCTCCTCTTGGTCG 
eef1a1l1 RT-PCR R GGAACGGTGTGATTGAGGGA 
eef1a1a RT-PCR F TCCTCCTCTGGGTCGTTTTG 
eef1a1a RT-PCR R GTAACCTTTCCGCTTGTCGC 
eef1a1b RT-PCR F TCCTCTTGGTCGTTTTGCAGT 
eef1a1b RT-PCR R TGTGGCTGACCCAAGTGTTT 
aeef1a2 RT-PCR F TACTGTTCTCTCTTGCCGCC 
aeef1a2 RT-PCR R TTTTCCCATCTCAGCTGCCT 
actb2 F GATCAAGATCATTGCCCCACC 
actb2 R GAGTCGGCGTGAAGTGGTAA 
Sequencing primers for CRISPR/Cas9 experiments 
eef1a2 CR GENO F (IDT) TGCAGACAGAAGAAAGCACCT 
eef1a2 CR GENO R (IDT) TTTGAGAAAGAGGCAGCTGAG 
gRNA3 GENO F CACCTTTATTTTTGCGTGAACA 
gRNA3 GENO R TCAAAAACATGATCACTGGGAC 
gRNA5 GENO F TCAACATGGGGAAAGAGAAGAT 
gRNA5 GENO R CACTTGCATCTTCCATTTTGAA 
gRNA7 GENO F TTTAATGTGAAGAACGTGTCCGTAA 
gRNA7 GENO R AGGTCATCATTTTGAATCACCC 
G70S New F GGTAGGCCCGGTCCTATAAA 
G70S New R CTTGTTTGGAATGTACCGTTAGT 
Expression analyses in Del and Ins4 eef1a2 mutant linesa 
eef1a2 F (Primerdesign)  AGGCGGATTGTGCTGTCTT 
eef1a2 R (Primerdesign) GGCGTGTTCCCTTGTTTGG 
eef1a1l1 F (Primerdesign) GAGGAAATCACCAAGGAAGTCA 
eef1a1l1 R (Primerdesign) GTTGTCACCGTGCCATCC 
eef1a1a F (Primerdesign) GATTGTGCTGTGCTGATTGTG 
eef1a1a R (Primerdesign) GTAAGCCAGAAGAGCGTGTT 
eef1a1b F (Primerdesign) CTTGCTGGCGTACACTCTC 
eef1a1b R (Primerdesign) GACTTCCTTCACAATCTCCTCAT 
3’ eef1a2 RT-PCR F AGTATCCTCCACTGGGACGC 
3’ eef1a2 RT-PCR R AGCTGATTTGGTCACTCTCCC 
Probe synthesis for ISH experiment 
eef1al1 3’UTR AntiF AGAAGGCTGCCAAGACCAAG 
eef1al1 3’UTR AntiR [T7]TTATTCATCAGCGTTTCCAAATTGT 
44 
 
eef1a1a 3’UTR AntiF TGTTGTGTTTGACTGCCAACTC 
eef1a1a 3’UTR AntiR [T7]ACAAGTGCTTGTGCAGGGTT 
eef1a1b 3’UTR AntiF AAACACTTGGGTCAGCCACA 
eef1a1b 3’UTR AntiR [T7]TGAGTGCAAGTGCAAACAAGAT 
eef1a2 3’UTR AntiF TGAATCTCCAAGACAGTCACCTT 
eef1a2 3’UTR AntiR [T7]TTGTCACAGGTTTGAGCAGC 
a- Primers used in two different experiments,  [T7] promoter sequence- 
TAATACGACTCACTATAGGG, Grey highlight- indicate primer sequences are 
copyrighted by Primerdesign Ltd. 
 
2.1.4 Antibodies 
The antibodies used in this project is listed in the table below together with the 
concentration and the application they were used. 
Table 2.4: List of antibodies employed in this project 
Antibody name Host species Application and 
dilution 
Company 
EEF1A2          (1o)  Rabbit WB  1:500 GeneTex 
EEF1A2           (1o) Rabbit WB  1:500 Proteintech 
Anti-EEF1A2  (1o) Rabbit WB  1:1000 Abcam 
Anti-EF1α        (1o) Mouse WB  1:1000 Merck Milipore 
Anti-EF1A       (1o) Rabbit WB 1:1000 GeneTex 
eEF1A2-2         (1o) Sheep  WB  1:50 Made in-house  
GFAP              (1o) Rabbit  IHC  1:500 Dako 
IRDye® anti-
rabbit                (2o) 
Goat WB   1:5000 LICOR 
IRDye® anti-
mouse              (2o) 
Goat WB   1:5000 LICOR 
Anti-rabbit 
biotinylated      (2o) 




HRP                  (2o) 
Rabbit WB  1:2000 Dako 
Anti-rabbit IgG-
HRP                  (2o) 
Goat  WB  1:2000 Cell signaling 
   
2.2 Methods 
2.2.1 Zebrafish model 
2.2.1.1 Animal Husbandry 
Zebrafish were maintained in the Yamuna fish room, MRC Human Genetics Unit 
(HGU) University of Edinburgh. They were raised in re-circulating in closed water 
system (Aquatic Habitats UK) at ~ 28.5oC with a pH range of 7.0 - 7.2. Room 
temperature was maintained at ~ 25oC on a diurnal light schedule of 14 hours of day 
(9 am to 11 pm) and 10 hours of night (11 pm to 9 am). AB zebrafish strains were used 
and were established from embryos collected from adult fish from within the facility 
using either the pairing or marbling mating methods.  
Embryos were placed in E3 solution in batches of 50 per 9cm Petri dishes or 100 in 
15cm Petri dishes and kept in the incubator at ~ 28.5oC until they become free 
swimming larvae at 5 days old. To ensure a healthy clutch was maintained, 
unfertilised, deformed or dead embryos were removed and the embryos were placed 
in fresh E3 solution every day. At 5 days old, the larvae were introduced into the water 
system and fed 3-4 times a day; one daily feed of paramecia, one feed of Artemia and 
one or two feed of dry food. Around 6 weeks of age, the fish are fed twice a day with 
adult dry food and live Artemia.  
2.2.1.2 Experimental procedures  
All procedures carried out was done in accordance with the UK Home Office 
regulations. Permission to perform all experiments was granted to Personal Project 





2.2.2 Methods for RNA analysis 
2.2.2.1 Collection and extraction of RNA from embryos and adult tissues 
Adult zebrafish were killed by immersing in tricaine for 10mins or until the cessation 
of gill movement. Tissues were quickly dissected and stored at -70°C in RNAlater® 
solution until RNA extraction. Zebrafish embryos were collected by natural spawning 
and raised in Petri dishes at 28.5°C until the desired developmental stages were 
reached according to Kimmel et al., 1995. Embryos were collected at the following 
stages: 1-cell, 2-cell, 4-cell, 8-cell, 16-cell, 256-cell, high, 50%-epiboly, 90%-epiboly, 
24 hours, 48 hours and 72 hours post fertilisation (hpf). A brief description of these 
developmental stages is summarised in table 2.5.  
Table 2.5: Description of embryonic developmental stages used for expression 
analysis taken from ZFIN (https://zfin.org/zf_info/zfbook/stages/index.html).  
Stage Period Begins (hpf) Landmark feature 
1-cell Zygote  0.00 Cytoplasm streams 
toward animal pole 




0.75 Partial cleavage 
4-cell 1.00 2X2 array of 
blastomeres 
8-cell 1.25 2X4 array of 
blastomeres 




2.50 7 blastomere tiers 









90%-epiboly Gastrula 9.00 Brain and 
notochord 
rudiments 
24hpf Pharyngula 24 Early 
pigmentation, 
heartbeat  
48hpf Hatching  48 Elongated pectoral 
fin buds 
72hpf Early larva 72 Protruding mouth 
 
Total RNA from tissues and approximately 50 embryos were extracted by 
homogenising in TRIzol® using a cordless pestle motor and RNase free pestle (VWR 
international). Muscle tissues were further homogenised by passing the lysate through 
a 1ml syringe with a 25G needle. RNA clean-up was done using the RNeasy Mini Kit 
(Qiagen) with on-column DNase treatment (RNase-free DNase set, Qiagen) following 
the manufacturer’s instructions. Concentration and integrity of extracted RNA were 
assessed using the Agilent 2100 Bioanalyzer. 
2.2.2.2 Synthesis of cDNA 
 RNA was synthesised into cDNA using the AffinityScript Multiple Temperature 
cDNA Synthesis Kit (Agilent Genomics), following the manufacturer’s instructions. 
A combination of oligo (dT) and random primers were used for all reactions. A ‘–RT’ 
control, containing all the reagents except the reverse transcriptase (Affinityscript RT) 
was also included to check for DNA contamination in the RNA preparation. cDNA 
was then stored at -20°C until required. 
2.2.2.3 RT-PCR 
Genomic contamination was assessed first for all cDNA using a primer for actb2. The 
primers were designed such that it amplifies cDNA at a product size of 360 base pair 
and genomic DNA if present, at a size of 648 base pair. Once it was ascertained that 
cDNA was free of genomic DNA, samples were run in duplicate with gene-specific 
primers and primer that amplified actb2 to serve as a loading control for the reaction. 
PCR was performed using the Phusion High-Fidelity DNA Polymerase (see table 2.3 
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for primer sequences and section 2.6.1 for PCR parameters). Products were run out on 
a 2% 0.5 x TBE agarose gel containing SYBRsafe and visualised on a transilluminator 
or a Fujifilm FLA-5100 imager.  
2.2.2.4 geNorm reference kit 
For accurate mRNA quantification, it is important to normalise real-time PCR data to 
a fixed reference gene, one that is not influenced by the experimental conditions. Some 
important factors to consider when choosing reference genes are discussed in Bustin 
et al., 2009. A study by Vandesompele et al., 2002 demonstrated the importance of 
using the geometric mean of multiple reference genes that have been carefully chosen 
for a more accurate normalisation factor for qPCR analysis. To select the best reference 
genes for this study, I used the geNorm gene kit for zebrafish (PrimerDesign Ltd UK). 
This consists of custom designed primers for 12 reference genes (Table 2.6) from the 
zebrafish genome which were analysed using a representative set of the samples. 
Primer sequences are not disclosed by the company. PCR was run as described in 
section 2.2.2.5. Data were analysed using the qbase+ analysis software (Biogazelle) 
which ranks the reference genes in order of their expression stability.   
Table 2.6: List of genes in the zebrafish geNorm kit (PrimerDesign, UK)  
Gene name Symbol 
Eukaryotic translation initiation factor 1B EIF1B 
NADH dehydrogenase  NADH 
Tyrosine 3-monooxygenase activation 
protein 
YWHAZ 
16S ribosomal RNA 16S 
ATP synthase ATPsynth 
Cytochrome P450 monooxygenase CYP2K17 
Actin, beta 1 actb1 
Glyseraldehyde-3-phosphate dehydrogenase GAPDH 
Ribosomal protein L13 RPL13 
Topoisomerase (DNA) II alpha TOP2 
Succinate dehydrogenase SDHA 




2.2.2.5 Quantitative PCR (qPCR) 
Gene expression levels of the genes studied in this project were examined using RNA 
extracted from adult fish. RNA and cDNA preparation was carried out as described in 
section 2.2.2.1 and 2.2.2.2. The cDNA templates were diluted 1:5 with RNase free 
water before it was used in the reaction. The qPCR reaction was performed using the 
Brilliant II SYBR Green qPCR Master Mix (Agilent Technologies) and the 7900HT 
Light Cycler (Roche). Primers sequences are given in Table 2.3. Custom designed 
primers from Primerdesign were prevalidated by the company using pooled full-length 
cDNA generated from whole adult zebrafish by me. 
Reaction set-up contained 5µl 2x Brilliant II SYBR Green, 0.5µl 6μM Primer mix, 
0.375µl reference dye diluted 1:50 in water and 0.125µl RNase free water for a final 
volume of 10µl which were assembled on ice. Cycling conditions used were as 
follows: 
Thermocycling conditions for qPCR  
Cycles Duration of cycle Temperature (°C) 
1 10 minutes 95 
50 30 seconds 95 
1 minute 60 
 
A dissociation curve was carried out at the end of the program to assess the specificity 
of the PCR reaction. 
Primer efficiency was assessed for all genes using seven 4-fold serial dilutions of 
cDNA pooled cDNA from whole adult fish (1:4, 1:16, 1:64, 1:256, 1:1024, 1:4096 and 
1:16384), all carried out in triplicate. Data were used to construct a standard curve for 
each target gene and reference genes and the efficiency of the reaction was calculated 
from the slope of the standard curve determined in the HT7900 system SDS software 
(Applied Biosystems) which is summarised in appendix table 2. Quantity of transcripts 
levels in the different tissues was determined using the appropriate standard curve for 
each gene.  
The mRNA quantity of each gene of interest was then normalised to three reference 
genes: ATPsynth, NADH and 16S which were selected using the geNorm kit 
(PrimerDesign Ltd UK) described in section 2.2.2.5, by dividing each target gene by 
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the geometric mean of the reference genes. To compare the amount of each zebrafish 
eef1a transcripts, the Pfaffl method (Pfaffl, 2001) was used to calculate the gene 
expression ratio of each transcript relative to the geomean of the reference genes for 
each tissue. All reactions were performed with three biological replicates in triplicate 
and a no-template control was included for each gene. 
GraphPad Prism v5 was used to make graphs and perform statistical analyses. To test 
for significance, Mann Whitney test or One-way ANOVA with Tukey Multiple 
Comparison tests was performed where appropriate.  
2.2.2.6 Whole mount in situ hybridisation (WISH) 
2.2.2.6.1 Probe synthesis 
DNA primers were used to amplify fragments from the 3’UTR region of each eef1a 
gene as this region shows less similarity across the gene families, thereby avoiding 
cross-hybridisation of probes. PCR was performed using Phusion HF DNA 
polymerase (see section 2.2.6.1 for protocol) and products were gel-purified using the 
QIAquick Gel Extraction Kit (QIAGEN) according to the manufacturer’s instructions. 
For each eef1a gene, PCR templates for antisense (experimental) and sense (control) 
probes were amplified. Primer sequences for sense probes are the same as that listed 
for antisense probes in Table 2.3 except that the T7 promoter sequence is tagged to the 
5’ of the forward primer. 
Digoxigenin (DIG)-labelled anti-sense and sense probed were generated with 1µg of 
purified PCR products as templates using T7 RNA-polymerase and DIG RNA 
labelling mix (Roche). Reaction setup was assembled at room temperature in the 
following order; 
Component  Volume (µl) 
Purified PCR product X (1µg) 
DEPC-treated water Up to 20 
10X transcription buffer 2 
DIG-RNA labelling mix 2 
T7 RNA polymerase 2 




The reaction was incubated for 2 hours at 37°C. To stop the reaction, 1µl of DNase 
(Turbo DNase, Ambion) was added to the mix and incubated at 37°C for 20 minutes. 
RNA probes were then precipitated from the reaction by adding 6µl of DEPC-treated 
water, 75µl of 100% ethanol and 10µl 1M lithium chloride (LiCl). Precipitation mix 
was left overnight at -20°C and was centrifuged at a speed of 12,000xg the next day at 
4°C for 30 minutes. The pellet was washed with 70µl of 70% ethanol and centrifuged 
at room temperature at a speed of 8,000xg for 5 minutes, after which it was air dried 
for 5-10 minutes. Pellets were dissolved with Diethyl pyrocarbonate (DEPC)-treated 
water and 1µl of RNAsein to protect the RNA from degradation. Concentration and 
integrity of the probes were measured using the NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific). All probes were aliquoted and stored at -80°C until needed. 
2.2.2.6.2 Preparation of embryos 
Embryos were collected and staged using the same method described in section 
2.2.2.1. At 9hpf, the embryos were dechorionated using forceps and gently transferred 
to E3 medium containing 0.003% phenylthiourea (PTU) to inhibit melanin synthesis. 
The medium containing PTU was replaced regularly until the desired stage was 
reached. After this they were fixed overnight in 4% paraformaldehyde (PFA) in 1X 
PBS. The next day, the embryos were dehydrated through an increasing series of 
methanol in 1X PBS (25%, 50% and 75% v/v) for 5 minutes each and three changes 
of 100% methanol for 10 minutes. Embryos were stored in 100% methanol at -20°C 
until needed.     
2.2.2.6.3 In situ hybridisation 
The hybridisation protocol used was modified from the method described by Thisse 
and Thisse, 2007 and was carried out in sterile 1.5ml Eppendorf tubes. Embryos were 
rehydrated through a decreasing series of methanol in 1X PBS (75%, 50% and 25% 
v/v) for 5 minutes and then 4 times in PBS-T for 5 minutes each. Embryos were then 
digested with 500µl of 10µg/ml Proteinase K diluted in PBS-T at room temperature to 
make them permeable and allow penetration of the RNA probes. Embryos at 24hpf 
were digested for 10 minutes, those at 48hpf for 20 minutes and larvae at 72hpf and 
5dpf were digested for 30 minutes. To stop the reaction, embryos were incubated in 
4% PFA in 1X PBS for 20 minutes. The embryos were then washed in five changes of 
500µl PBS-T for 5 minutes per wash to get rid of residual PFA. The embryos were 
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then prehybridised in 250µl prewarmed (15 minutes at 67°C) Hybridisation Mix 
(HM+) in the water bath at 67°C for 3 hours. Antisense and sense RNA probes were 
diluted separately in 250 µl of HM+ and denatured in a thermal cycler at 95°C for 
2mins and placed immediately on ice to prevent reannealing. The final concentration 
of probes used was in the range of 40-50ng. The HM+ was removed and was then 
replaced with the HM+ containing probes. The embryos were hybridised in the 
solution overnight in the water bath at 67°C.   
The HM+ containing probe solution was removed and stored at -20°C to be reused. The 
embryos were then washed in a decreasing series of heparin-free and tRNA-free 
Hybridisation Mix (HM-) diluted in 2x SSC (75%, 50% and 25% HM-) for 10 minutes 
per wash and then for 10 minutes in 100% 2x SSC. The embryos were washed 3 times 
for 30 minutes per wash in 0.2x SSC to prevent non-specific hybridisation of the 
probes. All these washes were performed in a water bath set at 67°C with the solutions 
prewarmed to 67°C prior to use. The embryos were then washed twice in 1x maleic 
acid buffer (MABT) for 10 minutes per wash at room temperature. Embryos were then 
incubated in blocking buffer at room temperature for 2 hours to avoid non-specific 
binding by the anti-DIG antibody. They were then incubated with the anti-DIG-AP 
antibody (Roche) diluted at 1:5000 in blocking buffer overnight at 4°C on an orbital 
shaker set at 40 rpm. 
The next day, the antibody solution was replaced with 1x MABT and the embryos 
were washed for 5 minutes. They were then washed four times with 1x MABT for 30 
minutes per wash to remove excess antibody and then washed with four changes of 
NTMT solution for 15 minutes per wash. All these washes were performed at room 
temperature with gentle agitation. This was then followed by staining the embryos with 
freshly prepared staining solution and the reaction was monitored under a dissecting 
microscope illuminated from above every 10 minutes. Staining was performed in the 
dark and with multi-well plates wrapped with foil to avoid excess exposure to light. 
The reaction was stopped by washing the embryos in five changes of 1x PBS-T for 5 
minutes per wash and then incubating in 0.1M EDTA for 20mins. They were again 
washed in five changes of 1x PBS-T for 5 minutes per wash to remove residual EDTA. 
Brightfield microscopy using a Zeiss upright microscope and the Micro-manager 
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imaging software was used to view and take pictures of stained embryos. Stained 
embryos were stored in 4% PFA at 4°C.      
2.2.3 eef1a constructs preparation and expression analysis 
2.2.3.1 Cloning of full-length eef1a transcripts 
2.2.3.1.1 Generation of full-length cDNA 
Total RNA was extracted from whole adult fish and cDNA synthesised as described 
in section 2.2.2. Full-length cDNA of eef1a genes were cloned into a pcDNA6.2C-
EmGFP vector using Gateway cloning technology. The forward and backward primers 
were designed to contain attB site to facilitate recombination. Kozak consensus 
sequence was included in the forward primer to allow protein expression in 
mammalian cells and stop codon removed from the reverse primer to allow for GFP 
expression. attB-PCR products were generated using the PCR reaction set-up and 
cycling parameters summarised below; 
PCR reaction set-up and thermocycling parameters for full-length eef1a cDNA 
Component  Volume (µl) 
5X Q5 Reaction Buffer 10 
10Mm dNTPs 1 
10µM F Primer 2.5 
10µM R Primer 2.5 
cDNA 2 
Q5 Hot Start High-fidelity 
DNA Polymerase 
0.5 
5X Q5 High GC Enhancer  10 
Water 21.5 
 
Step  Temperature (°C) Time  
Initial Denaturation 98 30 seconds 
 
   35 cycles 
98 
*59 (eef1a2),64 (eef1a1a and 





Final Extension 72 2 minutes 






2.2.3.1.2 PCR product clean up 
After amplification, PCR products were run on a 1% TAE agarose gel.  The amplified 
products were excised from the gel with a clean scalpel using a Safe Imager 
transilluminator and purified using the QIAquick Gel Extraction Kit (QIAGEN) 
according to the manufacturer’s instructions. 5µl of the purified products were run on 
a 1% 0.5x TBE gel to check the integrity of the DNA. The concentration of DNA was 
determined using the Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific).  
2.2.3.1.3 BP recombination reaction 
Purified attB-PCR products were cloned into a pDONR221 donor vector using the BP 
clonase kit following the manufacturer’s instructions to create an entry clone. In brief, 
a reaction containing 2µl of BP clonase, 150ng of pDONR221, 100ng attB-PCR 
product and TE buffer to a final volume of 10µl was made in a 1.5ml tube and 
incubated overnight at room temperature. 
2.2.3.1.4 Transformation of competent cells  
Library Efficiency DH5α competent cells were thawed on ice and 50µl aliquoted to 
1.5ml ice-cold tubes. One microliter of BP recombination reaction was added and 
incubated on ice for 30 minutes. Cells were heat-shocked for 30 seconds at 42°C and 
immediately transferred to ice. After 2 minutes, 450µl of SOC medium was added to 
each tube and the cells were agitated horizontally for 1 hour at 37°C.   
For each transformation, two LB plates containing kanamycin were used. The plates 
were pre-warmed at 37°C and 20µl cells spread on one plate and 100µl on the other 
plate. The plates were sealed with paraffin to avoid drying out and incubated overnight 
at 37°C. The pUC19 DNA vector was included as a control. 
2.2.3.1.5 Colony screening 
Four colonies were randomly chosen for each transformation and inoculated in 
individual Falcon tubes containing 4ml of LB broth containing 50μg/ml kanamycin. 
Cells were grown overnight at 37°C with constant shaking. The plasmid was purified 
from 3.5ml of the cell culture using QIAprep Spin Miniprep Kit (QIAGEN) following 
the manufacturer’s protocol. 10µl of the purified plasmids were sent to Technical 
Services, MRC HGU Unit for sequencing using M13 sequencing primer from the 
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facility. The remaining 500µl of all positive entry clones were mixed individually with 
500µl 50% v/v glycerol and stored at -70°C to provide a glycerol stock.  
2.2.3.1.6 LR recombination reaction 
Each gene was transferred to the pcDNA6.2C-EmGFP destination vector using the LR 
clonase II enzyme mix kit according to the manufacturer’s instructions. 
Transformation and screening of colonies for the correct insert were performed as 
described above. In this case, LB containing 100μg/ml ampicillin was used and T7 
promoter primers used for sequencing.  
2.2.3.2 Transient transfection  
HEK293T cell line, a kind gift from Dr. Chloe Stanton, were used for transfection. 
Transfection was performed using TurboFect Transfection reagent (Thermo Fisher 
Scientific) according to the manufacturer’s recommended protocol. Briefly, cells were 
seeded into 6-well cell culture plates at a seeding density of 2.4x104 in 4ml of DMEM 
(Gibco) with 10% Fetal Bovine Serum (FBS) growth medium 24 hours prior to 
transfection. 4μg of purified plasmid DNA containing the relevant construct was 
mixed with 6µl of TurboFect in 400µl of serum-free DMEM and incubated for 15 
minutes at room temperature. The transfection reagent/DNA mixture was added to the 
well and mixed gently. Cells were harvested after 24 hours and used for protein 
analysis as described in section 2.2.4.2.    
2.2.4 Method for protein analysis 
2.2.4.1 Protein extraction from tissues  
Tissues were immediately snap frozen in dry ice after dissection and stored at -70°C if 
not extracted immediately. Ice cold RIPA buffer (containing one EDTA-free protease 
inhibitor tablet per 10ml RIPA buffer) was added to the tissue. Tissues were 
homogenised on ice using a cordless pestle motor (VWR). Lysates were maintained 
under constant agitation at 4°C for 2 hours and then centrifuged for 20 minutes at 
12,000rpm at 4°C. The supernatant was gently aspirated and placed in a fresh pre-
chilled 1.5ml tube and the pellet discarded.  
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2.2.4.2 Protein extraction from cell culture 
Protein lysates from cultured cells were prepared in multi-well plates placed on ice. 
Cell medium was carefully aspirated and then the cells were washed once with ice-
cold PBS. Ice cold RIPA buffer (containing one EDTA-free protease inhibitor tablet 
per 10ml RIPA buffer) was added to each well and a cold plastic cell scraper was used 
to collect the cells at one side of the well. The cell suspension was transferred to a pre-
chilled 1.5ml tube and maintained under constant agitation for 30 minutes at 4°C. The 
lysate was centrifuged for 20 minutes at 12,000 rpm at 4°C. The supernatant was gently 
aspirated and placed in a fresh pre-chilled 1.5ml tube and the pellet discarded. 
2.2.4.3 Protein concentration determination 
Protein concentrations were quantified using the Pierce BCA protein assay kit (Pierce) 
for cell lysates and the DC Protein Assay (Bio-Rad) for tissue lysates following the 
manufacturers’ instructions. In brief, the Pierce BCA protein assay was carried out 
using the microplate method. Eight BSA standards were prepared by diluting 2mg/ml 
BSA stock in RIPA. 25µl of standards and samples were pipetted into the microplate 
wells in duplicate. Working reagent was prepared by mixing fifty parts of reagent A 
with one part of reagent B (50:1) and 200µl of the solution added to each well and 
mixed on a shaker for 30 seconds. The plate was incubated at 37°C for 30 minutes and 
cooled to room temperature. The absorbance was measured at 562nm using a 
FLUOstar Omega plate reader. 
The DC Protein assay was performed using individual cuvettes. The working reagent 
was prepared by mixing 20µl of reagent S to each ml of reagent A and 125µl added 
per cuvette. Five protein standards were made from a stock of 1.52mg/ml of BSA 
diluted in RIPA as follows: 0.25mg/ml, 0.5mg/ml, 0.75mg/ml, 1mg/ml and 1.5mg/ml. 
2µl of standards and samples were added and the cuvette vortexed briefly and left for 
5 minutes at room temperature. Absorbance was measured at 750nm using a Biomate 
3 Spectrophotometer (Thermo Fisher Scientific).  
The protein concentration of unknown samples was determined using a standard curve 




All samples were prepared at equal protein concentration using the results obtained 
from the protein concentration assay kits. Laemelli loading buffer was added to each 
sample at a 1:1 ratio. Samples were denatured by placing in a heat block at 100°C for 
5 minutes and then 10% (v/v) 1M dithiothreitol (DTT) was added. 
Precast gel (4-15% Mini-Protean TGX stain-free gel, Bio-Rad) or homemade gels 
were used. Homemade gels were prepared using the Bio-Rad mini-Protean glass 
plates. The glass plates were cleaned using 70% ethanol, assembled into the casting 
frame and clamped to the casting stand. A 10% separating gel was poured into the gap 
between the plates and overlaid with isopropanol until it overflowed to ensure the top 
of the gel was horizontal. Once the separating gel had set, the isopropanol was 
discarded and 4.3% stacking gel pipetted between the glass plates until it overflowed. 
The comb was gently inserted to avoid trapping air under the teeth and the gel left to 
set.  
Up to 20µl of samples were loaded into each well, with the first lane containing 10µl 
of a protein marker.  Gels were run in a Bio-Rad Protean III tank with running buffer 
at 200V for precast gel or 100V through the stacking gel and then 150V through the 
separating gel when using homemade gels. Gels were run until the blue dye front 
reached the bottom of the gel. 
2.2.4.5 Protein transfer 
Two pieces of Whatman filter paper and one piece of PVDF membrane (Millipore) 
were cut to the size of the gel. The membrane was activated by wetting it with 100% 
methanol for 15 seconds. The membrane and gel were equilibrated in the transfer 
buffer in different trays for 15 minutes. The transfer sandwich was assembled in a tray 
containing transfer buffer as follows: the gel holder cassette, placed with the black side 
facing down, sponge, filter paper, gel, filter paper and sponge. Air bubbles were 
removed using a glass pipette and the cassette carefully closed and locked. The cassette 
was placed in the module and put into a tank along with an ice pack and magnet. The 
tank was filled with transfer buffer, placed on a magnetic stirrer and transfer performed 
at 100V for 1 hour at 4°C.  
58 
 
2.2.4.6 Sypro Ruby Protein Blot Stain 
To determine if protein transfer was successful, membranes were stained using Sypro 
Ruby Blot Stain (Invitrogen) following the manufacturer’s instructions. In brief, 
membranes were allowed to dry completely after transfer and then washed faced down 
in a solution of 7% acetic acid with 10% methanol on a shaker for 15 minutes. 
Membranes were washed four times in water for 5 minutes each and incubated in 
Sypro Ruby Blot Stain for 15 minutes with rocking in an opaque box to prevent light. 
Finally, the membranes were washed 2-3 times for 1 minute each to remove excess 
stain. Protein bands were visualised using the Odyssey Fc imager (LI-COR 
Biosciences, UK). 
2.2.4.7 Immunoblotting using HRP-conjugated secondary antibodies 
Membranes were blocked for 1 hour in blocking buffer containing 0.1% v/v Tween 20 
and 5% w/v dried skimmed milk in TBS-T at room temperature. They were then 
incubated in primary antibody diluted in blocking buffer overnight at 4°C. Membranes 
were washed three times with TBS-T and incubated with the appropriate HRP-
conjugated secondary antibody diluted in blocking buffer for 1 hour at room 
temperature. Membranes were again washed in TBS-T three times for five minutes 
each and detected using Clarity Western ECL Substrate (Bio-Rad) according to the 
manufacturer’s instructions. 
2.2.4.8 Immunoblotting using LI-COR 
Membranes were blocked in Odyssey blocking reagent (LI-COR Biosciences, UK) for 
1 hour at room temperature. Membranes were incubated overnight at 4ºC with primary 
antibodies diluted to an appropriate concentration in Odyssey blocking buffer. They 
were washed three times in PBS-T for 5 minutes each wash and then incubated in 
secondary antibodies diluted 1:5000 in Odyssey blocking buffer. Membranes were 







2.2.5 Generation of mutant lines using CRISPR/Cas9   
2.2.5.1 Cloning of guide RNA into guide RNA expression vector 
For the CRISPR/Cas9 experiment, guide RNAs (gRNAs) were designed to target the 
zebrafish eef1a2. The gRNA expression vectors were constructed by cloning a pair of 
annealed oligonucleotides into a Bsal (New England Biolabs) digested pDR274 
(Addgene) backbone. Oligonucleotides corresponding to five different gRNA 
sequences (see Table 2.2) were annealed by mixing 9µl each of 100µM top and bottom 
strand with 2µl of annealing buffer (0.01M Tris-HCl pH 7.5, 0.05M NaCl, 1mM 
EDTA). The mixture was heated for 5 minutes at 95°C and cooled down slowly to 
room temperature. The pDR274 (a kind gift from Dr. Rodanthi Lyraki) was linearized 
by digesting it with Bsal in CutSmart buffer for 1 hour at 37°C and the enzyme was 
heat inactivated for 20 minutes at 65°C. The vector was dephosphorylated using 
Antarctic phosphatase (New England Biolabs) to prevent it from self-annealing and 
purified using the QIAquick PCR Purification Kit (QIAGEN) according to the 
manufacturer’s protocol. Annealed oligonucleotides were ligated to the digested vector 
by mixing 10nM of annealed oligonucleotide with ~ 50ng of purified linearized vector 
and incubating the reaction with 1µl of Quick ligase and 10µl of ligase buffer (New 
England Biolabs) at room temperature for 15 minutes. Library Efficiency DH5α 
competent cells were transformed with the ligation mix using the same method 
described in section 2.2.3.1.4. The presence of the correct insert was confirmed as 
described in section 2.2.3.1.5. 
 2.2.5.2 In vitro transcription of gRNA  
gRNA sequences were first amplified from purified gRNA expression vector with the 
cloned insert using Phusion High-Fidelity DNA Polymerase and primers which were 
a gift from Zhiqiang Zeng. The cycling conditions used were 98°C for 30 seconds, 30 
cycles of 98°C for 30 seconds, 58°C for 30 seconds and 72°C for 20 seconds, followed 
by 10 minutes at 72°C. PCR product was confirmed by running 5µl on a 2% 0.5x TBE 
agarose gel and purified using the QIAquick PCR Purification Kit (QIAGEN) 
according to the manufacturer’s instructions.  
In vitro transcription of gRNA was carried out using the Ambion MAXIscript T7 kit 
(Thermo Fisher Scientific) and 1µg of the purified PCR product as a template. The 
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reaction was incubated for 1 hour at 37°C and treated with Turbo DNase for 15 minutes 
at 37°C to get rid of the template DNA. The gRNAs were purified using the SigmaSpin 
sequencing reaction clean-up kit (Sigma Aldrich). They were aliquoted in RNase-free 
0.2ml tubes and stored at -80°C until use. 
2.2.5.3 Preparation of the nCas9 mRNA 
Purified pCS2-nCas9n vector (Addgene) plasmid was obtained from Dr. Rodanthi 
Lyraki. This plasmid contains the insert nuclear localised signal zebrafish codon-
optimised Cas9 (nls-zCas9-nls) and an SP6 promoter for in vitro transcription. The 
vector was linearized with NotI-HF (New England Biolabs) for 1.5 hours at 37°C and 
purified using the PCR column purification kit (QIAGEN). Approximately 370ng of 
the linearized vector was used as a template for in vitro transcription using the SP6 
mMESSAGE mMACHINE kit (Thermo Fisher Scientific) following the 
manufacturer’s instructions producing capped nCas9 mRNA molecules. The Cas9 
mRNA was purified using the RNAeasy kit (QIAGEN) following the ‘RNA cleanup’ 
protocol. Poly(A) tailing of the nCas9 mRNA was then carried out using E. Coli 
Poly(A) polymerase (E-PAP) and purified again using the RNAeasy kit (QIAGEN) 
and eluted in RNase-free water. Capping and poly(A) tailing of the mRNA is important 
for stabilising the nCas9 mRNA molecules, therefore increasing translation efficiency 
once injected into the zebrafish embryo. 
The other nls-zCas9-nls mRNA molecules used was prepared by Zhiqiang Zeng 
(Patton lab). The same preparation method described above was used excluding the 
poly(A) tailing procedure as in vitro transcription from the plasmid SP6 or T3 
promoter already produces a capped, polyadenylated mRNA.      
2.2.5.4 Microinjection of embryos 
A solution containing the nCas9 mRNA (300ng/µl) and gRNA were mixed in a 1:1 
ratio and microinjected directly into the cell of one-cell stage AB zebrafish eggs to 
generate eef1a2 null cells. Injections were carried out by Witold Rybski (Patton’s lab) 
and by me. For the CRISPR/Cas9-mediated HDR experiment, two test concentrations, 
92ng/µl and 183ng/µl of ssODN repair template (IDT) were used to increase the 
chances of the G70S mutation being incorporated. ssODN at these concentrations were 
co-injected separately with nCas9 mRNA (300ng/µl) and gRNA3 (92ng/µl) mixed in 
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a 1:1:1 ratio. Injections were conducted by Dr. Cameron Wyatt (Zebrafish Manager, 
IGMM). 
2.2.5.5 Genomic DNA isolation from zebrafish embryos and adult fish 
Isolation of genomic DNA was conducted using either single or pooled whole embryos 
and clipping from tail fins of individual adult fish. Extraction of genomic DNA from 
these materials was performed using either DNA Releasy reagent (Nippon Genetics) 
or 50mM NaOH.  
When using DNA Releasy reagent, embryos or tail fin clippings were placed in a 0.2ml 
PCR tube and covered with 20µl of DNA Releasy reagent. The tubes were then placed 
in a thermal cycler and DNA extracted using the following conditions: 65°C for 20 
minutes, 96°C for 2 minutes, 65°C for 4 minutes, 96°C for 1 minute, 65°C at 1 minute, 
96°C for 30 seconds and hold at 20°C.  
Protocol for extracting DNA using 50mM NaOH was described by Meeker et al., 
2007.  Tail fin clip or embryos were placed into 0.2ml PCR tubes containing 50µl of 
50mM NaOH and incubated for 20 minutes at 95°C. The tubes were cooled to 4°C and 
5µl of 1M Tris-HCL, pH 8, was added to neutralise the basic solution. In both methods, 
the tubes were centrifuged to pellet the debris, and the supernatant which contained 
the genomic DNA was stored at -20°C until use.    
2.2.5.6 TOPO cloning of PCR products to identify individual mutations  
Mutagenic efficiency of gRNAs and nCas9 mRNA were assessed after injection using 
DNA extracted from 5-10 pooled 2 days post fertilisation injected embryos. The target 
site was amplified using appropriate primers flanking target sites (see Table 2.3) and 
Taq DNA polymerase. PCR products were confirmed by gel electrophoresis and 
purified using a QIAquick PCR purification kit (QIAGEN).  
As it is likely that amplified DNA fragments would be heterogeneous, purified PCR 
products were cloned into the TOPO vector using the TOPO-TA cloning kit 
(Invitrogen) before sequencing. Two microliters of purified PCR products was mixed 
with 2µl of water, 1µl of water and 1µl of TOPO vector. The ligation mixture was 
gently mixed and left to incubate for 30 minutes at room temperature. The ligation 
reaction was used to transform One Shot TOP10 chemically competent E. coli cells 
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(Invitrogen). The presence of the lacZΔM15 gene in these cells makes them a good 
choice as it allows for a more accurate selection of positive clones using the blue/white 
colour screening method. For this reason, 40µg of X-gal was spread on LB-Kanamycin 
plates 1 hour before use. Cells were thawed on ice and 25µl of cells aliquoted to ice-
cold 1.5ml tubes. 2µl of the appropriate transformation reaction was added to each 
tube. The tubes were swirled gently to mix and incubated for 25 minutes on ice. Cells 
were heat shocked at 42°C for 1minute and placed immediately on ice for 2 minutes. 
Room temperature SOC medium (275µl) was added to each tube and the tubes were 
incubated at 37°C for 1 hour under constant agitation of 225rpm. Two LB-Kanamycin 
plates with X-gal were used for each transformation. The plates were pre-warmed at 
37°C and 50µl cells spread on one plate and 100µl on the other plate. The plates were 
sealed with paraffin to avoid drying out and incubated overnight at 37°C. Positive 
colonies, indicated by their white colour, were inoculated in individual wells 
containing 1ml of LB-Kanamycin broth in a 96-well deep well culture plate. The plates 
were sent to the Technical services, MRC HGU Unit for processing. T7 primers 
provided by the technical services were used for Sanger sequencing.  
2.2.5.7 Founder (F0) screening for mutation 
Genomic DNA extracted from tail fin clippings of injected fish at 3 months old were 
used to identify putative founder fish. Target sites were amplified using Taq DNA 
polymerase. Wild-type and no template controls were included in each reaction. 2ul of 
PCR product was sent off for analysis to Technical Services, MRC HGU using the 
Agilent 2100 Bioanalyzer.  
2.2.5.8 Germline transmission and establishing stable lines 
Putative founders were outcrossed with wild-type AB to confirm if the mutation could 
be passed to their offspring. Genomic DNA was extracted from 10-16 individual 
embryos and the target site amplified using Taq DNA polymerase and sequenced. 
When mutations were recovered, the rest of the F1 embryos were raised to adults.  
Genomic DNA was isolated from tail fin clippings of 3 months old F1 fish and the 
target site was amplified with the Phusion High Fidelity (HF) DNA polymerase and 
sequenced to identify the mutant fish. F1xF1 crosses between fish with identical 
mutations were carried out. Fish from these crosses were then screened by PCR using 
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the Phusion HF DNA Polymerase and Sanger sequencing to identify homozygous null 
F2 fish. Phusion HF DNA polymerase was used for the PCR experiments because of 
its proof-reading capacity so as to ensure the correct sequences of mutant alleles were 
identified.   
2.2.5.9 Restriction enzyme digestion to screen for G70S incorporation in F0 fish 
Genomic DNA around the target site for the G70S incorporation amplified with 
Phusion HF DNA polymerase was digested with two restriction enzymes; EcoRI High 
fidelity (HF) and MnlI. Using EcoRI, a digest of the G70S allele is expected to produce 
two products of sizes, 429 and 60 base pairs. Since the EcoRI site was engineered in 
the G70S repair template and is absent in the wild-type allele, PCR products containing 
the wild-type remains uncut. Using MnlI, a digest of the wild-type allele is expected 
to generate three products; 291bp, 190bp and 8bp, whereas the G70S will remain uncut 
as the incorporation of the G70S mutation and the PAM-blocking silent mutation 
disrupts the MnlI recognition sites.  
Reaction set-up for both enzymes was as follows: 
Component  15µl reaction 
Cutsmart buffer (NEB) 1.5 
H2O 8 
Restriction enzyme (NEB) 0.5 
DNA 5 
 
 Samples were incubated for 2 hours at 37°C in a BioRad C1000 Touch thermal cycler.  
2.2.6 PCR protocol 
DNA amplification was performed by polymerase chain reaction (PCR) using either 
the proof-reading Phusion High Fidelity DNA Polymerase (New England Biolabs) or 
Taq DNA Polymerase (Invitrogen). 
2.2.6.1 PCR with Phusion High Fidelity (HF) DNA Polymerase 
A typical reaction setup which was assembled on ice when using the Phusion HF DNA 




Component  25µl reaction 
10µM F Primer 1.25 
10µM R Primer 1.25 
cDNA/DNA/-RT/NTC 2 
2X Phusion Master mix 12.5 
H2O 8 
 
The PCR tubes containing the reaction mix were centrifuged briefly and transferred to 
a Bio-Rad C1000 Touch thermal cycler and processed with the following conditions; 
Step  Temperature  Time  
Initial Denaturation 98°C 30 seconds 
Denaturation 







15-30secs per kb 
Final Extension 72°C 10mins 
Hold  4°C  
The annealing temperature used for each primer set was determined using the NEB 
Tm calculator (https://tmcalculator.neb.com/#!/main).   
2.2.6.2 PCR with Taq DNA Polymerase   
DNA amplification was mostly performed using Taq DNA polymerase for routine 
genotyping experiments. The reaction setup assembled on ice was as follows: 
Component  X1 (µl) for 25ul 
10X PCR Buffer 2.5 
50mM MgCl2 0.75 
10mM dNTPs 0.5 
10µM F Primer 1.25 
10µM R Primer 1.25 
DNA/NTC 2 
Taq Polymerase 0.5 
H2O 16.25 
   







Step  Temperature   Time  
Initial Denaturation 94°C 3mins 
Denaturation 








Final Extension 72°C 10mins 
Hold  12°C  
 
2.2.7 General sequencing protocol 
When the sequencing reaction was carried out by me, the following protocol was used. 
Once the target site has been amplified and confirmed, the PCR product was treated 
with ExoSAP-IT (Affymetrix) to remove excess primers and incorporated dNTPs. 
Five microliters of PCR product were incubated with 1µl of ExoSAP-IT at 37°C for 
15 minutes, and then at 80°C for another 15 minutes to inactivate the ExoSAP-IT. The 
DNA sequencing reaction was carried out using the BigDye Terminator v3.1 Cycle 
Sequencing kit (Thermo Fisher Scientific). The reaction was set up as follows: 4µl 
clean PCR product, 1.5µl primer, 1µl Big Dye, 1.5µl Big Dye and 2µl water. The 
sequencing reaction was then run using the following program: 96°C for 1 minute and 
24 cycles of 96°C for 1 minute, 50°C for 15 seconds and 64°C for 4 minutes. 
The sequencing reaction was cleaned up by adding 2.5µl of 125mM EDTA and 30µl 
of absolute ethanol to each well. The reaction was mixed by inverting the sealed plate 
gently four times and the plate incubated at room temperature for 5 minutes. The plate 
was then centrifuged for 15 minutes at 3000 rpm. The ethanol was removed and 
replaced with 30µl 70% ethanol. The plate was again centrifuged for 15 minutes at 
3000 rpm and the ethanol removed. The plate was left to air dry at room temperature 
for 10 minutes. Plates were sent off to the Technical services, MRC Human Genetic 
Unit (HGU) for processing using a 3730 Genetic Analyser (Applied Biosystems). 
Chromatograms were viewed using the SnapGene Viewer (version 2.8.2, GSL, 
Biotech).   
2.2.8 PTZ treatment and behavioural monitoring 
Zebrafish larvae were sorted and placed individually in a 96-well plate (Greiner 
CELLSTAR) 24 hours before the experiment and then placed in an incubator at 28.5°C 
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until they was needed. Each well contained 70µl of E3 medium and one 5 dpf larva. 
Before starting the recording session, larvae were allowed to habituate for 10 minutes 
to minimise disturbance due to handling and transporting of the plate. Baseline 
recordings of 20 minutes were then obtained from the fish while in normal E3 medium. 
Experimental fish were then treated with 2.5mM PTZ (Sigma-Aldrich) diluted in E3 
medium while controls were left in normal E3 medium. Swimming behaviour of the 
fish was monitored for 80 minutes.  
Video recordings were performed with the assistance of Craig Nicol using a Nikon 
D800 camera with an attached 60mm macro lens mounted on a copy stand. The 
experiment was carried out in a quiet location with restricted access to avoid exposing 
the fish to unintended stimuli. Recording session (80 minutes) was done at intervals of 
20 minutes which is the recording limit of the camera. For Locomotion analysis, 
swimming behaviour of the fish was tracked using EthoVision XT9, an automated 
locomotion tracking software, by Dr. Pia Lundegaard. For seizure analysis, the video 
was scored according to Baraban et al., 2005 (summarised below) by Dr. Rodanthi 
Lyraki blind to the genotype and treatment of the fish. Graphs and statistical analysis 
were performed using GraphPad Prism 5. To test for significance, One-way ANOVA 
with Tukey Multiple Comparison tests or repeated measures ANOVA were performed 
where appropriate.  
Description of seizure stages according to Baraban et al., 2005 used for seizure analysis  
Seizure stage Description 
I Dramatic increase in swim activity 
II Rapid ‘whirlpool-like’ circling swim 
behaviour 
III Clonus-like convulsions followed by brief 








2.2.9.1 H & E staining  
Adult zebrafish were culled in an overdose of tricaine for 10 minutes or until the 
cessation of gill movement. Using a forceps, a longitudinal incision was made on the 
ventral side of the fish to allow for the introduction of the fixative into the body. The 
fish were fixed in 10% neutral buffered formalin (Sigma-Aldrich) and sent to the 
Easter Bush Pathology labs for processing.  Sections were cut at a thickness of 3 µM 
and haematoxylin and eosin (H&E) staining were performed by staff at the Easter Bush 
Pathology department.    
2.2.9.2 Immunohistochemistry 
Spinal cord sections were dewaxed in two changes of xylene for 5 minutes each and 
were rehydrated through a decreasing series of alcohol solutions, with 5 minutes in 
two changes of 100% ethanol and 5 minutes in two changes of 70% ethanol. Sections 
were then washed under running tap water for 5 minutes. Antigen retrieval was carried 
out by treating sections with Proteinase K (Dako) at room temperature for 10 minutes. 
Sections were then treated with 3% hydrogen peroxide to block endogenous 
peroxidase activity. They were again washed in water, followed by PBS for 5 minutes 
each. Slides were transferred to a Sequenza (Shandon) and washed briefly with PBS. 
They were treated for 10 minutes with 100µl goat blocking serum (Bethyl 
Laboratories) diluted 1:5 in PBS to prevent non-specific binding of the secondary 
antibody. 100µl GFAP antibody (Dako) diluted 1:500 in PBS was then added and the 
slides incubated overnight. The slides were washed twice with PBS for 5 minutes and 
incubated for 30 minutes with 100µl goat anti-rabbit biotinylated secondary antibody 
(Dako) diluted 1:500 in PBS. They were then washed for 5 minutes in PBS and treated 
with 3 drops of Strept ABC reagent (Vector Laboratories) for 30 minutes. Slides were 
again washed in PBS for 5 minutes, removed from the Sequenza and treated with DAB 
(Abcam) for 10 minutes. Excess DAB was removed by washing slides under running 
tap water. Sections were counterstained in haematoxylin solution (Shandon) for 5 
minutes, rinsed in water to remove excess stain and then differentiated in saturated 
lithium carbonate for few seconds. Sections were washed briefly in water and then 
dehydrated through two changes of 70% ethanol, 100% ethanol and xylene for 5 
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minutes. Slides were mounted using DPX (VWR) and imaged using an Olympus 
BX60 light microscope. 
2.2.10 Databases and online resources 
The two main online databases used in this work were Ensembl 
(https://www.ensembl.org/index.html) and ZFIN (http://zfin.org/) genome browsers 
(D. G. Howe et al., 2013; Flicek et al., 2014).  BLAST search and design of primers 
for qRT-PCR were performed using tools from the NCBI homepage 
(https://www.ncbi.nlm.nih.gov/). Other primers were designed using Primer3 
(http://primer3.ut.ee/) (Untergasser et al., 2012). Multiple alignments of DNA and 
protein sequences were done using Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers et al., 2011).  The phylogenetic 
tree was constructed by Dr. Dinesh Soares with the MEGA version 6 software (Tamura 
et al., 2013) using a maximum likelihood method. Conserved synteny analysis was 
conducted using the Synteny Database (Catchen, Conery and Postlethwait, 2009). 
Comparative modeling and visualisation of the 3-D structures of the zebrafish eEF1A 
isoforms were carried out through the Chimera-Modeller interface (Pettersen et al., 
2004; Webb and Sali, 2016). The coarse packing quality of the models was evaluated 
using the WHAT IF server (https://swift.cmbi.umcn.nl/servers/html/index.html). This 
checks the normality of the local environment of amino acids and assigns a score. A 
residue with a score of -0.5 or lower indicates something is ‘wrong’ with its packing 
quality within the model (Vriend and Sander, 1993). Solvent-accessibility of variant 
amino acid residues and those within a distance of 5 Å of a known binding site was 
calculated under Chimera (Sanner, Olson and Spehner, 2018). Phosphorylation site 
prediction was performed using the NetPhos version 3.1 server 
(http://www.cbs.dtu.dk/services/NetPhos/) (Blom, Gammeltoft and Brunak, 1999) 
using a threshold set at 0.5 so that only positive predicted phosphorylation sites are 
displayed. The NetPhos 3.1 server performs both generic and kinase specific 
predictions of serine, threonine or tyrosine phosphorylation sites in eukaryotic proteins 
using ensembles of neural networks. It then assigns a score to each sites with the 
confidence of its prediction indicated by how high the score is from 0.5, which is the 
threshold for showing only positive potential phosphorylation sites in the result output.   
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For the CRISPR/Cas9 experiments, the target finder tools CHOPCHOP 
(http://chopchop.cbu.uib.no/) and http://crispr.mit.edu/ were used to design guide 
RNAs and primers (CHOPCHOP) to amplify target sites for the zebrafish eef1a2. 
These target finder tools also search for potential off-target sites for each gRNA in the 
zebrafish genome. Sanger sequencing results were viewed using the SnapGene Viewer 
version 2.8.2. Double peak regions in the sequencing chromatograms were separated 
into wild-type and alternative sequences using the Poly Peak Parser software to 
identify indel mutations (http://yosttools.genetics.utah.edu/PolyPeakParser/) (Hill et 




















Chapter 3: Bioinformatics and expression analysis of 
Zebrafish eEF1A  
3.1 Introduction 
As detailed in chapter 1, eEF1A is important for protein translation where it helps 
recruit aminoacylated-tRNA to the acceptor site of the ribosome during protein 
synthesis. This process is GTP-dependent and is facilitated by its interaction with 
eEF1B, a GTP-exchange factor. Apart from this function, eEF1A also has other non-
canonical roles such as binding and bundling actin (see section 1.1.3 in chapter 1 for 
details). Different numbers of eEF1A genes are found in individual eukaryotic species. 
In the yeast Saccharomyces cerevisiae, two sequence-redundant genes, TEF1 and 
TEF2 are present. In Xenopus, four different genes; eef1a1 which is the somatic form, 
eef1a1o which is the oocyte form, 42Sp50, expressed only in the oocytes and eef1a2 
are present. While many pseudogenes exist in mammalian genomes, only two EEF1A 
genes, EEF1A1 and EEF1A2, has been shown to be actively expressed in human, rat, 
mouse, rabbit and pig (Knudsen et al., 1993; Chambers, Peters and Abbott, 1998; 
Kahns et al., 1998; Svobodová et al., 2015). They encode distinct proteins, eEF1A1 
and eEF1A2 which has been implicated in neurological diseases. Extensive studies of 
eEF1A in mammals revealed the differential expression of these two genes, with 
eEF1A1 widely expressed and eEF1A2 expression restricted to the brain, heart and 
skeletal muscle, where it gradually replaces eEF1A1 during development in these cell 
types. Although, eEF1A has been studied less extensively in non-mammalian 
vertebrates, studies by Newbery et al. 2011 in Xenopus species show a similar pattern 
of expression of eEF1A2 and that variant switching is conserved with the regulation 
of expression occurring at the post-transcriptional level rather than transcriptional as 
seen in vertebrates.  
The emergence of the zebrafish as an excellent tool for modelling disease processes 
has resulted in tremendous progress of the sequencing of its genome. Previous studies 
reported only one actively expressed eef1a gene in zebrafish (Gao et al. 1997). 
However, the zebrafish genomic sequence has developed to the point where it is clear 
that the zebrafish has more than one eef1a gene. This chapter describes work providing 
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an updated studies of eEF1A in zebrafish. Zebrafish eEF1A was investigated using 
bioinformatics and gene expression analysis approaches to confirm the existence of 
each eEF1A gene and investigate if they are functionally active. 
3.2 Results 
3.2.1 Bioinformatics analysis of eef1a in zebrafish 
3.2.1.1 Identification of eef1a genes in zebrafish 
To investigate the eef1a genes in zebrafish, its genome was searched using the 
Ensembl ( Zv9, release 79) and ZFIN databases (Bradford et al., 2011; Flicek et al., 
2014). Four eef1a genes, referred to as eef1a1l1, eef1a1a, eef1a1b and eef1a2 were 
identified which are located on different chromosome in the zebrafish genome. Table 
3.1 summarises some of the features of the eef1a genes. All of them contained eight 
exons, seven introns and an open reading frame (ORF) that encodes different proteins 
462 (eEF1A1L1, eEF1A1A and eEF1A1B) or 463 (eEF1A2) amino acid long. The 
exon-intron organisation for each eef1a gene is shown in figure 3.1. Exon 1 together 
with part of exon 2 form the 5’UTR, and part of exon 8 makes up the 3’UTR in all 
four eef1a genes. While the sizes of exons 3-7 are the same for all the genes, some of 
the introns of eef1a1a, eef1a1b and eef1a2 genes are greatly expanded compared to 
eef1a1l1 which has smaller introns similar to eEF1A1 gene in human and mouse 
species (Figure 3.2). The eef1a genes shared high sequence homology at the nucleotide 
level in the coding region and also at amino acid level, with eef1a1a and eef1a1b being 
highly related to one another as shown in table 3.2.  
Table 3.1. Main features of the eef1a genes in zebrafish  








eef1a1l1 19 1745 8 462 eEF1A1L1 
eef1a1a 13 2170 8 462 eEF1A1A 
eef1a1b 1 2160 8 462 eEF1A1B 
eef1a2 23 2030 8 463 eEF1A2 






Figure 3.1. Exon-intron organisation of the eef1a genes in zebrafish. Schematic representation of 
eef1a1l1 (red), eef1a1a (black), eef1a1b (blue) and eef1a2 (yellow) genes structures obtained from the 
Ensembl database. Exons are represented with blocks while introns are represented with lines. 
Untranslated regions (UTRs) in exons are shown with empty blocks. Length (in base pairs) of exons 
and introns, which are not drawn to scale, are indicated above and below respectively.  
 
 
Figure 3.2. Comparison of the intron-exon structure of the zebrafish eEF1A1L1 gene and eEF1A 
genes in human and mouse species. Gene structures of zebrafish eef1a1l1 (red), human EEF1A1 (gold) 
and EEF1A2 (black), mouse Eef1a1 (blue) and Eef1a2 (orange) obtained from the Ensembl genome 
browser. The zebrafish eef1a1l1 gene architecture is much more similar to that eEF1A1 gene of both 
vertebrate species. Exons are represented with blocks while introns are represented with lines. 
Untranslated regions (UTRs) in exons are shown with empty blocks. Length (in base pairs) of exons 
and introns, which are not drawn to scale, are indicated. 
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Table 3.2. Percentage identity matrix of zebrafish eEF1A variants at the 
nucleotide and amino acid sequence level calculated using Clustal Omega 
 eef1a1l1 eef1a1a eef1a1b eef1a2 
eef1a1l1 100 (100) 80 (92) 79 (91) 75 (89) 
eef1a1a 80 (92) 100 (100) 83 (97) 77 (91) 
eef1a1b 79 (91) 83 (97) 100 (100) 77 (90) 
eef1a2 75 (89) 77 (91) 77 (90) 100(100) 
   *Numbers in bracket indicate the percentage identity at the amino acid sequence level. 
3.2.1.2 Orthology assignment of zebrafish eef1a to human EEF1A genes 
Three different approaches were used to assign the zebrafish eef1a genes to their 
appropriate human orthologue. Firstly, a reciprocal best hit (RBH) BLAST was 
employed using each of the human protein eEF1A variants as the query sequence 
against the zebrafish genome using the reference sequence (RefSeq) protein database 
on the NCBI BLAST browser. A BLAST search of the human eEF1A1 protein against 
the zebrafish genome produced eEF1A1A and eEF1A1B as its top two hits with 
approximately the same magnitude of alignments with the following BLAST results; 
 Score Expect Identities Positives Gaps 
eEF1A1A 905 bits (2338) 0.0 438/462(95%) 448/462 (96%) 0/462 (0%) 
eEF1A1B 901 bits (2329) 0.0 436/462 (94%) 447/462 (96%) 0/462 (0%) 
 
A retro-BLAST with the zebrafish eEF1A1A and eEF1A1B against the human 
genome both found eEF1A1 as their best hit. Similar BLAST searches were done for 
eEF1A2 protein. The human and zebrafish eEF1A2 produced each other as their top 
hit with the results;  
 Score Expect Identities Positives Gaps 
eEF1A2 910 bits (2351) 0.0 436/463(94%) 454/463 (98%) 0/463 (0%) 
 
However, an eEF1A1L1 BLAST search hit the human eEF1A1 and eEF1A2 with 




 Score Expect Identities Positives Gaps 
eEF1A1 882 bits (2279) 0.0 425/462(92%) 441/462 (95%) 0/462 (0%) 
eEF1A2 875 bits (2262) 0.0 417/460(91%) 448/460 (95%) 0/460 (0%) 
 
Secondly, a phylogenetic analysis was performed with the MEGA6 software (Tamura 
et al., 2013) using all four zebrafish eEF1A protein sequences and those from other 
vertebrate species. The phylogenetic tree was built by Dr. Dinesh Soares using the 
maximum likelihood method (see figure 3.3 legend for details). Result from this 
analysis showed that zebrafish eEF1A1A is paralogous to eEF1A1B, and both of them 
are co-orthologous to human eEF1A1. The phylogenetic tree also suggests that 
zebrafish eEF1A2 is orthologous to the human eEF1A2. However, eEF1A1L1 did not 
segregate with the eEF1A1 clade and appears to possess sequence features similar to 





































                                 
Figure 3.3. Molecular Phylogenetic analysis of eEF1A1 and eEF1A2 orthologues by Maximum 
Likelihood method. The evolutionary history was inferred by using the Maximum Likelihood method 
based on the Poisson correction model (Zuckerkandl and Pauling, 1965). The tree with the highest log 
likelihood (-2809.8575) is shown. The percentage of trees in which the associated taxa clustered 
together is shown next to the branches. Initial tree(s) for the heuristic search were obtained automatically 
by applying Neighbour-Join and BioNJ algorithms to a matrix of pairwise distances estimated using a 
JTT model, and then selecting the topology with superior log likelihood value. The tree is drawn to 
scale, with branch lengths measured in the number of substitutions per site. The reliability of each 
branch was assessed using 1,000 bootstrap replicates and reliable assignment values indicated. The 
analysis involved 24 amino acid sequences. All positions with less than 95% site coverage were 
eliminated. That is, fewer than 5% alignment gaps, missing data, and ambiguous amino acids were 
allowed at any position. There were a total of 462 positions in the final dataset. Evolutionary analyses 
were conducted in MEGA6 (Tamura et al., 2013). The orthologues of eEF1A1 and eEF1A2 sequences 
fall into well-supported clades, consistent with their known paralogous classification and functional 
divergence. The eEF1A1l1 sequence from zebrafish on the other hand appears to be more divergent, 
does not fall into the eEF1A1 group of sequences and appears to possess sequence features of both 




The third approach involved the use of the Synteny Database (Catchen, Conery and 
Postlethwait, 2009) to identify conserved synteny regions between the zebrafish and 
human genomes. Conserved synteny make use of gene position and order to identify 
orthologous chromosomal regions in different species, unlike RBH BLAST and 
phylogenetic analyses which infers orthologous genes based on sequence similarities. 
Therefore, conserved synteny served as an independent line of evidence to confirm 
results obtained using the other two approaches. The Synteny Database was used to 
search for conserved regions between the eef1a genes region in zebrafish and in 
humans using the recommended sliding window size of 100-gene. A gene trace clearly 
showed strong conservation between zebrafish eef1a1a gene located on chromosome 
13 (Dre13) and the human EEF1A1 on chromosome 6 (Hsa6) with ten pairs of 
orthologous genes surrounding the EEF1A1/eef1a1a orthologues with SLC17A5, 
MB21D1 and DDX43 genes as near neighbours in both species (Figure 3.4A). The 
orthologous syntenic cluster associated with zebrafish eef1a1b (Dre1) showed only 
RIMS1 and KCNQ5 as the orthologous genes surrounding the EEF1A1/eef1a1a 
orthologues (Figure 3.4B). However, a paralogous syntenic cluster for zebrafish 
eef1a1a and eef1a1b showed a strong local conservation between these regions and 
contained 13 paralogous gene pairs including eef1a1a and eef1a1b, as well as the 
directly adjacent paralogues of rims1 and kcnq5 as their near neighbours (Figure 3.4C). 
This confirms eef1a1a and eef1a1b as paralogues and indicates eef1a1b arose from the 
duplication of the genomic region containing the eef1a1a gene.   
Similar analysis was carried out for zebrafish eef1a2. The orthologous syntenic cluster 
between the zebrafish eef1a2 and human EEF1A2 showed a strong conservation with 
a total of 96 pairs of orthologues between the two species using a 100-gene sliding 
window. However, the gene trace (shown in Figure 3.4E) was drawn using a 25-gene 
sliding window for the sake of clarity and shows 22 pairs of orthlogues, with NKAIN4 
and EEF1A2 forming a subcluster in both species. Searching for any conserved region 
for eef1a1l1 between zebrafish and the human genomes produced an orthologous 
syntenic cluster for a region on human chromosome 6 (Hsa6) containing the EEF1A1 
gene. However, this region did not contain any pair of orthologous genes but only 
related genes that belonged to the same family; EEF1A1/eef1a1l1, TFAP2B/tfap2e and 
SLC17A5/slc17a3 (Figure 3.4D). 
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Taken together, these results show that zebrafish eef1a1a and eef1a1b are paralogues 
and are co-orthologues to human EEF1A1, while eef1a2 is the orthologue of the human 
EEF1A2 gene. However, zebrafish eef1a1l1 did not appear to have any orthologous 

























Figure 3.4. Conserved synteny analysis for zebrafish eef1a genes. Gene trace representation of the conserved syntenies between zebrafish eef1a genes and the human 
EEF1A genes were generated using the Synteny DB discovered using a 100-gene sliding window. Orders of the genes (indicated as squares) but not their physical 
location are preserved. Coloured squares indicate genes that belong to the cluster while grey squares show genes within the region but not members of the cluster. Lines 
connecting coloured squares between the two clusters represent orthologous or paralogous gene pairs. Lines of the same colours (referred to as subclusters) indicate 
strong local conservation. A-B. Orthologous syntenic cluster for eef1a1a and eef1a1b showing syntenic conservation between the human chromosome 6 (Hsa6) which 
contain EEF1A1 and zebrafish chromosome 13 (Dre13) for eef1a1a and Dre1 (eef1a1b) C. The eef1a1a and eef1a1b paralogous syntenic cluster showing a strong 
conserved region between Dre13 and Dre1 which contains eef1a1a and eef1a1b respectively. D. Orthologous syntenic cluster generated for eef1a1l1 shows a weak 
conservation with Has6, but genes from the two clusters are not orthologous pairs but belong to the same family. E. The zebrafish eef1a2 orthologous gene trace showing 
a very strong conservation with the Hsa20 which contains EFF1A2, both of which form a subcluster with NKAIN4. For clarity, the window size used in generating the 




3.2.1.3 Comparative analysis of zebrafish eEF1A sequence 
Although, it is still not understood why two near-identical eEF1A isoforms exist, it is 
clear that there are some functional differences between the two isoforms in humans. 
It was therefore hypothesised that some form of functional divergence might also have 
occurred among the zebrafish eEF1A isoforms. To investigate this, a comparative 
analysis of zebrafish eEF1A was carried out using a similar approach to that described 
in the study by Soares et al., 2009. A multiple sequence alignment of the zebrafish  
eEF1A protein (Figure 3.5) show the number of variant amino acid residues in 
eEF1A1L1 from eEF1A1A, eEF1A1B and eEF1A2 to be 37, 42 and 53 respectively, 
while eEF1A1A differ from eEF1A1B and eEF1A2 at 12 and 44 positions respectively 
out of 462 (for eEF1A1A/eEF1A1B) and 463 ( for eEF1A1A/eEF1A2). Also, 
eEF1A1B differ from eEF1A2 at 48 positions out of 463. The position and the residues 
present for each of the eEF1A proteins are summarised in appendix table 1, while 
figure 3.6 shows their location on the 3-D models. Alignment of the human eEF1A 
protein sequences together with the zebrafish eEF1A protein sequences show some 
variant residues to be wholly conserved, such that eEF1A1 from the two species have 
the same amino acid residue as do eEF1A2 from human and zebrafish at that same 
position. Zebrafish eEF1A1L1 which has no orthologue in human fall more in the 
eEF1A1 cluster at these positions than with the eEF1A2 orthologues, with eEF1A1L1 
having the same amino acid as the eEF1A1 orthologues in 13 out of the 16 wholly 
conserved positions. 
Published data obtained from the study of Soares et al. 2009 were then mapped unto 
the aligned sequences (Figure 3.5). These data include functional annotations, some of 
which have been confirmed in vivo, which shows translational and actin-related 
activities based on the yeast eEF1A protein. Yeast eEF1A shows high sequence 
identity with the zebrafish eEF1A proteins (~82% (eEF1A1L1), ~81% (eEF1A1A and 
eEF1A1B) and ~79% for eEF1A2) which is similar to both human eEF1A variants 
(~81%). Twenty six residues shown to be involved in the binding of the yeast eEF1A 
with the C-terminal of eEF1Bα are highly conserved in the zebrafish eEF1A with only 
2 (out of 26) variations for eEF1A1A, eEF1A1B and eEF1A2 and 1 (out of 26) 
variation for eEF1A1L1. The residues Ala76 and Val89 in yeast are substituted with 
Ser76 in eEF1A1A, eEF1A1B and eEF1A2 and Ile89 in all the zebrafish proteins. 
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However, these substitutions are conserved with the human proteins. Also, the 
equivalent residues involved in the binding of aminoacyl-tRNA in the zebrafish 
eEF1A, (His295, His296 and Arg322), are conserved in all the eEF1A variants. 
Similarly, residues Gly19, Lys20, Ser21, Thr22, Asn153, Lys154 and Asp156 which 
are shown to be essential for forming the guanine-binding pocket for GDP/GTP 
binding were also conserved. Three positions, 296, 329 and 333 (298, 331 and 335 in 
zebrafish eEF1A) demonstrated to bind actin through site mutagenesis studies in yeast 
are variable in the zebrafish eEF1A variants. Both 331 and 335 positions are also 
variable between the two human eEF1A variants. The eEF1A1 orthologues (and 
eEF1A1L1) have asparagine at position 331, while eEF1A2 orthologues have serine 
at this position. At position 335, eEF1A1A, eEF1A1B and eEF1A2 all have a 
glutamine residue as seen in human eEF1A2, while eEF1A1L1 shares the same 
methionine residue seen in human eEF1A1. Position 298 involved a non-conservative 
change of Ala298 in eEF1A1B and eEF1A1B (same as both human eEF1A variants) 




eEf1a1a         1 MGKEKLHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 
eEf1a1b         1 MGKEKLHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 
eEF1A1_HUMAN    1 MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 
eEf1a2          1 MGKEKIHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 
eEF1A2_HUMAN    1 MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 
eEf1a1l1        1 MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVL 
eEF1A_YEAST     1 MGKEKSHINVVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAELGKGSFKYAWVL 
 
 
eEf1a1a        61 DKLKAERERGITIDISLWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAAGV 
eEf1a1b        61 DKLKAERERGITIDISLWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAAGV 
eEF1A1_HUMAN   61 DKLKAERERGITIDISLWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAAGV 
eEf1a2         61 DKLKAERERGITIDISLWKFETTKYYITIIDAPGHRDFIKNMITGTSQADCAVLIVAAGV 
eEF1A2_HUMAN   61 DKLKAERERGITIDISLWKFETTKYYITIIDAPGHRDFIKNMITGTSQADCAVLIVAAGV 
eEf1a1l1       61 DKLKAERERGITIDIALWKFETSKYYVTIIDAPGHRDFIKNMITGTSQADCAVLIVAGGV 
eEF1A_YEAST    61 DKLKAERERGITIDIALWKFETPKYQVTVIDAPGHRDFIKNMITGTSQADCAILIIAGGV 
 
 
eEf1a1a       121 GEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPSYSQKRYEEIVKEVSTYIKK 
eEf1a1b       121 GEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPNYSQKRYEEIVKEVSTYIKK 
eEF1A1_HUMAN  121 GEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPPYSQKRYEEIVKEVSTYIKK 
eEf1a2        121 GEFEAGISKNGQTREHALLAYTLGVKQLIVAVNKMDSTEPSYSEKRYDEIVKEVSAYIKK 
eEF1A2_HUMAN  121 GEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPAYSEKRYDEIVKEVSAYIKK 
eEf1a1l1      121 GEFEAGISKNGQTREHALLAFTLGVKQLIVGVNKMDSTEPPYSQARFEEITKEVSAYIKK 
eEF1A_YEAST   121 GEFEAGISKDGQTREHALLAFTLGVRQLIVAVNKMDSVK--WDESRFQEIVKETSNFIKK 
 
 
eEf1a1a       181 IGYNPDTVAFVPISGWNGDNMLEASPNMSWFKGWKITRKEGNAAGTTLLEALDAIQPPTR 
eEf1a1b       181 IGYNPDTVAFVPISGWNGDNMLEASPNMTWFKGWKITRKDGSSSGTTLLEALDAIQPPTR 
eEF1A1_HUMAN  181 IGYNPDTVAFVPISGWNGDNMLEPSANMPWFKGWKVTRKDGNASGTTLLEALDCILPPTR 
eEf1a2        181 IGYSPASVPFVPISGWHGDNMLEPSSNMPWFKGWKLDRKEHHAGGVTLLEALDTIMPPTR 
eEF1A2_HUMAN  181 IGYNPATVPFVPISGWHGDNMLEPSPNMPWFKGWKVERKEGNASGVSLLEALDTILPPTR 
eEf1a1l1      181 IGYNPASVAFVPISGWHGDNMLEASSNMGWFKGWKIERKEGNASGTTLLDALDAILPPSR 
eEF1A_YEAST   179 VGYNPKTVPFVPISGWNGDNMIEATTNAPWYKGWEKETKAGVVKGKTLLEAIDAIEQPSR 
 
 
eEf1a1a       241 PTDKPLRLPLQDVYKIGGIGTVPVGRVETGLLKPGMVVTFAPVNVTTEVKSVEMHHEALS 
eEf1a1b       241 PTDKPLRLPLQDVYKIGGIGTVPVGRVETGILKPGLVVTFAPVNVTTEVKSVEMHHEALS 
eEF1A1_HUMAN  241 PTDKPLRLPLQDVYKIGGIGTVPVGRVETGVLKPGMVVTFAPVNVTTEVKSVEMHHEALS 
eEf1a2        241 PTDKPLRLPLQDVYKIGGIGTVPVGRVETGVLRPSMVVTFAPVNITTEVKSVEMHHESLS 
eEF1A2_HUMAN  241 PTDKPLRLPLQDVYKIGGIGTVPVGRVETGILRPGMVVTFAPVNITTEVKSVEMHHEALS 
eEf1a1l1      241 PTDKPLRLPLQDVYKIGGIGTVPVGRVETGVLKPGMVVTFAPANVTTEVKSVEMHHESLT 
eEF1A_YEAST   239 PTDKPLRLPLQDVYKIGGIGTVPVGRVETGVIKPGMVVTFAPAGVTTEVKSVEMHHEQLE 
 
 
eEf1a1a       301 EALPGDNVGFNVKNVSVKDIRRGNVAGDSKNDPPQEAANFTAQVIILNHPGQISAGYAPV 
eEf1a1b       301 EALPGDNVGFNVKNVSVKDIRRGNVAGDSKNDPPQEAASFTAQVIILNHPGQISAGYAPV 
eEF1A1_HUMAN  301 EALPGDNVGFNVKNVSVKDVRRGNVAGDSKNDPPMEAAGFTAQVIILNHPGQISAGYAPV 
eEf1a2        301 EALPGDNVGFNVKNVSVKDIRRGNVCGDSKSDPPQEASGFTAQVIILNHPGQISSGYSPV 
eEF1A2_HUMAN  301 EALPGDNVGFNVKNVSVKDIRRGNVCGDSKSDPPQEAAQFTSQVIILNHPGQISAGYSPV 
eEf1a1l1      301 EATPGDNVGFNVKNVSVKDIRRGNVAGDSKNDPPMEAANFNAQVIILNHPGQISQGYAPV 
eEF1A_YEAST   299 QGVPGDNVGFNVKNVSVKEIRRGNVCGDAKNDPPKGCASFNATVIVLNHPGQISAGYSPV 
 
 
eEf1a1a       361 LDCHTAHIACKFAELKEKIDRRSGKKLEDNPKSLKSGDAAIVEMIPGKPMCVESFSEYPP 
eEf1a1b       361 LDCHTAHIACKFAELKEKIDRRSGKKLEDNPKSLKSGDAAIVDMIPGKPMCVESFSEYPP 
eEF1A1_HUMAN  361 LDCHTAHIACKFAELKEKIDRRSGKKLEDGPKFLKSGDAAIVDMVPGKPMCVESFSDYPP 
eEf1a2        361 IDCHTAHIACKFAELKEKIDRRSGKKLEDNPKSLKSGDAAIVDMIPGKPMCVESFSQYPP 
eEF1A2_HUMAN  361 IDCHTAHIACKFAELKEKIDRRSGKKLEDNPKSLKSGDAAIVEMVPGKPMCVESFSQYPP 
eEf1a1l1      361 LDCHTAHIACKFAELKEKIDRRSGKKLEDNPKALKSGDAAIVEMVPGKPMCVESFSTYPP 
eEF1A_YEAST   359 LDCHTAHIACRFDELLEKNDRRSGKKLEDHPKFLKSGDAALVKFVPSKPMCVEAFSEYPP 
 
 
eEf1a1a       421 LGRFAVRDMRQTVAVGVIKGVEKKTATSGKVTKSAQKAQKAK- 
eEf1a1b       421 LGRFAVRDMRQTVAVGVIKGVEKKTSTSGKVTKSAQKAQKNK- 
eEF1A1_HUMAN  421 LGRFAVRDMRQTVAVGVIKAVDKKAAGAGKVTKSAQKAQKAK- 
eEf1a2        421 LGRFAVRDMRQTVAVGVIKNVEKKIGGSGRVTKSAQKAQKSSK 
eEF1A2_HUMAN  421 LGRFAVRDMRQTVAVGVIKNVEKKSGGAGKVTKSAQKAQKAGK 
eEf1a1l1      421 LGRFAVRDMRQTVAVGVIKSVEKKIGGAGKVTKSAQKAAKTK- 
















Figure 3.5. Multiple sequence alignment of the zebrafish and human eEF1A isoforms with the 
yeast eEF1A as a template.  Results of the alignment were shaded using BoxShade v3.21 where black, 
grey and white background indicates strictly conserved, conservative substituted or non-conserved 
regions respectively. Functional annotations obtained for yeast eEF1A is shown using different 
symbols. Domains are shown with filled rectangles, with domain I, II and III indicated with aqua, green 
and pink respectively. Circles show domain-domain contacts, with the red    and yellow   circles 
indicating conserved and non-identical residues respectively. Also shown on the yeast sequence are      ;                                
-residues in the disordered region of the yeast crystal structure,     - involved in the binding of the C-
terminal region of eEF1Bα. Residues identified in yeast mutagenesis studies to be; -actin 
bundling/disorganisation,    -affect translational fidelity,   -reduce dependence on eEF1Bα. *- human 
eEF1A2 mutations which are completely conserved in the four zebrafish eEF1A isoforms. Adapted 
from Soares et al. 2009. 
          
3.2.1.4 Variant residues analysis using the 3-D models of zebrafish, human and 
yeast eEF1A proteins 
Functional analysis of the variant residues based on their position in the 3-D structure 
provides better insight than analysis of the linear sequence, especially when comparing 
highly homologous proteins. To this end, I constructed structural models of the 
zebrafish eEF1A proteins using the Modeller software through the Chimera interface 
(Pettersen et al., 2004). The yeast eEF1A (1F60) structure was used as a template and 
the variant residues analysed further. As with yeast, all the zebrafish eEF1A proteins 
models are made up of three domains; domain I (1-240), domain II (241-336) and 
domain III (337-443). Residues at position 444-462 (463 for eEF1A2) are equivalent 
to the disordered residues of the yeast eEF1A and so were not included in the resulting 
models. The variant residues within the zebrafish eEF1A proteins are spread across 
the three domains. Six variable positions are found to be completely buried in all the 
eEF1A models. Positions 87 and 361 are conservative changes and are wholly 
conserved within orthologues, with eEF1A1L1 falling into the eEF1A1 group. Two 
other positions, 189 and 326, did not involve conservative substitutions but were also 
wholly conserved within the eEF1A and eEF1A2 orthologues, with eEF1A1L1 in the 
eEF1A1 group again. While eEF1A1L1 and eEF1A2 has the same residue as the yeast 
eEF1A at positions 118 and 151 respectively, the others have the same residues with 
both human eEF1A variants at these sites. Positions 216, 161 and 339 are found to be 
completely buried only in the zebrafish eEF1A1A, eEF1A1B and eEF1A2 modeled 
structures respectively. Position 216 involves a conservative change (Ile216 for 
eEF1A1L1, eEF1A1A and eEF1A1B, Leu261 for eEF1A2). On the other hand, 
changes at position 161 and 339 are not conservative, therefore the quality of the 
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packing properties of the residues was evaluated using the WHAT IF server (see 
section 2.2.10 in chapter 2).  Asn161 (eEF1A1B) and Gly339 (eEF1A2) has a packing 
score of -1.1 and 0.6 respectively. Packing scores of -0.5 or lower indicates something 
is ‘going on’ with the packing quality of that residue. However, judging from the good 
packing scores, these residues likely fit into the protein interior and suggests that 
eEF1A1B and eEF1A2 do not have different domain structures from the other eEF1A 
variants.            
Existing structural data for the domain contacts for the yeast structure from the study 
of Soares et al. 2009 were also mapped on the multiple aligned sequences shown in 
figure 3.5. This showed 40 out of 42 residues involved in domain-domain contact to 
be absolutely conserved among the zebrafish eEF1A variants, yeast eEF1A and the 
two human eEF1A variants. Two positions; 335 and 417 (K333 and Glu415 in yeast) 
with residues that connects domain II and III are variable in zebrafish. It is worth 
mentioning that a two sequence insertion in vertebrate eEF1A isoforms relative to the 
yeast eEF1A is found between position 159 and 160 in the yeast eEF1A, thereby 
leading to a discrepancy in the numbering of residues after position 159. The glutamine 
residue is present at position 335 for eEF1A1A, eEF1A1B and eEF1A2 (same as 
human eEF1A2), while eEF1A1L1 has a methionine, as in human eEF1A1. Zebrafish 
eEF1A1A and eEF1A1B share the same residue (Glu417) with yeast (Glu415 in yeast) 
and a conservative change of aspartic acid (Asp417) is present in human eEF1A1. 
While eEF1A2 has Gln417, as in human eEF1A2, eEF1A1L1 is the only zebrafish 
variant with threonine at this position. However, the main–chain oxygen atom of all 
the variant residues at these two positions maintained their inter-domain H-bond 
interaction with the side-chains of residues Cys411 for residues at position 335 and 
Lys244 for position 417. This suggest that all the eEF1A proteins are predicted to have 
the same conformation as that seen in yeast, at least in the context of the eEF1Bα-
bound structure.        
Similar to what is seen for human eEF1A isoforms, the majority of the variable 
residues between the zebrafish eEF1A isoforms are present on one side and show 
similar clustering arrangement as the variable amino acid between the human eEF1A 
isoforms (Figure 3.6). The Chimera software was then used to check if any of the 
positions containing variant amino acid residues were in close proximity (within 5Å) 
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to some of the functional annotations shown in figure 3.4. Position 298, which 
involved a non-conservative change of Ala298 in eEF1A1A and eEF1A1B (same as 
both human eEF1A variants) to Ser298 in eEF1A2 and eEF1A1L1, was found to lie 
within 5Å of Glu293 and His296, (equivalent to yeast Glu291 and His294) which are 
involved in eEF1Bα and aminoacyl-tRNA binding respectively. A double mutant form 
of yeast eEF1A with a H294A Q296R mutation (equivalent to position 296 and 298 in 
zebrafish eEF1A isoforms) was shown to promote actin cable formation when 
overexpressed in yeast cells but did not affect the total translation in the cells (Gross 
and Kinzy, 2007). Another variant position 355 which also entails a non-conservative 
substitution of Ala355 (eEF1A1A, eEF1A1B and both human eEF1A variants) with 
Ser355 (eEF1A2) and Gln355 (eEF1A1L1) lies within 5Å of Tyr357. The Tyr357 
residue is equivalent to the yeast Tyr355 which is also implicated in actin-related 
functions in yeast (Gross and Kinzy, 2007). Tyr357 is also in close proximity with 
another variable position, 358. This position is wholly conserved within the eEF1A 
orthologues with Ala358 for the eEF1A family (and eEF1A1L1) and Ser358 for the 
eEF1A2 family in human and zebrafish. Position 326 close to Phe310 (equivalent to 
yeast eEF1A Phe308) also involved in actin organisation, is variable between eEF1A 
isoforms in the zebrafish (Ala326 in eEF1A1A, eEF1A1B and eEF1A1L1, Cys326 in 
eEF1A2 only) but is wholly conserved within the eEF1A orthologues in both species. 
Close to Asp156, one of the residues important for GDP/GTP binding, is another 
variant position, 197, which has Asn in eEF1A1A and eEF1AB (same as human 
eEF1A1) and His197 in eEF1A2 and eEF1A1L1 (as with human eEF1A2).        
 
 



























Figure 3.6. Mapping of variant amino acids and known binding sites onto the surface of zebrafish 
eEF1A isoforms. Two views rotated by 180o about the y-axis of the 3-D models of eEF1A1L1 (purple), 
eEF1A1A (orange), eEF1A1B (grey) and eEF1A2 (blue) shown with the location of exposed variant 
amino acids (green) mapped on the surface compared in a pairwise fashion. Also highlighted on the 
surface of the models are: location of the C-terminal eEF1Bα-binding sites (cyan), GDP/GTP-binding 
sites (yellow) and aminoacyl-tRNA-binding residues (red). Residues His295 and Arg322 (equivalent to 
the yeast His293 and Arg320) are involved in both eEF1Bα and aminoacyl-tRNA-binding but have been 
indicated as only aminoacyl-tRNA-binding residues and coloured red for the sake of clarity. Variant 
amino-acid present in the equivalent disordered region of the yeast eEF1A are not represented.   
   
3.2.1.5 Prediction of phosphorylation sites in the zebrafish eEF1A variants  
Protein phosphorylation is the most common type of post-translational modification 
used to regulate protein function in eukaryotic cells (Levy, Michnick and Landry, 
2012). Phosphorylation is mediated by protein kinases which catalyses the transfer of 
the γ-phosphate from ATP to specific amino acids of the protein; which in eukaryotic 
cells are serine, threonine and tyrosine (Ubersax and Ferrell Jr, 2007). Interestingly, 
most of the differences between the zebrafish eEF1A proteins involved substitution of 
serine or threonine residues. Also, the tyrosine residues present at position 141 and 
167 in eEF1A1A, eEF1A1B and eEF1A2 are substituted with phenylalanine in 
eEF1A1L1. This is similar to what was observed in the study by Soares et al., 2009 in 
human eEF1A, although no change involved tyrosine in humans. Using an in silico 
approach, differential predicted phosphorylation profiles in human eEF1A1 and 
eEF1A2 were observed in their study. I therefore carried out a phosphorylation 
analysis of zebrafish eEF1A isoforms using the NetPhos 3.1 server (Blom, Gammeltoft 
and Brunak, 1999) (see section 2.2.10). The sequence of each variant was analysed 
using this server to identity likely serine, threonine or tyrosine residues that are 
phosphorylatable. A total of 27 out of 33 positions that involved change in serine or 
threonine residues within the eEF1A isoforms were predicted to be potential sites for 
phosphorylation. While 26 common phosphorylation sites were predicted, each eEF1A 
isoforms had their own specific predicted phosphorylation sites, with eEF1A2 having 
the most (12 in total). Seven out of nine residues which have been demonstrated 
experimentally to be phosphorylated in the human eEF1A variants are also predicted 
to be phosphorylatable in zebrafish (Figure 3.7). The isoform specific sites and the 
NetPhos prediction score for each position are shown in (Table 3.3). The higher the 
NetPhos score, the more likely that the predicted site is a true phosphorylation site. 
Some other predicted sites were shared by two or more of the eEF1A variants. Also, 
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one of the Tyr that was lost in eEF1A1L1 was predicted to be a phosphorylation site 
in eEF1A1A, eEF1A1B and eEF1A2 at position 167. The NetPhos score was high 
indicating Tyr167 to likely be a true phosphorylation site with eEF1A1A and 
eEF1A1B having a score of 0.659 and a higher score of 0.931 in eEF1A2. Also, worth 
noting is the high NetPhos score, >0.90 for all the four predicted eEF1A1B-specific 
sites indicating these sites are most likely true phosphorylation sites. The variant-
specific residues and Tyr167 predicted as phosphorylation sites were present on the 
surface of the modeled structures except for Tyr183 (eEF1A1L1) and Tyr85 
(eEF1A2). However, they all have their hydroxyl groups exposed (Figure 3.8) 
suggesting they are accessible to a kinase which is required for phosphorylation to 
occur. Although these prediction results will need to be validated, it provides 
preliminary findings that suggest the zebrafish eEF1A isoforms might be chemically 














Figure 3.7. Sequence alignment showing predicted phosphorylation sites for zebrafish eEF1A 
proteins. Phosphorylation sites are indicated with P, colour coded according to variants. P = all eEF1A 
variants, P= eEF1A1L1-specific, P= eEF1A1A-specific, P =eEF1A1b-specific, P = eEF1A2-specific, 
P = eEF1A1L1, eEF1A1A and eEF1A1B, P = eEF1A1A and eEF1A1B, P = eEF1A1B and eEF1A1L1, 
P = eEF1A1A, eEF1A1B and eEF1A2, P = eEF1A1A and eEF1A2, P = eEF1A1L1 and eEF1A2. 
Equivalent positions of the experimentally validated phosphorylated residues of the human eEF1A 








Table 3.3: Predicted isoform-specific phosphorylation sites in zebrafish eEF1A proteins 
Protein Residue  Position  NetPhos Score 
eEF1A1L1 Tyrosine 183 0.544 
Serine 239 0.515 
Threonine 303 0.835 
Serine 354 0.522 
Serine  440 0.663 
eEF1A1A Serine  205 0.506 
eEF1A1B Serine  222 0.991 
Serine  223 0.964 
Serine  339 0.924 
Serine  440 0.932 
eEF1A2 Threonine  83 0.541 
Tyrosine  85 0.586 
Tyrosine 86 0.509 
Serine 184 0.649 
Serine 187 0.567 
Threonine  234 0.660 
Serine 275 0.976 
Serine 331 0.558 
Serine 338 0.538 
Serine 358 0.881 
Serine 416 0.633 



















Figure 3.8. Location of isoform-specific potential phosphorylation sites on the 3-D structure of the 
zebrafish eEF1A protein. Ribbon representation of the 3-D model of zebrafish eEF1A isoforms 
showing predicted phosphorylation sites (side-chain of the residues at this sites are depicted with stick 
representation)   calculated using the NetPhos 3.1 server (Blom, Gammeltoft and Brunak, 1999) specific 
for A. eEF1A1L1 (purple) B. eEF1A1A (orange) C. eEF1A1B (green) and D. eEF1A2 (blue).Ser-462 
is not shown on eEF1A2 structure as it present within the equivalent disordered region in the yeast 
eEF1A structure. Predicted phosphorylated tyrosine residue at position 167 which is lost in eEF1A1L1 





3.2.2 Expression analysis of eef1a isoforms during zebrafish 
development and adult tissues 
To investigate the expression pattern and functional relationships of eef1a in zebrafish, 
I evaluated the expression of the four eef1a homologues during embryonic 
development and in various adult tissues. I performed both RT-PCR and quantitative 
PCR analyses on cDNA generated from RNA isolated from different developmental 
stages and adult tissues. At first, specific primers for each eef1a gene suitable for qRT-
PCR were designed and their specificity were confirmed from results obtained from 
sequencing RT-PCR products amplified from whole adult fish (data not shown).  
3.2.2.1 Expression of eef1a isoforms during development 
Twelve different stages during embryogenesis and early development in zebrafish, 
namely 1-cell, 2-cell, 4-cell, 8-cell, 16-cell, 256-cell, high, 50%-epiboly, 90%-epiboly, 
24 hours post- fertilisation (hpf), 48 hpf and 72 hpf stages, were analysed for eef1a 
mRNA using conventional RT-PCR (Figure 3.9). Expression of eef1a1l1 was detected 
at all developmental stages analysed, including the one-cell zygotic stage, suggesting 
eef1a1l1 is also maternally expressed. Expression of the other three eef1a genes, 
eef1a1a, eef1a1b and eef1a2, did not show any maternal expression as they were not 
detected during the early embryonic stages analysed from the one-cell to the 90%-
epiboly stage which begins 9 hpf. Expression of eef1a1a and eef1a1b were detected at 
the 24 hpf, 48 hpf and 72 hpf developmental stages. While it cannot be concluded on 
which developmental stage eef1a1a and eef1a1b were first expressed, an increment in 
their expression level could be seen between 24 hpf and 48 hpf (Figure 3.9B), and it 
could be possible it is around the 24 hpf stage, rather than a stage much closer to the 
90%-epiboly stage, that expression of these genes is induced. The eef1a2 gene is first 
expressed at 48 hpf, being the last eef1a gene to be detected during development in the 
zebrafish. 
To identify the expression pattern of eef1a genes during 24 hpf, 48 hpf and 72 hpf 
developmental stages, I performed whole-mount in situ hybridisation (ISH) using 
digoxigenin (DIG)-labelled antisense RNA probes to mark eef1a-expressing regions 
and DIG-labelled sense RNA probes as a control to check signal specificity (Figure 
3.10). Probes for each eef1a gene were designed from the 3’UTR region of the gene 
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where there is maximum sequence difference between the genes. This helps to avoid 
cross-hybridisation further ensuring specificity of the hybridisation reaction. The 
WISH experiment for eef1a1l1 showed that it is widely expressed from the head to the 
trunk at 24 hpf. At 48 hpf, its expression is enriched in the developing brain of the fish 
but is then reduced at 72 hpf and shows a more localised expression pattern with strong 
signal observed in the eye and tectum in the larva (Figure 3.10A). Simultaneous 
hybridisation with DIG-labelled sense RNA probe for all three stages was also 
performed and did not produce any signal and the fish remained clear (data shown for 
only 48 hpf embryo). For eef1a1a, eef1a1b and eef1a2 (48 and 72 hpf), I was unable 
to obtain a clear expression pattern, likely as a result of low transcript levels, as a 
longer incubation time of a minimum of 10 hours was required when analysed. 
Although background signal was produced with the sense probe, some difference in 
the staining intensity around the head region can be seen with staining with the 
antisense probe being more pronounced than the sense probe. However, further 
optimisation of the hybridisation parameters for these probes would be required to 


















     
Figure 3.9. Expression of eef1a genes during zebrafish development assayed by RT-PCR. A. Gel 
pic showing expression of eef1a1l1 in 1-cell, 2-cell, 4-cell, 8-cell, 16-cell, 256-cell, high, 50%-epiboly 
and 90%-epiboly embryonic stages. The other eef1a genes were undetected at these stages (data not 
shown). B. mRNA expression of eef1a in 24, 48 and 72 hpf stages. eef1a1l1 was detected in all stages 
while eef1a1a and eef1a1b were detected in 24 and 48 hpf. eef1a2 was the last isoform to be expressed 
during development at 48 hpf. As a loading control, expression of actin was also assessed in the same 
samples. RT-PCR was performed and gel run in duplicates using samples from the same cDNA. NTC 






























Figure 3.10. Whole-mount in situ hybridisation analysis of eef1a expression in different 
developmental stages in zebrafish. Expression of eEF1A mRNA was analysed at the indicated 
developmental satges A. At 24 hpf, eef1a1l1 is expressed in the whole embryos and is then enriched in 
the brain at 48 hpf. At 72 hpf, its expression becomes more localised and is noticeable in the eyes and 
tectum of the larva. A representative larva hybridised with the sense probe do not show any staining 
indicating the eef1a1l1 anti-sense probes are specific. B-C. Expression of eef1a1a and eef1a1b at 72 
hpf. D. Expression of eef1a2 at 5 dpf. Abbreviations: E- eye, fb- forebrain, hbv- hindbrain ventricle, l- 
lens, ov- otic vesicle, pb- pectoral fin bud, s- somite, t- tectum, y-yolk. 
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3.2.2.2 Expression of eef1a isoforms in adult tissues 
Expression of all four eef1a genes in adult tissues was examined in total RNA isolated 
from brain, muscle, spleen, testis, intestine, liver and ovary by conventional RT-PCR 
analysis (Figure 3.11A). Three eef1a genes, eef1a1l1, eef1a1a and eef1a1b, were 
detected in all the adult tissues examined. Expression of eef1a2 is readily observed in 
brain, muscle, spleen, testis and ovary tissues but only just detectable in the intestine. 
No expression is observed in liver for eef1a2. 
Using q-PCR, I quantified the expression levels of the eef1a transcripts in adult brain, 
muscle and liver tissues with prevalidated primers designed by Primerdesign. 
Simultaneous detection of ATPsynth, NADH and 16S expression was performed to be 
used as reference genes. Expression of these three genes were shown to be stable when 
measured in a representative set of cDNA samples from brain, muscle and liver tissues 
using the geNorm kit (Primerdesign, UK) (see Appendix figure 1). The geNorm 
analysis software ranks candidate reference genes by the stability measure M, where a 
lower M value indicates a more stable gene. A set of the three reference genes with the 
lowest M values were used to ensure accurate quantification of the eef1a transcripts in 
the tissues analysed. Each of the eef1a genes was normalised by the geometric mean 
of ATPsynth, NADH and 16S to obtain their transcripts expression levels in the brain, 
muscle and liver tissues. Similar to the RT-PCR results, eef1a1l1, eef1a1a and eef1a1b 
are found in the brain, muscle and liver while eef1a2 is only detected in the brain and 
muscle. However, the eef1a genes are not present in equal amount in the tissues in 
which they were detected. Expression of eef1a1l1 is significantly higher in liver when 
compared with brain and muscle (p<0.01 for brain and p < 0.05 for muscle, one-way 
ANOVA). On the other hand, eef1a1a, eef1a1b and eef1a2 show similar expression 
level patterns with a higher expression level in brain tissue than in muscle and liver (in 
the case of eef1a1a and eef1a1b) tissues (Figure 3.11B).  
The relative transcript levels of the four eef1a genes vary substantially across the three 
tissues examined above (Figure 3.11C). As a whole, eef1a1l1 transcripts are the most 
abundant with about 7,980, 7,830 and 240-fold higher overall expression ratios than 
eef1a1a, eef1a1b and eef1a2 respectively. However, expression levels of all the eef1a 
transcripts are similar in brain tissue with the higher expression level of eef1a1l1 
transcripts observed in the muscle (1,040, 1,280 and 490-fold higher than eef1a1a, 
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eef1a1b and eef1a2 respectively) and liver (22,900 and 22,200-fold higher in eef1a1a 
and eef1a1b respectively) tissues. The expression level of eef1a2 transcripts in muscle 
tissue is approximately two and three-fold higher than that of eef1a1a and eef1a1b 














   








Figure 3.11. Expression analysis of the four eef1a genes in adult tissues. A. Expression of eef1a1l1, 
eef1a1a, eef1a1b and eef1a2 in various adult tissues detected by RT-PCR. eef1a1l1, eef1a1a and 
eef1a1b are expressed in all the tissues analysed, while eef1a2 is expressed in all the tissues except liver. 
As a loading control, expression of actin was also assessed in the same samples. RT-PCR was performed 
and gel run in duplicates using samples from the same cDNA. For each gene, -RT controls were included 
for all analysed tissues and showed no amplification. B. Expression levels of eef1a in brain, muscle and 
liver tissues. Data are presented as the expression levels normalised to the geometric mean of ATPsynth, 
NADH and 16S. Results are means + S.E.M.; n=3 in each group. Asterisk show where there is a 
significant difference in transcript expression levels in the tissues (*p < 0.05, **p < 0.01 and ***p < 
0.0001, one-way ANOVA) C. Comparison of the relative expression levels of eef1a transcripts in brain, 
muscle and liver tissues. Results are presented as the gene expression ratio of the target mRNA to the 








3.2.2.3 Analysis of eEF1A2 antibodies specificity 
Detection of eef1a mRNA expression does not necessarily indicate they are translated 
into stable proteins, especially given the findings of Newbery et al. 2011 which shows 
the expression of eEF1A in Xenopus to be regulated at the post-transcriptional level. 
It is therefore essential to be able to analyse expression of eef1a at the protein level in 
zebrafish. Using the available eEF1A2 antibodies, I investigated the expression of 
zebrafish eEF1A2 further. One in-house generated eEF1A2 antibody (hereafter 
referred to as eEF1A2-2) and three commercial antibodies against eEF1A2 were 
tested. The eEF1A2-2 antibody has previously been shown in our laboratory to be 
specific for mouse and Xenopus eEF1A2. Protein extracts from zebrafish and mouse 
brain, muscle and liver tissues were used to perform western blot following the method 
described in Newbery et al. 2011 and probed for eEF1A2 using the eEF1A2-2 
antibody. A band was observed in protein lysates obtained from adult zebrafish and 
mouse liver tissues which were used as a negative control. This suggests a cross-
reactivity of the antibody with other eEF1A variants, since eEF1A2 is not expressed 
in the liver in both species. It is worth mentioning that a different batch of eEF1A2-2 
which had been purified by precipitation with ammonium sulphate only was used since 
the affinity purified eEF1A2-2 that was demonstrated to be specific in our laboratory 
was unavailable. This could explain why the lack of specificity of eEF1A2-2 was 
observed in my hands. Specificity of the three commercial antibodies (hereafter 
referred to as eEF1A2-Genetex, eEF1A2-Proteintech and eEF1A2-Abcam) were also 
tested using protein extracts from adult zebrafish brain, liver and muscle tissues. Since 
eef1a2 expression was not detected at the mRNA level in the liver, it was used as a 
negative control while the muscle tissue from mouse which is known to express only 
eEF1A2 was used as a positive control. A band of the correct size was observed in the 
liver for both eEF1A2-Genetex and eEF1A2-Proteintech antibodies, suggesting these 
antibodies were not specific for eEF1A2 alone.  
No band was recognised in the liver by eEF1A2-Abcam (Figure 3.12A) and it was 
then used to investigate the expression of eEF1A2 in different zebrafish tissues. 
Contrary to the findings of eEF1A2 expression at the mRNA level, no signal was 
detected for the muscle. No band was also observed in the other tissues: intestine, 
ovaries and heart which showed mRNA expression of eEF1A2 using eEF1A2-Abcam 
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antibody (data not shown). While a signal was readily detected in the brain, longer 
exposure time of about 30 minutes was required to produce a signal in the spinal cord 
using eEF1A2-Abcam antibody. To confirm the absence of a signal in the muscle was 
not due to the low abundance of eef1a2 mRNA based on the qPCR results, protein 
extracts from muscle tissues at concentrations of 20µg, 30µg, 40µg and 50µg were 
probed with eEF1A2-Abcam antibody. No signal was observed even when the blot 
was exposed overnight during the detection process. Simultaneous probing of samples 
from the same muscle extract was carried out using an antibody against the zebrafish 
eEF1A (now known as eEF1A1L1) from GeneTex, anti-Ef1a (Figure 3.12B). A band 
was readily observed in the muscle samples at all concentrations. Bearing in mind that 
the specificity of the antibody for zebrafish has not been tested and also that there is 
no expression data available for the zebrafish eEF1A2 protein, it is important that 









Figure 3.12. eEF1A2 expression in zebrafish tissues using eEF1A2-Abcam antibody. A. Western 
blot showing protein extracts from adult zebrafish brain, liver and muscle tissues probed with eEF1A2-
Abcam at a concentration of 1:1000. Control is muscle tissue from mouse. B. Western blot showing 
protein extracts from adult zebrafish brain, spinal cord and muscle tissues (at different concentrations 
of 20µg, 30µg, 40µg and 50µg) probed with eEF1A2-Abcam (left). Samples of the different 
concentration of the muscle, run in parallel, were probed with eEF1A2-Abcam (left) and anti-Ef1a 
(right) antibodies at concentrations of 1:1000. Muscle 1, 2, 3 and 4 is samples at concentrations of 20µg, 
30µg, 40µg and 50µg respectively. Transfer of protein were confirmed by staining blots with syproruby 
to visualise total protein on blots.      
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3.2.2.4 Cloning and expression of GFP-tagged eef1a construct and eEF1A2-
Abcam antibody validation 
With the presence of four eEF1A proteins in the zebrafish which have highly similar 
amino acid sequences, it is crucial that antibodies against any of the eEF1A isoforms 
are validated to ensure they are specific. For this purpose, I generated full-length 
eEF1A1L1, eEF1A1A, eEF1A1B and eEF1A2 transcripts from cDNA synthesised 
from brain RNA extracts which were expressed with a GFP tag at the C-terminus. This 
is to help differentiate them from the endogenous eEF1A in the cell lines where they 
would be expressed as these zebrafish eEF1A proteins will have a higher molecular 
weight when expressed together with the GFP tag. Transcripts of all four eEF1A 
isoforms were confirmed by Sanger sequencing and then cloned into the pcDNA6.2/C-
EmGFP-DEST expression vector using the Gateway® cloning technology (see section 
2.2.3.1). Sequencing of constructs was performed to check sequences of the eef1as 
cDNA and that of the GFP tag were in frame. Each construct (hereafter referred to as 
eEF1A1L1-GFP, eEF1A1A-GFP, eEF1A1B-GFP and eEF1A2-GFP) were transfected 
into HEK293 cells and their expression were confirmed by western blot using an 
antibody, anti-EF1α (Merck Milipore), which is known in our laboratory to pick up 
both mammalian eEF1A isoforms (Figure 3.13). 
The specificity of eEF1A2-Abcam antibody was further investigated using protein 
extracts from HEK293 cells that were transfected with eEF1A1L1-GFP, eEF1A1A-
GFP, eEF1A1B-GFP and eEF1A2-GFP constructs for western blot. Similar results 
were obtained using secondary antibodies for either LICOR or chemilumescent 
detection of the eEF1A2 in the samples, with a clearer result obtained using the 
chemilumescent method (Figure 3.14). A band of the correct size was observed for the 
cells transfected with eEF1A1A-GFP, eEF1A1B-GFP and eEF1A2-GFP but not 
eEF1A1L1-GFP suggesting that eEF1A2-Abcam is not specific for eEF1A2 in 








Figure 3.13. Expression of eEF1A constructs confirmed by Western blot analysis. eEF1A 
constructs tagged with GFP were transfected into HEK293 cells and their expression determined by 
western blot. Blots were probed for the tagged protein with anti-EF1α (Merck Milipore), which 
recognises all eEF1A isoforms. Band of the right size was observed for all four eEF1A constructs. 
The GFP tag adds ~ 27kDa, therefore expected band size is ~ 77kDa (Mol. weight of eEF1A= 50kDa). 
Only endogenous eEF1A1 was observed in protein lysates from HEK293 cells transfected with the 
empty vector or water (mock) which acts as the negative controls.     
 
 
Figure 3.14. Validation analysis of eEF1A2-Abcam antibody using the expression eEF1A 
constructs. Specificity of eEF1A-abcam was tested using the same lysates from HEK293 transfected 
with the different GFP-tagged eEF1A constructs. Immunoblotting was performed by A. LICOR and B. 
chemilumescent detection method. Transfer of protein were verified by staining blots with syproruby 




Initial studies suggested that the zebrafish has only one eEF1A gene in its genome 
(Gao et al., 1997). However, the recent completion of the sequencing of the zebrafish 
genome has shown that more than one eEF1A genes exist in the zebrafish. Although 
the zebrafish sequencing project is still work in progress, it is clear that four eEF1A 
genes are present in the zebrafish genome. These genes, eef1a1l1, eef1a1a, eef1a1b 
and eef1a2, are located on chromosomes 19, 13, 1 and 23 respectively. The structure 
of these genes show that they are not processed (intronless) pseudogenes and are 
predicted to be actively transcribed, encoding different functional zebrafish eEF1A 
proteins. All of them share high sequence identity at both nucleotide and amino acid 
levels. Due to their high similarities, three different approaches were used to assign 
these genes to their appropriate human orthologue. All approaches gave strong support 
to the classification of eef1a1a and eef1a1b as co-orthologues of the human EEF1A1, 
while eef1a2 is the orthologue of the human EEF1A2. The eef1a1b gene showed strong 
syntenic conservation with the genomic region containing the eef1a1a gene on 
chromosome 13 and is therefore a paralogue of eef1a1a and probably arose from the 
teleost-specific genome duplication that took place at the base of the teleost fish 
evolutionary lineage (Christoffels et al., 2004). The eef1a1l1 gene did not have any 
orthologue in the human genome but was clearly different from the other eef1a genes 
and is 92% identical to eEF1A1A and eEF1A1B and ~89% identical to eEF1A2 at the 
amino acid sequence level.  
In silico functional analysis similar to the study of Soares et al. 2009, although less 
comprehensive, was carried out for the zebrafish eEF1A using their structural data 
calculated for the yeast eEF1A. Also 3-D models of the zebrafish eEF1A proteins were 
constructed using the yeast eEF1A crystal structure as the template. This showed that 
all four zebrafish eEF1A isoforms consists of three structural domains: I (1-240), II 
(241-336) and III (337-443) similar to the yeast eEF1A structure and the domain-
domain contacts are almost conserved in them with variation at only two positions. At 
the two variable positions; 335 and 417, the variant residues still retain inter-domain 
interactions with their respective linker residues in domain III and II respectively. 
Also, the amino acid residues involved in the binding of the C-terminal fragment of 
eEF1Bα, aminoacyl-tRNA and GDP/GTP were completely conserved in the zebrafish 
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eEF1A isoforms, which is in line with the functional importance of these residues in 
translation. It is reasonable to assume that all four zebrafish eEF1A isoforms have 
similar translational elongation activity and may adopt an identical conformation to 
that shown in the crystal structure for the complex of the yeast eEF1A with the C-
terminal fragment of eEF1Bα (Andersen et al., 2000). 
Structural differences between the zebrafish eEF1A isoforms was analysed using in 
silico approach to analyse the location of variant residues within known binding sites 
or in close proximity (within a distance of 5Å) to them. Noteworthy of mentioning is 
the non-conservative change Ala298Ser (eEF1A1A and eEF1A1B/eEF1A2 and 
eEF1A1L1) which is unique to the zebrafish and is invariant in the human isoforms 
and is equivalent to the yeast eEF1A Gln296. This position is close to the binding site 
for eEF1Bα (Glu291 in yeast) and aminoacyl-tRNA (His294 in yeast). Interestingly, 
previous studies has implicated this position and others to be involved in actin-related 
functions in yeast (Gross and Kinzy 2007). They identified the mutant strains; one with 
a mutation at this site and 294 (H294A Q296R), K333E (equivalent to the variant 
position 335 in zebrafish eEF1A) and Y355C, (equivalent to 357 in zebrafish eEF1A), 
with normal translation function but that were able to reduce disorganisation of actin 
caused by overexpression of eEF1A. Similarly, a mutation N329S, which corresponds 
to the change that occur at position 331 (Asn331Ser) in the zebrafish isoforms, reduced 
the actin bundling activity with the translation function unaffected in yeast eEF1A 
(Gross and Kinzy, 2005). Two other position, 355 (unique to zebrafish) and 358 
(identical change in zebrafish and human) lie close to Tyr357 (yeast eEF1A2 Tyr355). 
It is therefore most likely these differences in amino acids between the zebrafish 
eEF1A isoforms at these positions 298, 331, 335, 355 and 358 confers different actin 
interacting properties on the isoforms. This does not however rule out the possibility 
of the Ala298Ser change having an effect on the eEF1B and aminoacyl-tRNA binding 
properties of the four isoforms since it lies within 5Å of both binding sites. 
A difference in the affinity of GDP and GTP between eEF1A1 and eEF1A2 has been 
reported, although it does not seem to influence protein synthesis using in vitro assays. 
While eEF1A1 binds more strongly to GDP, eEF1A2 shows more affinity for GTP 
than GDP (Kahns et al. 1998). They suggested that the non-conservative change 
(eEF1A1 Asn197His eEF1A2) could be one of the possible reasons for the difference 
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in guanine nucleotide binding between eEF1A1 and eEF1A2. Interestingly, this 
change also occurs in the zebrafish eEF1A isoforms, with eEF1A1A and eEF1A1B 
having an asparagine residue whereas eEF1A1L1 and eEF1A2 have a histidine residue 
at this position. Lying very close to 197, is Asp156, which is important for GDP/GTP 
binding and makes an hydrogen bond with Asn197 that is absent when this residue is 
replaced with a histidine in the structured eEF1A1L1 and eEF1A2 models as observed 
by Soares et al, 2009. The zebrafish isoforms may therefore exhibit differential affinity 
for guanine nucleotide binding which would further suggest likely functional 
differences within the isoforms. 
There is evidence to suggest that post-translational modification of eEF1A isoforms 
might play a key role in the functional differences between the two isoforms (Kahns 
et al, 1998, Soares et al, 2009, Soares and Abbott, 2013). As it is likely the zebrafish 
eEF1A variants might have slightly different biological roles even though they share 
translational function, the pattern of post-translational modification will reflect this. 
Indeed this was the case as the eEF1A isoforms exhibited differential predicted 
phosphorylation patterns when analysed in silico. Predicted variant-specific 
phosphorylation sites are exposed and have their side chain exposed such that they can 
interact with a kinase (as this is obviously essential for phosphorylation to occur). 
Some of the predicted sites overlap with putative binding sites or variant residues that 
lie close to a functional site. For example, the eEF1A2-specific Ser358 which has a 
strong NetPhos score of 0.88, and is close to the actin-related residue mentioned above. 
Interestingly, phosphorylation of Ser358 in human eEF1A2 by c-Jun N-terminal 
kinase has been confirmed in vitro (Gandin et al. 2013). Other predicted 
phosphorylation sites for which experimental evidence of post-translational regulation 
also exists include Ser21, Thr88 and Ser300. Ser21, which is one of the residues 
involved in GDP/GTP-binding (Figure 3.5) was shown to modulate the half-life as 
well as the apoptotic roles of eEF1A isoforms (Sanges et al., 2012). Interestingly, 
phosphorylated Thr88 (predicted for eEF1A1A, eEF1A1B and eEF1A1L1) was found 
only in the human eEF1A1 isoform (Sanges et al., 2012). Although the score for Thr88 
(0.53) is barely above the threshold for all the three zebrafish isoforms, the confidence 
of the prediction is increased by being in predictive agreement with findings from 
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Sanges et al., 2012. Similar to Ser21, phosphorylation of Thr88 improved the stability 
of human eEF1A1 in vivo.  
While all of the eEF1A1B-specific sites have been predicted with strong confidence 
and involves non-conserved serine residues, eEF1A1A specific site, Ser205 which is 
conserved in all the eEF1A variants has a score just on the threshold of 0.5. This 
suggests that eEF1A1B might have diverged in some other functions from eEF1A1A 
even though it is the most closely related paralogue compared with the other zebrafish 
isoforms. This possibility has been demonstrated by Chen et al., 2017, where they 
found heterozygous mutation in eEF1A1B to cause infertility in male tilapia 
(Oreochromis niloticus).  Unlike in human, the amino acid differences in the zebrafish 
eEF1A variants involves a loss of two tyrosine residues in eEF1A1L1. One of these 
positions, Tyr167 is likely a phosphorylation site in the eEF1A1A, eEF1A1B and 
eEF1A2, with a notably high prediction score of 0.9 in eEF1A2. Position 298, as 
mentioned above has been implicated in actin-related function in yeast and lies in close 
proximity to binding sites for eEF1Bα and aminoacyl-tRNA, was predicted to be 
phosphorylated in eEF1A1L1 (NetPhos score, 0.75) and eEF1A2 (NetPhos score, 
0.83). Interestingly, eEF1A1A and eEF1A1B has alanine at that position and this 
residue is very highly conserved with other higher vertebrates’ eEF1A orthologues. 
Modification of Ser298 could likely regulate the translation and/or actin-binding 
functions of eEF1A1L1 and eEF1A2 and possibly serve as a molecular switch for these 
isoforms between these two functions similar to what was observed with Ser21 
(Sanges et al., 2012). It has been suggested that differences in phosphorylation may 
contribute to the different oligomeric state observed in human eEF1A with eEF1A1 
having an enhanced ability to self-associate than eEF1A2 (Timchenko et al., 2013). 
While Timchenko et al., 2013 noted that the different oligomeric state did not affect 
the translation activity of the isoforms, it is likely to be of biological importance. For 
instance, in the study of Sanges et al., 2012, phosphorylation of Ser21 residue which 
affects eEF1A stability and apoptotic activity was found to be more pronounced when 
both isoforms were preincubated before the kinase assay was performed. Whether this 
is the case with the zebrafish eEF1A isoforms will require separate investigation.  
Gene expression analyses using RT-PCR confirms the presence of all four eef1a genes. 
Expression of the zebrafish eef1a genes were detected in a developmental-specific 
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manner which is a common feature of the different eEF1A genes in most species. 
During embryogenesis, eef1a1l1 was the only gene shown to have maternal 
contribution as well as zygotic expression. Interestingly, eef1a1l1 (formerly referred 
to as eef1a) has been shown to be an embryonic essential gene and is required for early 
embryonic development in zebrafish (Amsterdam et al, 2004). According to this study, 
mutation in eef1a1l1 causes abnormal phenotypes which becomes apparent from 2dpf 
in the fish. At 3dpf, the larva develops small head and eyes, reduced growth and 
eventually die at 5dpf due to failure of the swim bladder to inflate. It is worth noting 
that ISH results presented in this work shows eef1a1l1 to have a ubiquitous expression 
at 24hpf and an enriched expression in the head region and eyes of the fish at 48hpf. 
The next eef1a genes to be detected were eef1a1a and eef1a1b, while eef1a2 was the 
last to be expressed. The detection of eef1a2 at a later developmental stage is consistent 
with that of mammals, where its expression is observed much later in development 
gradually replacing eEF1A1 in skeletal muscle and neurons. 
Expression of eef1a genes was also determined in adult zebrafish using a range of 
tissues. In all the tissues analysed, mRNA of eef1a1l1, eef1a1a and eef1a1b were 
detected. The eef1a2 gene showed a tissue-specific expression pattern as its mRNAs 
was not present in the liver and was only just detected in the intestine. This is again 
another characteristics that appears to be conserved in vertebrates. The difference 
between the zebrafish eef1a2 and the mammalian and Xenopus orthologue however, 
is the presence of eef1a2 mRNA in the spleen and ovary tissues of the adult zebrafish. 
Whereas the expression pattern of eef1a1a and eef1a1b is in contrast to that of their 
mammalian orthologue, it is similar to that of Xenopus where eEF1A1 mRNA was 
also detected in the adult muscle (Newbery et al, 2011). Despite the co-expression of 
the eef1a genes in the tissues, quantification of transcripts levels in the brain, muscle 
and liver suggests that they are not present in equal amounts. While eef1a1l1 mRNA 
was more abundant in muscle and liver compared to the other eef1a genes, the levels 
of all the eef1a mRNA were the same in the brain. Similar levels of eef1a mRNA in 
the brain might stem from the presence of a more heterogeneous cell types in this tissue 
compared to the liver and muscle tissues. A follow up experiment looking at cell-
specific expression of these isoforms might shed more light on this. The eef1a2 
transcript was the second most abundant in the muscle but was only ~2-3 fold higher 
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than eef1a1a and eef1a1b. As expected and consistent with being paralogues, eef1a1a 
and eef1a1b exhibited the same expression pattern. 
Regulation of eEF1A expression resulting in the switching of eEF1A variants in the 
muscle and neuron, though conserved, occurs through different mechanism in 
mammals and Xenopus. While in mammals, this occurs at the transcriptional level, 
regulation of eEF1A expression is post-transcriptional in Xenopus (Chambers, Peters 
and Abbott, 1998; Kahns et al., 1998; Helen J Newbery et al., 2011; Svobodová et al., 
2015). Although it is not yet understood why Xenopus shows a different mechanism 
from mammalian species, Newbery et al 2011 postulated that it could likely be an 
adaption for the need of a quick response of eEF1A switching during metamorphosis. 
This is reasonable considering the dramatic developmental changes that accompany 
this process and occur in the whole organism simultaneously. It is therefore possible 
that the post-transcriptional mode of regulating eEF1A expression does not only occur 
in Xenopus species but might be conserved in lower vertebrates. Unfortunately, the 
complexity of the zebrafish eEF1A coupled with the dearth of antibodies for zebrafish 
made it impossible to reach a definite conclusion for this hypothesis. However, results 
obtained using an antibody against eEF1A2 from Abcam (ab82912) advertised to be 
specific for zebrafish indicates it might also cross-react with the other eEF1A variants, 
particularly eEF1A1A and/or eEF1A1B. This stresses the need to validate antibodies 
first before employing it for further analysis particularly with zebrafish to avoid 
misleading results. This is particularly relevant as this antibody was used in a recent 
study by Cao et al. 2017 to show the absence of eEF1A2 in their knockdown zebrafish 
model at 2dpf. My RT-PCR results revealed that all of the eef1a mRNA are already 
present at this stage and it is around this period that eef1a2 is first detected. A striking 
observation of my western blot results (summarised below) using the eEF1A2-abcam 
antibody was the absence of a band in a range of adult zebrafish tissues except brain 
where the four eef1a genes are co-expressed at the mRNA level and spinal cord. 
Interestingly, the manufacturers (Abcam) also tested eEF1A2-abcam antibody using 
protein lysates from adult zebrafish brain, heart, and skeletal muscle tissues, but only 
observed a band with the brain lysate (personal communication) which is in line with 
my own results. Although the specificity of anti-Ef1a (GeneTex) which was raised 
against eEF1A1L1 is questionable, it does confirm the presence of eEF1A in muscle. 
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It is difficult to interpret this intriguing observation. It is however possible that eEF1A2 
and eEF1A1A and /or eEF1A1B are not present in these other tissues assuming the 
eEF1A2-abcam recognises only these isoforms and not eEF1A1L1 and control of the 
zebrafish eEF1A occurs at the post-transcriptional level as in Xenopus. Alternatively, 
these isoforms might have different post-translational modification in the different 
tissue types which eEF1A2-abcam might not recognise.     
Summary of western blot results using different antibodies to probe tissues from 
adult zebrafish for eEF1A 
Antibody Brain Muscle  Liver  Spinal 
cord 
Intestine  Ovaries  Heart  
eEF1A2-2 Y Y Y NA NA NA NA 
eEF1A2-
Genetex 
Y Y Y NA NA NA NA 
eEF1A2-
Proteintech 
Y Y Y NA NA NA NA 
eEF1A2-
Abcam 
Y N N Y N N N 
Anti-Ef1a NA Y NA NA NA NA NA 
 Y- Band of the correct size detected, N- no band detected, NA- Not analysed      
Although, I was unable to investigate expression at the protein level, my findings 
suggest that while the zebrafish eEF1A isoforms have similar role in translation, the 
differences in residues, predicted phosphorylation sites and expression profile 
observed could possibly promote functional divergence in them thereby supporting a 
subfunctionalisation model for the four zebrafish eEF1A isoforms.  
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Chapter 4: Modelling eEF1A2 disease-causing 
mutation in zebrafish  
4.1 Introduction 
Since 2012, twenty different mutations in EEF1A2 have been identified in about 50 
patients. These individuals usually present with epilepsy, intellectual disability and in 
some cases autism (discussed in section 1.2.2 in Chapter 1). Modeling of these 
mutations in different living models will not only provide insight into the underlying 
mechanism of these mutations but will also help in the identification of new treatment 
for these disorders.  
Here, I describe experiments aimed at recreating the G70S mutation in zebrafish using 
CRISPR/Cas9 technology. Due to time constraints, this experiment was carried out 
concurrently with those described in chapter 5. I was however aware of the possibility 
that knocking out eef1a2 might not have any phenotypic effect in zebrafish because 
the other eef1a genes might compensate for its loss. In which case, zebrafish carrying 
a heterozygous missense mutation will be non-informative if the G70S mutation acted 
through a loss of function mechanism. As there are studies that provide evidence that 
suggests eEF1A can form dimers (Bunai et al., 2006; Sanges et al., 2012),  it is also 
possible that the G70S mutation could exert a dominant-negative effect on the wild-
type eEF1A2 or even the other eEF1As present in zebrafish. Also, it is still unknown 
whether the missense mutations in eEF1A2 results in a loss or gain of function effect 
in humans. In the study of  Davies et al., 2017, four Eef1a2G70S/-  mice generated from 
a CRISPR/Cas9-mediated gene editing experiment were found to show the typical 
wasted mouse phenotypes despite the expression of G70S protein in their brain at 
levels comparable to those of wild-type mice. This finding suggests that the function 
of eEF1A2 is compromised by the mutation since the G70S protein was unable to 
compensate for the loss of the wild-type Eef1a2 in the other allele. Also, one 
Eef1a2G70S/G70S mouse had a more severe phenotype compared to its Eef1a2 null 
littermates and had to be culled at 18 days which is earlier than that of wasted mice, 
which are usually culled at 21 days when the onset of the phenotype begins. This 
preliminary finding supports a gain-of-function mechanism is also at play with the 
G70S mutation.      
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These findings further stress the need to generate animal models that can accurately 
recapitulate the human phenotype as this will help inform decisions as regards 
developing new drug therapies. For example if these mutations are found to only lead 
to a loss of function of the mutant protein, then boosting wild-type eEF1A2 expression 
levels in the patients will be an efficient therapeutic strategy. However, this approach 
will be deleterious if the mutant protein has a dominant negative effect on the wild-
type. For this reason, it is therefore important to generate zebrafish with the missense 
mutations as eEF1A2-null zebrafish models might not be sufficient to model the 
human disorder.             
4.1.1 Guide RNA (gRNA) synthesis 
Guide RNA (gRNA) was originally designed with the intention to generate eef1a2 null 
zebrafish lines, however, for the sake of clarity it is described in here.   
Guide RNA target sites for zebrafish eef1a2 were designed using online target finders tools at 
http://crispr.mit.edu/ and at http://chopchop.cbu.uib.no/ (CHOPCHOP).  To increase the 
chances of abolishing expression of eef1a2, the majority of the gRNAs were designed to target 
sites on early exons. Also, gRNAs with no predicted off-target sites found by the finder tools 
were selected. Target sequences were amplified from genomic DNA extracted from AB wild-
type fish using the Phusion High-fidelity DNA polymerase and sequenced to confirm that no 
confounding sequence variants were present, as these can lead to a mismatch between the 
gRNAs and their target sites resulting in the inefficiency of the CRISPR/Cas9-mediated 
genome editing. Synthesised gRNAs were separately co-injected with nCas9 mRNA into 1-
cell stage zebrafish embryos. For each gRNA, target sites were amplified from pooled genomic 
DNA isolated from 10-15 injected 3 days post fertilisation (dpf) embryos. As it is likely that 
injected embryos will be mosaic, PCR products were cloned into TOPO-A vector and used to 
transform competent E. coli cells. Between 22 and 48 individual colonies were sequenced and 
used to estimate the mutagenesis efficiency of the experiment by dividing the number of 
colonies with mutant sequence insert by the total number of colonies with insert sequence I 
was able to read (see Table 4.1). The nCas9 mRNA which was co-injected with gRNA1, 
gRNA2 and gRNA7 was found to be inefficient, which could explain the low mutation rate 
observed with these gRNAs. The other nCas9 mRNA (gift from Zhiqiang Zeng) co-injected 
with gRNA3 and gRNA5 proved to be more efficient (see section 2.2.5.3 in Chapter 2). Higher 
mutagenic activity was seen in embryos injected with gRNA3 compared with gRNA5 injected 
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embryos which nevertheless also generated several mutations (Figure 4.1).  High survival rate 
was also observed in embryos injected with either gRNA3 or gRNA5.  
Table 4.1: Mutagenesis efficiency of CRISPR/Cas9 genome editing to target eef1a2 in 
zebrafish 








*gRNA1 2 48 35 0 0/35 (0) 
*gRNA2 2 48 24 0 0/24 (0) 
  gRNA3 3 38 31 24 24/31 (77.4) 
  gRNA5 2 36 31 9 9/31 (29) 
*gRNA7 6 22 8 1 1/8 (12.5) 

























Figure 4.1. Mutation rate analysis of gRNA3 and gRNA5 in CRISPR-Cas9 experiment. A-B. 
Examples of mutation sequences recovered from genomic DNA clones of lysed injected F0 embryos. 
(A) Shows those generated by gRNA3 and (B) shows those generated by gRNA5. Sequences 
highlighted in yellow indicates gRNAs target sites with the PAM site highlighted in purple. Inserted 











4.1.2 CRISPR/Cas9-mediated HDR experimental design  
The G70S (c.208G>A) mutation, which involves an amino acid residue that is highly 
conserved, was the first disease-causing EEF1A2 mutation discovered and has been 
identified in the largest number of individuals. Patients with this mutation usually 
present with epilepsy, intellectual disability and hypotonia (see Table 1.2 in chapter 
1). This mutation occurs on exon 3 and is only 8 base pairs away from the target site 
of gRNA3 which was also used in another CRISPR/Cas9 experiment described in 
chapter 5. Encouraged by the high mutagenic activity observed at this site with 
gRNA3, I speculated that it might be suitable to facilitate a targeted knock-in approach 
to recreate the G70S (c.208G>A) mutation in the zebrafish. To this end, I designed a 
single-stranded oligonucleotide (ssODN) repair template containing the G70S point 
mutation that spanned the same region targeted by gRNA3 as it is expected that is 
where DNA cleavage was likely to occur. Flanking the G>A point mutation in the 
ssODN template were 151 and 52 base pair homology arms on the 5’ and 3’ sides 
respectively.  A silent mutation was introduced in the PAM site targeted by gRNA3 
changing it from a NGG sequence (GGG) to a non-NGG sequence (GAG) on the 
ssODN repair template. This was done to avoid subsequent DNA cleavage from 
occurring following the incorporation of the repair template. Also, the repair template 
contained a two base substitution (CTTC) 153 base pairs upstream of the G70S 
mutation site. This change does not affect eef1a2 as it is situated well into the intron 
but it introduces a novel EcoRI restriction enzyme site to aid genotyping of the fish. 














Figure 4.2. G70S zebrafish CRISPR/Cas9 experimental design. A. Schematic representation of 
zebrafish eef1a2 showing the distance of the gRNA3 target site from the G70S point mutation in exon 
3. B. Sequence of the 200bps repair template containing the point mutation (in purple). A novel 
restriction enzyme site (in red) was introduced into the intron which is represented by the orange 
nucleotides. Target site sequence is in blue. PAM site is mutated from GGG to GAG to avoid cleaving 
of the repair template once integrated. C. The translated amino acid sequence of WT and a G70S 
template showing that the PAM-blocking mutation (highlighted in orange) is silent and does not alter 








4.1.1 Microinjection and screening of founders for mutation  
The ssODN repair template along with gRNA3 and Cas9 mRNA was microinjected 
into one-cell embryo stage by the fish facility Manager, Dr. Cameron Wyatt. The repair 
template was injected at two test concentrations; 92ng/µl and 183ng/µl into 108 and 
131 embryos respectively. Injected embryos were placed in E3 solution in batches of 
50 per 9cm Petri dish and kept in the incubator at ~ 28.5oC.  Dead or deformed embryos 
were discarded and the healthy ones were placed in fresh E3 medium daily. At 5 days 
post fertilisation, injected embryos were transferred to tanks and raised until they were 
2 months old. Table 4.2 summarises the number of injected fish at different ages that 
were alive during the course of the experiment.          
 Table 4.2: Number of surviving fish at different ages injected with 92ng/µl and 
183ng/µl ssODN  
ssODN 
concentration 
Number of injected 
one-cell embryos 
Number of injected 
embryos at 5dpf 
Number of injected 
F0 at 2 months old 
G70S 92ng/µl 108 100 46 
G70S 183ng/µl 131 113 40 
 
DNA was isolated from fin-clips of 2 month old injected fish (F0) and the region 
around the EcoRI restriction enzyme site and mutation site was amplified. 
Incorporation of the PAM-blocking and G70S silent mutation will result in the loss of 
the two MnlI site (Figure 4.2A), as such MnlI would fail to digest G70S mutant 
amplicons, thereby identifying founders with this mutation. Also, the amplified PCR 
product of 489 base pairs digested with EcoRI will generate bands of 429 and 60 base 
pairs if the repair template was incorporated by homology-directed repair (HDR) since 
this restriction enzyme site was engineered into the repair template only. The 
restriction enzymes, MnlI and EcoRI, were then used to digest PCR products to 
determine if the knock-in experiment was successful (Figure 4.3).                     
A total of eighty-six F0 fish were genotyped using both restriction enzymes but none 
of them were found to have incorporated the repair template or have the G70S 
missense mutation. Insertion and deletion mutations, mainly around the target site of 
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gRNA3, were consistently revealed on sequencing cloned PCR products obtained from 
a total of 21 founders (Figure 4.3C). These results, therefore suggests that the 
CRISPR/Cas9-mediated HDR experiment was unsuccessful.   
Since no founder with the desired mutation was identified, this work could not be taken 
further and there was insufficient time to attempt another experiment to produce a 




















Figure 4.3. CRISPR/Cas9 experiment generated indels but failed to generate a G70S mutation in 
ssODN injected founders. A. Sequence of PCR product for wild-type (WT) and G70S. Orange 
sequence indicates target site while PAM site is underlined. MnlI cut sites (highlighted in grey) is shown 
in the wild-type PCR product. These sites have been destroyed by the PAM-blocking mutation (G >A 
in the G70S product) and the G70S point mutation (shown in purple). Yellow highlight indicates EcoRI 
cut site contained in the repair template by a CT to TC substitution. B. Example gel electrophoresis of 
PCR products and restriction enzymes (MnlI and EcoRI) digest from 23 founders. NTC indicate a ‘no 
template control’ while ‘+’ indicate a positive control that cuts with EcoRI. Predicted band sizes using 
NEBcutter V2.0 are shown to the right of the digest gels. PCR product size; 489bp. MnlI (middle) - WT 
band sizes: 291bp, 190bp and 8bp. G70S band uncut (489bp). EcoRI (bottom) - WT band uncut (489bp). 
G70S band sizes: 429bp and 60bp. + band sizes: 171bp and 73bp. C. Example sequence results from 
cloned PCR products from founders. Note that some of the generated indels destroy one or both of the 
MnlI cut sites which could explain the partial digest of some amplicons by MnlI.                         
 
4.2 Discussion 
There has been a remarkable development of different tools for gene manipulation 
such as the zinc finger nucleases (ZFN), transcription activator-like effector nucleases 
(TALEN) and the more recent clustered regularly interspaced short palindromic repeat 
(CRISPR) system. With these genome editing technologies, mutations at a desired 
location in the genome can be efficiently generated in various model organisms. 
CRISPR/Cas9  has been shown to be highly efficient in inducing mutations at rates 
comparable or even exceeding that of ZFN and TALEN, which were the most used 
methods before the CRISPR/Cas9 system was adapted for use in the zebrafish 
(Hruscha et al. 2013, Hwang et al. 2013, Jao et al 2013). However, CRISPR/Cas9 
offers the advantage of being cheaper, easier to design and less time consuming than 
ZFN and TALEN, making it an excellent alternative to these other methods. 
After successfully identifying a gRNA with high mutagenic activity which was 
fortunately in close proximity to the G70S mutation, I sought to use this gRNA in a 
CRISPR/Cas9-mediated HDR experiment to recreate the point mutation in the 
zebrafish eef1a2. The G70S (G>A) point mutation is only 8 base pairs away from the 
target site of gRNA3 with a mutagenic efficiency of 77.4%.  A repair template was co-
injected with gRNA3 and Cas9 mRNA to take advantage of the homology-directed 
repair (HDR) pathway to introduce our desired mutation. A ssODN was used as the 
donor repair template and designed to contain the point mutation and a silent mutation 
at the PAM site, to avoid further targeting once it has been integrated into the gene. In 
addition, a novel EcoRI restriction site was engineered into the ssODN to assist in 
genotyping the fish. Due to time and space constraints, screening for the G70S 
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mutation was carried out in the founders. Unlike non-homologous end joining (NHEJ) 
induced gene disruption, HDR requires screening for a precise mutation and can be 
time-consuming especially in zebrafish where there are high levels of mosaicism 
among founder fish. For this reason, founders were pre-screened using restriction 
fragment length polymorphism (RFLP) analysis. G70S founders were to be identified 
based upon their loss of MnlI sites and the ability of their PCR products to be digested 
when treated with EcoRI. Unfortunately, the expected cut pattern was not observed in 
any of the founders. Although a partial cut was observed when some of the PCR 
products were digested with MnlI, sequencing results obtained from some founders 
showed similar NHEJ-induced indel distribution which disrupted the MnlI sites. Also, 
EcoRI failed to digest the amplicons further supporting that the partial cut might be 
due to these indel mutations and not as a result of the G70S mutation being 
incorporated. There is, however, the possibility that fish with a point mutation could 
be missed using this approach as a result of the high null background. As such it is best 
to analyse F1 generation when possible to avoid this complication due to mosaicism 
in founders. However, the mutation must occur in the germline of the founders and 
breeding large number of fish for screening might be needed. Taken together, these 
results suggest that HDR did not occur and that the induced double-stranded breaks 
were likely repaired by the NHEJ pathway only.   
HDR is a rare event with DSBs being predominantly repaired by the NHEJ pathway 
which occurs at least 10-fold higher than HDR during early embryonic development 
in the zebrafish (Dia et al. 2010, Li et al. 2015). Although the efficiency of the NHEJ 
pathway was high and reliably generated indels, none of the fish had incorporated the 
G70S point mutation. A similar experiment was performed by Armstrong et al, 2016 
where they successfully introduced a point mutation in tardbp and fus but with very 
low efficiencies. Surprisingly, the gRNA target sites for tardbp and fus used in their 
study had low efficiencies of 21% and 17% respectively. It is, however, possible that 
the position of their point mutation, being within the gRNA target sites, favoured the 
integration of the repair template. Interestingly, a systematic characterisation of the 
distance of the mutation to the cut site showed that a distance of 10bp reduces HDR 
efficiency by half in human IPS cells (Paquet et al. 2016). Several other studies have 
demonstrated the feasibility of precise gene modification using CRISPR/Cas9-
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mediated HDR, but its efficiency is still considerably low in zebrafish and results have 
been inconsistent in zebrafish (Cornet, Di Donato and Terriente, 2018; Zhang, Zhang 
and Ge, 2018). This has become a limiting factor in harnessing the combined 
advantage of the CRISPR/Cas9 technology and the zebrafish model stressing the need 
for further investigations pertaining to the development of an efficient CRISPR/Cas9-
mediated HDR protocol that could be routinely used in the laboratory. This might 
require a systematic approach to optimise the best conditions of the several factors 
showed to influence HDR efficiencies such as the activity rate of the gRNA, distance 
of mutation from the target site and design of repair template. Interestingly, in the study 
by Armstrong et al, 2016, two ssODN templates that differ in length showed different 
HDR efficiency, with the 100 base pairs template having a slightly higher efficiency 
than the one which was 23 base pairs in length. Also, while Armstrong et al, 2016 
postulated that a higher HDR efficiency would have been achieved if gRNAs with high 
efficiencies were used, results from my study shows that several other factors order 
than the use of poor gRNAs might have been responsible.      
Interestingly, a recent study by Zhang et al. 2018 demonstrated that employing a 
combination of the optimal condition of these factors significantly increased the rate 
of CRISPR/Cas9-mediated HDR. The approach used in this study that was most 
effective involved the use of a plasmid DNA donor, suppressing NHEJ and enhancing 
HDR rates by the use of drug antagonists: SCR7 (inhibits NHEJ) and RS-1 (HDR 
enhancer), Cas9 protein and a CRISPR/Cas9 blocking mutation. A combination of 
these parameters and a gRNA with a mutation rate of 80% resulted in a high HDR 
efficiency rate of about 74% and a germline transmission rate of 25%. Another 
advantage of this study is that it was designed such that point mutations can be easily 
identified in founders with a high background of indel mutations when screening, 
avoiding the need to breed large number of fish. The protocol described by Zang et al. 
2018 could, therefore, be adapted as a guide in designing another round of 
CRISPR/Cas9 experiment to generate a G70S mutant zebrafish line. It is important to 
note that the point mutation incorporated in this study was within the target site which 
could have also contributed to the high level of efficiency obtained in this study. 
However, there is the possibility that the distance of the G70S point mutation from the 
target site might not dramatically reduce the expected level of efficiency reported as it 
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is only 8 base pairs away from the gRNA3 target site. Interestingly, it might even 
increase the chances of generating fish heterozygous for the G70S mutation which will 
be equivalent to the genotype seen in humans as well as other genotypes for 
comparative studies. This is because optimisation of the adequate distance between the 
target site and the mutation position by Paquet et al. 2016 showed that a distance of 5-
20 base pair favours heterozygous editing, while a gRNA targeting <10 bp from the 
mutation was ideal for homozygous editing. Although Paquet et al 2016 carried out 
this work in human IPS cells, this relationship between the cut to mutation distance 
and zygosity might also be applicable to the zebrafish. It might, therefore, be possible 
to make use of gRNA3, avoiding the need to design and assess the mutation efficiency 
of another target site.   
CRISPR/Cas9 genome editing was recently used in our laboratory to generate mice 
with G70S with a high level of efficiency (Davies et al., 2017). Although no mice 
heterozygous for G70S mutation were recovered, this study provided some 
preliminary findings that suggest the G70S mutation might also act through a gain of 
function. Given the importance of the functional impact of the G70S mutation in 
developing treatment strategies, a G70S zebrafish mutant line will be useful as an 
additional model to confirm this finding. I will also be interested in modeling other 
disease-causing eEF1A2 mutations using the method from the study of Zhang et al, 
2018 since it is possible these mutations might operate through different mechanisms 
as suggested by the phenotypic heterogeneity in the patients. For example, the D252H 
mutation which could be used in future studies together with our recently generated 
mice and LUHMES cells D252H models. Moreso, since I was able to generate and 
characterise a homozygous null zebrafish line (discussed in chapter 5), results on the 








Chapter 5: Generation and characterisation of eef1a2 
knockout zebrafish model 
5.1 Introduction 
Complete loss of Eef1a2 in mouse causes motor neuron degeneration in the spinal cord 
anterior horn, muscle wasting and death by 4 weeks. More recently, a heterozygous 
null mutation in Eef1a2 has been shown to cause a minor social discrimination in mice, 
even though these mice appear normal (J.E Hope, Ph.D. thesis). Studies using this 
model have no doubt provided valuable information on eEF1A2 function in vivo. 
However, homozygous Eef1a2 null mice show postnatal mortality and are therefore 
not a suitable model for drug discovery studies. Also, the use of rodent models in the 
development of new drugs is costly, time-consuming, ethically challenging and usually 
performed at low-throughput. On the other hand, zebrafish has been shown to be an 
ideal model system for the screening of new drug molecules. This model provides a 
whole-animal system for investigating the onset and course of a pathological process 
in vivo and at the same time, allows for high-throughput screening of several small 
molecules simultaneously which saves time and is cost-effective, which is particularly 
useful in the pharmaceutical drug discovery field (Lieschke and Currie, 2007). For this 
reason, I aimed to investigate whether the zebrafish could be used as a complementary 
model to fill this need.  
Bioinformatics and expression analysis described in chapter 3 identified four eef1a 
genes with a clear indication of the presence of a eEF1A2 orthologue in the zebrafish 
which is similar in amino acid sequence (94%) to that of the mouse. This also provides 
some evidence of sub functionality among these genes as they showed distinct 
expression profiles during the development of the zebrafish embryo. However, this 
interpretation is confounded by the co-expression of all the eef1a transcripts in a range 
of adult tissues which might also indicate functional redundancy. It is important to note 
that regulation of eEF1A expression in Xenopus occurred at the post-transcriptional 
level (Newbery et al 2011), therefore making the interpretation of the RNA level 
expression data not straightforward. 
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In this chapter, I describe work focused on eef1a2 as this will provide an essential 
underpinning for assessing the suitability of the zebrafish as a model for our studies. 
This was achieved by 
 Generating a eef1a2 knockout zebrafish model using a CRISPR/Cas9 
system  shown to be efficient in zebrafish (Hwang et al., 2013) and the 
subsequent validation of  two independent mutant lines  
 Characterising mutant lines to determine the effect of eef1a2 disruption 
on phenotype and survival in zebrafish    
  
5.2 Results                 
5.2.1 Generation of eef1a2 null zebrafish lines  
To generate a null eef1a2 zebrafish model using CRISPR/Cas9, I designed and 
constructed five different guide RNA sequences (gRNAs) targeting the eef1a2 gene. 
This is described in full details in section 4.1.1 in chapter 4. Two of these gRNAs; 
gRNA3 and gRNA5 which showed the highest mutagenic activity were then selected 
for further investigations. Embryos injected with gRNA3 and gRNA5 showed a high 
survival rate of 93% and 67% respectively. At 2 months old, nine CRISPR-injected 
fish for each gRNAs were genotyped using genomic DNA isolated from tail fin 
clipping to identify potential founders using the Agilent 2100 Bioanalyser. If 
mutagenesis is successful in the F0, PCR products will be made up of a mixture of 
wild-type and different mutant sequences since founders are usually mosaic. The 
presence of multiple sequences creates heteroduplex DNA which could be seen for all 












Figure 5.1. PCR products amplified from F0 fish injected with gRNA3 or gRNA5 in the CRISPR-
Cas9 experiment. Screening of potential F0 mutants injected with gRNA3 (top) or gRNA5 (bottom). 
Level of mismatches forms heteroduplexes (red line). Black star indicates founder (F0) used to generate 
mutant lines. WT1, WT2 and WT3 indicate PCR products from fin clipping obtained from three 










5.2.2 Germline transmission and establishing stable mutant lines 
In order to employ these mutants for further characterisation, it is important to generate 
fish with identical mutations in every cell. This is only possible after germline 
transmission of the mutations of the putative founder fish, which are genetically 
mosaic. To confirm that mutations could be transmitted to their offspring, nine of the 
screened F0 of each gRNAs were in-crossed separately and individual F1 embryos 
were sequenced. gRNA5 injected F0 had a low germline transmission frequency of 
18.8% (mutant F1/examined F1= 6/32) while a much higher germline transmission 
frequency of 82.9% (mutant F1/examined F1= 25/35) was observed in F0 injected with 
gRNA3.  
To establish stable null mutant lines, putative founders were outcrossed with wild-type 
fish to avoid transmitting unlinked off-target mutations. Mating was successful with 
founder A2 (gRNA3) and three mutant alleles were recovered (Figure 5.2A). Two 
alleles, a 4 base pair insertion (hereafter referred to as Ins4) and 2 base pair deletion 
(hereafter referred to as Del2) were chosen for further analysis. Heterozygous fish 
carrying the same eef1a2 mutation were crossed and the mutation was confirmed in 
F2 homozygote offspring using Phusion High fidelity DNA polymerase (Figure 5.2B-
C). Complete loss of Eef1a2 in mice causes a wasted phenotype from 21 days of age 
with rapid deterioration and the homozygous mice die by 28 days (Shultz, L.D, Sweet, 
H.O, Davisson, 1982). Interestingly, both eef1a2 mutant lines reached adulthood 
without showing any obvious abnormal phenotypes and were fertile (Figure 5.2D). As 











Figure 5.2. Establishing eef1a2 mutant zebrafish line. A. Schematic of outcross mating of founder 
fish with wild-type showing recovered F1 sequences with the number for each sequence indicated in 
brackets. Target sequences (yellow highlight) and PAM site (purple) with red showing inserted bases. 
B-C. Predicted effect of the mutant allele (upper panel) and Sanger sequencing data from homozygous 
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fish which confirmed mutant alleles for Del2 and Ins4 mutant lines (bottom panel). Aberrant residues 
are shown in red D. No overt difference in homozygous Del2 (6 months) and Ins4 (8 months) adult fish 
from wild-type (6 months) adult fish.     
  
5.2.3 Del2 and Ins4 mutant lines show reduced eef1a2 transcript levels. 
Selected alleles are predicted to cause a frameshift lesion which introduces a premature 
stop codon. It is likely that the mRNA transcripts from these alleles would be subjected 
to nonsense-mediated decay, since the premature stop codon occurs early and is 
located > 50 – 55 nucleotide upstream an exon-exon junction (Brogna and Wen, 2009; 
Popp and Maquat, 2016). The Del2 allele is predicted to encode a truncated 
polypeptide with 11 aberrant amino acid residues starting with an Arg to Gly 
substitution at position 67, while the Ins4 allele encodes a truncated polypeptide 
containing 14 aberrant amino acids (Figure 5.2B-C). To investigate the severity of 
these mutant alleles, I examined the levels of eef1a2 transcript by real-time 
quantitative PCR in adult homozygous Del2 and Ins4 mutant zebrafish tissues. Two 
different set of primers, eef1a2P and 3’eefla2, were used for both lines while a third 
primer set; eef1a2S was used only in Ins4. The location of the primers in relation to 
the target site is illustrated in figure 5.3. The 3’eef1a2 primer set which is located 
further downstream from the target site was designed to assess nonsense-mediated 
decay efficiency. Both Del2 and Ins4 mutations lead to a decrease in transcripts levels 
compared with those seen in the wild-type siblings. Using primers eef1a2P and 
3’eef1a2, eef1a2 levels were reduced by approximately 81% and 92% in the Del2 
homozygous adult brain compared to their wild-type siblings. On the other hand, 
eef1a2P and 3’eefla2 showed a eef1a2 transcript level reduction of approximately 86% 
and 95% respectively in the Ins4 homozygous adult brain compared to wild-type. 
Similarly, eef1a2S showed a decrease of eef1a2 mRNA of approximately 82% in F2 
Ins4 homozygous adult brain and muscle tissues compared with wild-type (see 
Appendix figure 2A).  
These primer sets were then used to assess the transcript levels of eef1a2 in the brain 
of adult homozygous 12bp deletion mutants. As expected, there was no significant 
decrease in transcript levels as this is an in-frame mutation and is not predicted to cause 
a truncated protein (see Appendix figure 2B). These results suggest that the Del2 and 
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Ins4 allele leads to an increased messenger RNA degradation rate possibly through 
nonsense-mediated decay (NMD). It is, therefore, possible that Del2 and Ins4 are 



























Figure 5.3. Reduced eef1a2 transcript levels in Del2 and Ins4 mutants. A. Schematic of the eef1a2 
gene with untranslated region, exons and introns depicted as open box, filled box and line respectively. 
The position of the three different primer sets; eef1a2S (Blue triangle), eef1a2P (black triangle) and 
3’eef1a2 (red triangle) is illustrated in relation to the gRNA3 target site (PAM site sequence in red).  B-
C. eef1a2 mRNA expression (normalised to three reference genes: ATPsynth, NADH and 16S) as 
assessed by qPCR in (B) F2 Del2 homozygous (4 months) and (C) F3 Ins4 homozygous (3 months) and 
age-matched wild-type adult brain. Transcript levels of eef1a2 were reduced in both lines using two 
different sets of primers suggesting NMD is taking place. Results are means + S.E.M.; n=3 in each 





5.2.4 Characterisation of mutant fish by histology  
Since the eef1a2 mutant zebrafish had a normal physical appearance and did not show 
any obvious phenotype, I decided to perform a histological analysis of the central 
nervous system in adult mutant fish to establish whether any changes could be 
identified at a cellular level. Loss of function of Eef1a2 in mice has been well 
characterised and shown to cause severe neuromuscular abnormalities such as motor 
neuron degeneration of the anterior horn of the spinal cord and muscle wasting which 
is of neurogenic origin (Newbery et al., 2005; Doig et al., 2013). As a preliminary 
study, a detailed histological examination of longitudinal brain sections, 3µm-thick, 
obtained from one male homozygous Ins4 adult fish (5 months old) was carried out by 
Dr. Jorge del Pozo, a diagnostic pathologist at Easter Bush Veterinary Centre (EBVC). 
He observed lower neuronal density in the cerebellum and medulla oblongata in the 
Ins4 mutant compared with its age-matched male wild-type sibling (see Appendix 
figure 3). Interestingly, Shultz et al 1982 reported loss of Purkinje cells in the brain of 
wasted mouse. Therefore, a follow-up study was carried out using three male fish per 
genotype including the homozygous Del2 mutants as a complementary line which 
would also be predicted to be effectively null. Longitudinal brain sections of 3µm-
thick were also generated from each fish and stained with H&E at the EBVC. For each 
fish, I analysed the number of Purkinje cells in the cerebellum at three areas around 
the corpus cerebelli (Figure 5.4A). This region was chosen as it was best represented 
in all the fish and allowed uniformity of sampled areas. Using one-way ANOVA, there 
was no significant difference in the density of Purkinje cells in the cerebellum of Ins4 
and Del2 mutants when compared to wild-type (Figure 5.4B). It is, therefore, possible 
that the difference initially observed was artefactual.       
Thin sections of spinal cord from homozygous Ins4 and Del2 adult fish were evaluated 
for gliosis. Gliosis is the reactive response to a variety of injuries to the central nervous 
system from trauma to neurodegeneration (Goc et al., 2014). During this process, 
microglia and astrocytes are activated and expression of glial genes are upregulated, 
one of which is GFAP (O’Callaghan and Sriram, 2005). Glial fibrillary acidic protein 
(GFAP) is a widely used biomarker to evaluate gliosis and high level of staining of 
this protein has been shown to occur in the anterior horn of the spinal cord of wasted 
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mouse (Newbery et al., 2005). I, therefore, stained spinal cord sections from 
homozygous Del2 and Ins4 mutants with an antibody against GFAP. Spinal cord 
sections of homozygous Del2 and Ins4 mutants did not show increased staining for 
GFAP when compared to wild-type (Figure 5.4C). These results suggest the absence 























                
     
 
 








Figure 5.4. Del2 and Ins4 characterisation by histology. A. Representative Screenshot of 
ImageJ counter window used for analysing the Purkinje cell density in the cerebellum. The three 
sampled areas around the corpus cerebelli (CCe) (indicated with yellow squares) show individual 
Purkinje cells counted for square 1 (blue), square 2 (cyan) and square 3 (green) B. Graph showing 
average number of Purkinje cells per µm2 in homozygous Del2 and Ins4 fish compared to wild-type 
adult cerebellum. No significant difference was observed (One-way ANOVA). Results are means + 
S.E.M.; n=3 fish per genotype. C. Anti-GFAP antibody stained transverse sections of homozygous Del2 
and Ins4 spinal cord shows no sign of neurodegeneration. Negative control of a no primary (No Pri) 









5.2.5 Transcript levels of the other eef1a genes 
To investigate whether there might be an underlying compensatory mechanism from 
the other eef1a genes leading to the healthy appearance of the two mutant lines 
generated, quantification of transcript level of the other eef1a genes (eef1a1l1, eef1a1a 
and eef1a1b) was performed in homozygous Del2 and Ins4 mutants. Pre-validated 
custom primers for eef1a1l1, eef1a1a and eef1a1b from Primerdesign and the same 
brain cDNA used to quantify eef1a2 transcripts levels in section 5.2.3 were used for 
this experiment. Using the Mann Whitney test, transcripts level of the other eef1a in 
Del2 and Ins4 mutants were not significantly different from wild-type fish (Figure 5.5).  
There is the possibility of the endonuclease activity of Cas9 to lead to random off-
target mutations. The chances of this occurring are further favoured with the presence 
of four homologous eef1a genes and the use of a gRNA that targets exonic region 
which displays high similarities across the gene family. With this in mind, these data 
were also used to investigate any off-target effect of the CRISPR/Cas9 experiment 
involving the other eef1a genes. Since no significant change in the expression level of 











Figure 5.5. Transcript levels of the other eef1a gene in del2 and Ins4 adult brain. A. eef1a1l1 (left), 
eef1a1a (middle) and eef1a1b (right) mRNA expression levels in del2 homozygous adult brain. B. 
eef1a1l1 (bottom left), eef1a1a (bottom middle) and eef1a1b (bottom right) mRNA expression levels 
in Ins4 homozygous adult brain. Transcript levels of the other eef1a genes (normalised to three reference 
genes: ATPsynth, NADH and 16S) were not significantly different compared to wild type. Results are 







5.2.6 Behavioural characterisation of homozygous Ins4 mutant larvae 
It was recently discovered in our laboratory that homozygous Eef1a2 null mice on a 
pure C57BL/6 background, generated from a CRISPR/Cas9 experiment, were 
susceptible to audiogenic seizures. This finding was particularly interesting as epilepsy 
has been noted to occur in individuals with missense mutations in eEF1A2, with the 
mutation being de novo in almost all cases. Both of these findings suggest eEF1A2 to 
be an epilepsy susceptibility gene. I decided to investigate the susceptibility of eef1a2 
null fish to chemical-induced seizures especially as zebrafish are considered good 
models to study epileptic seizures in humans as they can be used for high-throughput 
screening for effective AEDs which has already been demonstrated by Baraban, 
Dinday and Hortopan, 2013 (discussed in section 1.3.3). For this experiment, 
pentylenetetrazole (PTZ) was chosen since it a common and well-established 
compound used to induce seizures in zebrafish. Also, PTZ-induced seizures in 
zebrafish larvae have been fully characterised and found to closely resemble seizure 
behaviour and changes evoked in rodents (Baraban et al., 2005). Titration of five 
different PTZ concentrations; 1mM, 2mM, 2.5mM, 5mM and 15mM dissolved in 
normal E3 medium was carried out using 5 dpf wild-type larvae to identify the 
optimum concentration of PTZ that gives the best results of inducing a seizure 
phenotype in wild-type prior to performing the experiment on the mutants. The PTZ 
concentration at 2.5mM induced a mild increase in activity in the larvae and was 
selected as the working concentration. The rationale behind this was that an increase 
in hyperactivity by the eef1a2 null mutants at this concentration compared to wild-type 
would be easily detected if a synergic effect of eef1a2 knockout and PTZ treatment 
occurs. Only homozygous Ins4 and wild-type larvae were used, as homozygous Del2 
mutants were not available at the time this experiment was conducted. Twenty four 5 
dpf larvae per treatment group were placed in individual wells of a 96-well plate.  
To quantify locomotor activity, zebrafish larvae were monitored using a mounted 
Nikon camera (Figure 5.6A) and EthoVision XT9 locomotion tracking software which 
was performed by Dr. Pia Lundergaad. Twenty minute baseline recordings were 
obtained from fish in E3 embryo medium alone. Afterward, for each genotype, 24 
larvae were treated with 2.5mM PTZ dissolved in normal E3 medium and 24 larvae 
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maintained in normal E3 medium to serve as controls, and activity was monitored for 
80 minutes divided into 4 blocks of 20 minutes. Activity did not differ significantly 
across the groups when in normal E3 medium after analysing the whole 20 minutes of 
baseline recording (Figure 5.6B). On the addition of 2.5mM PTZ, treated fish showed 
a marked increase in locomotor activity when compared to untreated controls (Figure 
5.6C). Interestingly, a significant increase in activity was observed for 2.5mM PTZ 
treated Ins4 fish compared to 2.5mM PTZ treated wild-type fish in the first 20 minutes 
after treatment using repeated measures ANOVA. However, this difference is lost 
when activity is analysed for the rest of the video (Figure 5.6C). Notably, a decline in 
larval movement was observed in wild-type and Ins4 2.5mM PTZ treated fish from 40 
to 80 minutes while untreated fish activity remained at a stable level for the entire 
monitoring session (Figure 5.6C). 
 To investigate whether these behaviours observed in the PTZ treated fish could be 
seizure related, the video for only the first 20 minutes following PTZ treatment was 
analysed by Dr. Rodanthi Lyraki who was blinded to genotype and treatment for 
seizure-like behaviour according to Baraban et al, 2005 (see section 2.2.8 for 
description) to obtain an unbiased result. All three stages of seizure were evoked in 
Ins4 and wild-type larvae treated with 2.5mM PTZ, with the least number of fish 
reaching stage III within 20 minutes of PTZ treatment (Figure 5.7). The latencies to 
the first sign of the stages of seizure-like activities were analysed for both PTZ treated 
group. Although all PTZ treated Ins4 and wild-type fish exhibited stage I behaviour, it 
was challenging for Dr. Rodanthi Lyraki, who performed the analysis, to accurately 
pinpoint the specific time some of them showed the first signs of stage I. Analysis of 
the available data using Two-way ANOVA showed no significant difference in the 
latency for both genotypes to show the first sign of any of the three stages of seizure 










Figure 5.6. Locomotor activity analysis of Ins4 and wild-type zebrafish larvae exposed to 2.5mM 
PTZ or E3 medium. A. Schematic of experimental set-up used for obtaining video recordings for 
analysis. B. Bar plot showing the average larval locomotor activity of 5 dpf Ins4 and Wild-type larvae 
in E3 medium (baseline activity) over a 20 minutes period. In the absence of PTZ, no significant 
difference in the average total distance moved was observed among the group (One-way ANOVA, p-
value 0.6). WT (control) and Ins4 (control) were maintained in E3 medium, which was also the vehicle 
used in dissolving PTZ, for the entire recording sessions. C. graph showing the behavioural profile of 
larvae exposed to E3 only or with 2.5mM PTZ. The average total movement is shown per 20 minutes 
interval of the tracking session. ** is the confidence level for time point when the total distance moved 
for Ins4 (2.5mM PTZ treated) was significantly increased compared to wild-type (2.5mM PTZ treated) 











Figure 5.7. Seizure behaviour analysis in Ins4 and wild-type zebrafish larvae. A. Graph showing 
the latency to the first sign of seizure activity for three seizure stages in homozygous Ins4 and wild-type 
5 dpf larvae after 20mins of treatment with 2.5mM PTZ. Seizure scoring was performed blind. Results 
are means + S.E.M.; n=24 larvae per genotype. B. graph showing number of Ins4 and wild-type larvae 
exposed to 2.5mM PTZ that reached each seizure stages. Note that PTZ evokes stage III behaviour at 
this concentration in few larvae.      
148 
 
5.3 Discussion   
In this chapter, I aimed to investigate the function of eef1a2 in zebrafish as a 
complementary animal model to mouse. To this end, I generated two mutant lines, 
namely Del2 and Ins4, using CRISPR/Cas9 technology. Both alleles are predicted to 
cause a frameshift mutation in exon 3 which if translated would encode a truncated 
polypeptide (79 and 81 amino acids long for Del2 and Ins4 respectively). However, 
the mRNA transcribed from both alleles is likely to be degraded through the activation 
of nonsense-mediated mRNA decay and would not be translated. This process is 
usually activated when a premature stop codon occurs early and is located > 50 – 55 
nucleotides upstream of an exon-exon junction (Brogna and Wen, 2009, Popp and 
Maquat, 2016) as is the case with both mutations. In line with this, Del2 and Ins4 
mutant lines showed a significant decrease in eef1a2 mRNA expression in adult brain 
and muscle. This does not preclude the possibility of translation re-initiation occurring 
downstream of the mutation. However, the 3’eef1a2 primer set which was designed to 
amplify the 3’ end of the gene showed a more dramatic decrease of eef1a2 mRNA in 
both mutant lines, making the possibility of any other products less likely. The 
unavailability of a specific eEF1A2 antibody made it impossible to confirm whether 
these mutants were true null. Nevertheless, the findings that mutant transcripts are 
likely targets of nonsense-mediated decay suggests both the Del2 and Ins4 mutations 
are deleterious. Therefore, the eef1a2 mutants I generated should be good models for 
investigating the role of eEF1A2 in disease. 
In contrast to wasted mice, where complete loss of function of eEF1A2 is lethal, 
homozygous zebrafish eef1a2 mutants appeared healthy and reached adulthood and 
showed no obvious abnormal phenotype. Adult homozygous Del2 and Ins4 mutants 
were fertile and produced viable embryos. With no observable phenotype displayed 
by fish of either the Del2 or Ins4 lines, they were further characterised for other 
phenotypes at the cellular level using immunohistological techniques. With the wasted 
mouse phenotype in mind, which has been shown to be of neurogenic origin (Doig et 
al., 2013), a comparative analysis of the central nervous system was performed. 
Although Purkinje cell degeneration was shown to occur in the cerebral cortex of 
wasted mice by Shultz and colleagues, 1985, adult fish from both mutant lines did not 
show any Purkinje cell loss in the brain. It is worth mentioning, however, that this 
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observation by Schulz et al, 1985 has not been replicated till date by other studies that 
have also characterised the wasted mouse model (Chambers, Peters and Abbott, 1998; 
Khalyfa et al., 2001; Newbery et al., 2005). No evidence of motor neuron degeneration 
was observed in the spinal cord of fish from both mutant lines, although this 
experiment was limited by the lack of a suitable control for gliosis.  
One likely explanation for this difference could be due to species differences. As 
detailed in chapter 3 of this thesis, the zebrafish genome contains four eef1a genes that 
encode different closely related proteins which presumably retained the main function 
in protein synthesis. Also, eef1a2 mRNA was found to be co-expressed with the other 
eef1a mRNAs. Although it was not possible to confirm this at the protein level, the 
apparent lack of phenotype is indicative of the possibility of paralogue redundancy and 
could explain why a deleterious mutation in eef1a2 is well tolerated in zebrafish. Also, 
unlike mammals, the zebrafish CNS has regenerative capacity throughout its life. This 
confounding factor poses an obstacle especially as motor neuron degeneration is the 
benchmark outcome expected in the zebrafish eef1a2 mutants. If regenerative 
responses are activated in these mutants, the neurodegenerative phenotypes might be 
subtle and easily masked by the continuous replacement of dead neurons with new 
ones. Interestingly, eEF1A genes have been identified to be differentially expressed 
during regeneration processes. A transcriptomic analysis of tail regeneration in Anolis 
carolinensis (green anole lizard) revealed eEF1A2 to be differentially expressed in the 
regenerating tail at the 25th day after autotomy and was upregulated 10-fold compared 
to lizard embryos (Hutchins et al., 2014). Another study identified all four eef1a genes 
to be differentially expressed at five different time points of regeneration after crushed 
injury in the zebrafish spinal cord using genome-wide expression profiling technique 
(Hui et al., 2014). From the regeneration data generated from this study, it was noted 
that the eef1a genes showed an expression pattern of up and down regulation across 
the five time points analysed. It is, therefore, possible that any of the eef1a genes could 
contribute to the regeneration process if this is the case. Another possible explanation 
could be that Del2 and Ins4 fish, unlike the wasted mice model, may not be true null 
mutants and may retain some degree of residual function of eef1a2. However, the 
consistency of the eef1a2 reduction observed with three different set of primers makes 
it unlikely.  
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While this project was ongoing, a study was published where the authors suppressed 
eef1a2 expression using morpholinos. Interestingly, Cao et al, 2017 observed skeletal 
muscle weakness, cardiac failure and small head phenotypes in eef1a2 morphants. The 
discrepancy between my findings and those of Cao et al, 2017 may have to do with 
the different approaches used to disrupt eef1a2 function. It is now a common 
occurrence that CRISPR-induced mutants fail to replicate morpholino-induced 
phenotypes since the development of efficient genome editing techniques in zebrafish. 
However, it is worth noting that the study by Cao et al, 2017 did not assess the 
possibility of an off-target mRNA effect involving another eef1a gene(s). It is therefore 
not clear if the observed phenotypes are specific to the knockdown of eef1a2 alone or 
a combined effect of the knockdown of one or more of the other eef1a genes. It is 
important to note that an eef1a1l1 mutant, from a large retroviral-mediated insertional 
mutagenesis screen, displayed a small head size (Amsterdam et al. 2004) which was 
one of the phenotypes observed in the eef1a2 morphants in the study of Cao et al, 
2017. Although the phenotypes observed were consistent using both translational and 
splice-site targeting morpholinos, it is still possible that they may have been the result 
of a common off-target toxic effect induced by both morpholinos. This type of 
situation has been demonstrated in the study by Robu et al., 2007, where they observed 
that these two different types of morpholinos induced off-target effects mediated 
through p53 activation in the zebrafish embryo. Interestingly, a recent study showed 
that many morpholino-induced phenotypes, even though rescued by co-injecting with 
the wild-type mRNA, could still be due to off-target effects in zebrafish (Kok et al., 
2015). This study by Kok et al, 2015 also observed that off-target phenotypes induced 
by the use of morpholinos occurred much more frequently than was previously 
thought. This brings to light the dire need for a much better control to validate 
morpholino-mediated experiments. For example, validation of the morpholinos used 
in the Cao et al, 2017 study can be performed using embryos from the eef1a2 mutant 
lines as a negative control. If a phenotype is observed in them, it could indicate an off-
target effect and it might be possible to use these mutants background to identify the 
best concentration of the morpholinos that would not lead to off-target effects. Another 
validation approach is to check for p53 mRNA induction in the morpholino- injected 
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embryos as this usually points to the activation of non-specific effects by the 
morpholinos (Robu et al., 2007).  
On the other hand, CRISPR/Cas9 has been shown to have negligible off-target effects 
in zebrafish. Using next-generation sequencing (NGS), Hruscha et al., 2013 
demonstrated that the off-target effect was limited in founder fish. This study was 
small, analysing the gRNA target site for only one gene, but only 2.2-2.5% of all the 
reads were found to have mutations at the predicted off-targets in the pool of ten 
individual embryos injected with the gRNA (Hruscha et al., 2013). Their observation 
of the limited off-target effect of CRISPR experiments in zebrafish was supported by 
another larger study. In this study, they analysed the target sites for five gRNAs of 
different genes. They performed NGS using PCR products pooled from five predicted 
off-target sites for each gRNA and detected a 3 base pair deletion in only one of the 
25 off-target loci tested (Varshney et al., 2015). Although no off-target sites were 
found for gRNA3, which was used to generate the mutant lines, by the online CRISPR 
design tool, CHOPCHOP at the time it was accessed, there is still the possibility of 
random off-target mutations at other sites particularly as annotation of the zebrafish 
genome is still work in progress. The presence or absence of these off-target mutations 
can be assessed in Del2 and Ins4 mutant lines by amplifying and sequencing DNA 
from regions with the highest homology to the target site of gRNA3. I did not analyse 
the Del2 and Ins4 lines for potential off-target mutations, but my use of fish starting 
from the F2 generation resulting from an outcross of the F0 with wild-type fish should 
minimise the possibility as these unintended mutations would segregate away from the 
Del2 and Ins4 eef1a2 mutation. Also, evaluation of the other eef1a mRNAs levels in 
Del2 and Ins4 mutants were not significantly different when compared to wild-type 
fish. This provides strong evidence to suggest that eef1a2 paralogues were not affected 
by the CRISPR/Cas9 experiment.  
Another possible explanation for the inconsistencies could be that these two strategies 
induce different responses to eef1a2 gene inactivation in zebrafish. For example, a 
study by Rossi et al., 2015 found that severe mutations induced by a knockout 
approach, as is the case with Del2 and Ins4 mutants, resulted in compensatory 
upregulation of specific proteins which could account for the phenotypic rescue 
observed in knockdown experiments.  Although the mutant lines I generated did not 
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show upregulation of the eef1a2 paralogues suggesting no compensation occur in adult 
tissues at the mRNA level, this does not completely rule out this possibility. Perhaps 
there might be some compensation at the levels of specific cells, or during a critical 
developmental period in the fish or upregulation of these other eef1a genes occur at 
the protein level instead which will not reflect from analysing mRNA levels. Further 
experiments are needed to draw a conclusion on whether or not a compensatory 
response is activated in the mutant lines. However, this supports the idea of functional 
redundancy of eef1a genes as the more likely mechanism at play to compensate for the 
loss of eef1a2 in Del2 and Ins4 mutants.  
The identification of eEF1A2 as a likely epilepsy susceptibility gene in human and a 
recent observation in our laboratory of homozygous Eef1a2 null mice showing 
vulnerability to audiogenic seizures prompted a behavioural analysis in the mutant 
lines. To test if eef1a2 null fish were sensitised to seizure, 2.5mM PTZ was applied 
directly to the bathing E3 medium of the fish. Locomotor activity was found to 
significantly increase in 2.5mM treated 5 dpf homozygous Ins4 and wild-type larvae 
within 20 minutes after treatment compared to their baseline activity and to untreated 
fish. Homozygous Ins4 fish showed a significant increase in locomotor activity 
compared to wild-type when treated with 2.5mM PTZ in the first 20 minutes. Activity 
was not significantly different between the groups at the other time points. 
Interestingly, studies by Afrikanova et al. 2013 has shown that combining larval 
activity over longer time points could mask a subtle effect when performing the 
locomotor assay. Seizure analysis showed Ins4 and wild-type demonstrated all three 
stages of seizure behaviour within the first 20 minutes. The decline in total larval 
movement in both groups between 20 and 80 minutes could likely be as a result of the 
majority of treated larvae spending time in stage 3 with prolonged exposure to PTZ. 
This will result in a loss of posture and a subsequent decrease in swimming activity in 
those larvae. A similar trend was observed in the studies by Afrikanova et al. 2013. It 
was surprising to observe stage 3 behaviour using PTZ at a lower concentration 
(2.5mM) since this stage was reported in studies that routinely used a much higher 
PTZ concentration of 15-20mM (Baraban et al., 2005; Afrikanova et al., 2013). 
However, only a few larvae (about 37% and 25% wild-type and Ins4 respectively) 
exhibited stage 3 behaviour within 20 minutes of PTZ treatment compared to studies 
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of Baraban et al. 2005 (nearly 75%). As shown in these studies and initial pilot 
experiments I carried out, higher concentrations of PTZ induces a more severe and 
robust seizure activity within a short time frame, which will not allow the difference 
in PTZ response of wild-type and mutant larvae to be detected. One possible factor 
that could influence the outcome of this study is strain difference, with Baraban et al. 
2005 and Afrikanova et al. 2013 using TL and Ekkwill fish respectively, whereas I 
used AB fish for this work. Another possibility could be the experimental protocol 
employed here. For example, in contrast to both studies, I performed this assay under 
constant light (as opposed to constant darkness in these other studies) due to the 
available apparatus and used younger larvae at 5 dpf (7 dpf, Baraban et al. 2005; 6 dpf, 
Afrikanova et al. 2013) since they are not regulated and do not require a license to 
work with. Although the nature of my experimental set-up could make the fish more 
vulnerable to external stimuli, the activity of untreated fish did not differ significantly 
for the entire recording sessions. Also, the stable level of activity of untreated fish was 
in line with the expected swimming pattern of zebrafish larvae tracked under constant 
light (MacPhail et al., 2009). This suggests that the effect of unwanted external stimuli, 
if any, was negligible and did not greatly influence the outcome of the experiment.  
The significant increase in locomotor activity observed in Ins4 larvae compared to 
wild-type within 20 minutes after PTZ treatment could indicate Ins4 larvae are 
spending more time in stage 1 and stage 2 or are more sensitised to PTZ-induced 
seizures, and hence move more during a seizure. It is tempting to assume the latter as 
the most likely reason particularly as stage 1 behaviour was more easily recognisable 
for Ins4 (21 out of 24) than wild-type (14 out of 24) by Dr. Lyraki who was blind to 
the genotype. However, a more detailed analysis of the 20 minutes tracking session 
into short intervals, for example, 5 minutes, will be valuable to better understand the 
kinetics of their response to PTZ more precisely. However, bearing in mind that only 
one mutant line; Ins4 was used to perform this assay, it is important that the PTZ-assay 
is first repeated using the Ins4 and also the Del2 mutant line. Furthermore, potential 
off-target events should be assessed in both mutant lines to ensure no other loci were 
affected by the CRISPR/Cas9 experiment. If after performing these experiments, 
seizure susceptibility is still observed, this could demonstrate a likely predisposing 
effect of the loss of function of eef1a2 in zebrafish. A similar effect was seen in our 
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laboratory where homozygous Eef1a2 null F0 mice generated from a CRISPR/Cas9-
mediated HDR experiment were susceptible to audiogenic seizure in response to 
environmental sound (Davies et al., 2017). Both of these models; mice and zebrafish, 
could then be used for complementary studies to understand the underlying mechanism 
by which mutation in eEF1A2 results in epilepsy. Drug screening with the zebrafish 






















Chapter 6: Summary and future directions. 
6.1 Summary 
 The unequivocal role of eEF1A2 in neurodevelopment was first evident in the wasted 
mouse model. More recently, missense mutations in eEF1A2 have also been identified 
in WES data obtained from about 50 patients with severe cases of neurodevelopmental 
disorders. Up until now, work in our laboratory has focused on the use of  mice and 
cell lines as model systems to better understand the relationship between eEF1A2 and 
neuronal diseases. With the mounting evidence of the utility of the zebrafish in 
neuroscience research, this animal was chosen as a model to be used for further 
complementary studies, with particular interest in its high-throughput screening 
capacity as a whole organism which is quick, easier and cost-efficient compared to 
rodents (Kalueff et al., 2014). 
6.1.1 Bioinformatics and expression analysis of Zebrafish eEF1A 
The first step taken to determine if the zebrafish was an appropriate model for research 
into eEF1A2 was to re-evaluate information on eEF1A genes in zebrafish, as previous 
literature worked on the premise that only one eEF1A was present in its genome. Using 
bioinformatics and gene expression analysis, I showed that the zebrafish has four 
eEF1A genes; eef1a1l1, eef1a1a, eef1a1b and eef1a2. While eef1a1l1 did not have an 
orthologue in the human genome, eef1a1a and eef1a1b were identified as the co-
orthologues of the human EEF1A1 gene. In addition, eef1a2 was identified as the 
orthologue of the human EEF1A2 and the two were shown to be 94% identical at the 
amino acid sequence level. In silico functional analysis of the zebrafish eEF1A 
isoforms suggest that they all share a similar translational function but could likely 
have other functional differences between them. In support of this finding, isoform-
specific phosphorylation sites were predicted for each eEF1A isoform which could 
further strengthen their functional differences. The eEF1A genes were 
developmentally regulated as their expression was detected at different developmental 
stages. Consistent with the expression pattern of the mammalian eEF1A2 gene, eef1a2 
was expressed much later than the other eef1a genes in development, around 48hpf. 
Although it is difficult to directly compare developmental stages between the zebrafish 
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and mammalian species, eef1a2 could be regarded as the ‘adult’ form of the eukaryotic 
elongation factor in zebrafish as is the case for eEF1A2 in mammals (Knudsen et al., 
1993; Lee, Wolfraim and Wang, 1993; Chambers, Peters and Abbott, 1998; Khalyfa 
et al., 2001; Svobodová et al., 2015). 
I also investigated the expression pattern of the eef1a genes in adult fish using a range 
of adult tissues. The zebrafish eef1a2 appear to have a tissue-specific expression 
pattern as it was not detected in the liver, another feature it has in common with 
eEF1A2 gene in mammalian species. However, one difference between eEF1A from 
these species, is that the zebrafish eef1a2 transcripts were detected in some other 
tissues such as the spleen and ovary which are negative for eEF1A2 expression both 
at the mRNA and protein level in mammals (Khalyfa et al., 2001; Anand et al., 2002; 
Newbery et al., 2007; Svobodová et al., 2015). Since I was unable to determine 
expression of eEF1A2 at the protein level in these tissues, it is still unknown if these 
transcripts are actually translated in which case, a conclusion could be made on 
whether the zebrafish eEF1A2 shows a completely different expression pattern from 
that of mammals. Another difference was observed with the expression pattern of the 
eEF1A1 orthologues. In zebrafish, expression of eef1a1a and eef1a1b mRNA was 
noted in all the adult tissues analysed including muscle which is known to be negative 
for their mammalian orthologue. However, this is consistent with the Xenopus eEF1A 
expression pattern at the mRNA level, where regulation of eEF1A occurs at the post-
transcriptional level instead (Helen J. Newbery et al., 2011). Since eEF1A isoform 
switching is biologically important as it appears to be evolutionarily conserved in 
vertebrates, it is most likely that this also occurs at the translational level in the 
zebrafish. Unfortunately, I was unable to test this hypothesis due to the lack of specific 
antibodies for each of the eEF1A proteins. However, the results from the analysis of 
the specificity of antibodies against eEF1A2 demonstrate the value of validating 
commercial antibodies even if advertised as specific for a particular species, before 
using them for further investigation.    
Another key difference is the presence of an eEF1A gene, eef1a1l1, which has no 
corresponding orthologue in mammalian species. My expression data suggests this 
gene to be the ‘embryonic’ form of the eukaryotic elongation factor in zebrafish. 
Furthermore, eef1a1l1 transcript is the major form detected in the adult muscle and 
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liver tissues, in contrast to mammalian species where only eEF1A2 and eEF1A1 are 
expressed in the mature adult muscle and liver tissue respectively. It is possible that 
eEF1A1L1 has some of the non-canonical functions in common with these other 
eEF1A isoforms. However, equivalent amounts of each eef1a transcripts were noted 
in adult brain tissue. Since brain tissue is made up of a more heterogeneous cell 
population than liver and muscle, it is also possible that there are other isoform-specific 
‘moonlighting’ functions between the zebrafish eEF1A isoforms. It is however worth 
noting that this results are based on the mRNA expression of the eEF1A isoforms and 
should be confirmed at the protein level.  
All the findings presented here suggest that functional diversification might have 
occurred among the zebrafish eEF1A isoforms while presumably retaining their main 
role in protein elongation, which is somewhat similar to the case of the eEF1A 
isoforms in mammals. These additional functions could be biologically important and 
confer some evolutionary advantage in the zebrafish, which could explain why all four 
eEF1A isoforms were positively selected for their maintenance in its genome. Studies 
by Kinoshita et al., 2001 also showed two eEF1A gene was present in medaka (Oryzias 
latipes) which displayed a tissue and stage-specific pattern of expression. In the flatfish 
(Solea senegalensis), five eEF1A genes were isolated which also showed differential 
expression in ten different tissues examined and during larval development (Infante et 
al., 2008). One of the eEF1A genes, termed SseEF1A4, was suggested to have a role 
in metamorphosis as its expression was upregulated by thyroid hormones in larvae. 
More recently, a heterozygous mutation of eEF1A1B in tilapia (Oreochromis 
niloticus) has been demonstrated to give rise to viable fish but caused spermatogenesis 
arrest and infertility in males (Chen et al., 2017).    
6.1.2 Modelling an eEF1A2 disease-causing mutation in zebrafish 
I attempted to knock-in the G70S epilepsy causing mutation in the zebrafish eEF1A2 
using a gRNA originally generated and used in creating eEF1A2 null zebrafish. 
Unfortunately, I was unable to identify any fish with the G70S encoding mutation 
incorporated and most of the mutants carried indel mutations. The high rate of indel 
mutations is in itself not surprising, considering they are generated by the NHEJ 
pathway which occurs at a much higher rate than HDR (Dai et al., 2010; Li et al., 
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2015). However, together with the low efficiency of the knock-in, this posed a 
challenge in the screening process to identify any point mutations. Low HDR 
efficiencies and the high rate of indel mutations are common pitfalls in CRISPR/Cas9-
mediated HDR in zebrafish (Armstrong et al., 2016; Zhang, Zhang and Ge, 2018). It 
is, therefore, necessary to determine optimum conditions that will combat these two 
factors. The recent CRISPR/Cas9-mediated HDR protocol for zebrafish described by 
Zhang et al. 2018, seems to show more promise as it is the only study that has reported 
a high efficiency. Another attractive feature of Zhang et al. 2018 study is that it was 
also designed to make screening for the point mutation a less challenging task by 
generating specific primers that only amplified the HDR-induced mutation, which is 
useful if one’s efficiency is not as high as was obtained in their study. Since this 
protocol shows some promise, it will be a good starting point to attempt another knock-
in experiment in the zebrafish. However bearing in mind the lack of reproducibility of 
other studies which have also demonstrated the successful use of the CRISPR-Cas9 
technique for HR in zebrafish, it should be tested first with only one eEF1A2 epilepsy-
causing mutation. Once a working protocol is obtained and the protocol optimised, 
generating mutant lines with the other missense mutations would be worthwhile since 
it is possible they may perturb function via a different mechanistic pathway.  
If I were able to generate a G70S zebrafish mutant, I would characterise this mutant 
line with a focus initially on seizure activity, which is an easier and more valid human-
relevant phenotype to model in the zebrafish and can be performed in the first instance 
on larval stages which are not regulated. This can be achieved by using automated 
video locomotion tracking devices to screen for seizure-like behaviours as well as 
using electrophysiology to look for spontaneous electrographic seizure discharges. If 
these mutants do not exhibit spontaneous seizure behaviours, seizure susceptibility can 
also be investigated using the PTZ-induced seizure assay(Baraban et al., 2005).  It will 
also be interesting to carry out a microarray-based transcriptomic analysis to identify 
if any differentially expressed genes including the other eEF1A genes, which could 
compensate for the loss of eEF1A2 function, occur in the mutants. This could also 
provide insights into the molecular pathways underlying the epileptic phenotypes. 
Another epilepsy-causing mutation I would like to generate and characterise alongside 
the G70S in zebrafish is the D252H mutation. The advantage of generating these two 
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mutant lines is that they will be useful for further complementary studies since the 
G70S and D252H mutation have already been modelled in mouse (Davies et al., 2017 
and unpublished data) and LUHMES cells (only D252H in LUHMES) in our 
laboratory. This will hopefully contribute immensely to disentangling the role of 
eEF1A2 in epilepsy and ultimately to provide better treatment strategies especially as 
they can be employed for high throughput screening of different small molecules. 
6.1.3 Generation and characterisation of eef1a2 null zebrafish model 
Having confirmed the presence of an eEF1A2 orthologue in the zebrafish, it was 
essential to investigate the function of this gene in the zebrafish and determine if loss 
of function mutation of eef1a2 would result in a similar phenotype to that seen in 
wasted mice, a well-characterised model for early onset motor neuron degeneration. 
For this purpose, I generated two mutant lines, Del2 and Ins4, using CRISPR/Cas9 
gene editing. Although I was unable to confirm these lines as true nulls because of the 
lack of a specific antibody against eEF1A2, a marked decrease of eef1a2 at the mRNA 
level was noted in both lines, suggesting these mutations could lead to a loss of 
function similar to that seen in the wasted mouse. However, my results show that loss 
of eef1a2 does not lead to any obvious defects and that the fish are viable as adults. No 
evidence of neurodegeneration was noted in the spinal cord as assessed using 
immunohistological examination. I have proposed at least three possible confounding 
factors that could explain this discrepancy; (i) Del2 and Ins4 might not be true nulls as 
seen in wasted mice and could retain some residual eEF1A2 function (ii) the presence 
of multiple eef1a genes, any of which could compensate for the loss of eef1a2 as they 
are co-expressed at the mRNA level leading to redundancy and (iii) the ability of the 
zebrafish CNS to regenerate throughout its life which could mask any neuronal loss 
caused by these mutations.     
One mutant line, Ins4, was characterised behaviourally and was found to show 
significant susceptibility to PTZ-induced seizures compared to their wild-type 
siblings. As I was unable to carry out a complementary testing using the Del2 line in 
the seizure behaviour analysis, caution must be taken when interpreting this results. 
However, this finding seems to corroborate a recent observation in our laboratory, 
where eEF1A2-null mice showed susceptibility to audiogenic seizures which resulted 
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in the death of these mice (Davies et al, 2017). It is, therefore, possible that the seizure 
phenotypes observed in humans are mediated by conserved mechanisms in these other 
species. If this is the case, further complementary studies with the zebrafish and mice 
models will be invaluable in future research.           
6.2 Future directions 
6.2.1 Potential of using the zebrafish and its eEF1A isoforms to 
understand the functions of eEF1A in vertebrates 
The fundamental question as to why there are two eEF1A isoforms with very high 
sequence identity in mammals has remained unanswered. Resolving this question 
could likely help us understand how mutation or dysregulation in the expression of 
eEF1A2 causes disease. The most reasonable explanation for the existence of different 
isoforms is the presence of some other isoform-specific non-canonical functions that 
may be suitable for only certain cells types or at certain developmental stages. Results 
from characterising the zebrafish eEF1A genes have shown that some features are 
conserved with mammalian species and could offer insights into understanding the 
functional differences within the eEF1A family. However, one important feature that 
will be interesting to confirm in the zebrafish is the occurrence of eEF1A isoform 
switching in different tissues. With evidence that this process is a biologically 
important one demonstrated by its conservation in different vertebrate species (Lee, 
Wolfraim and Wang, 1993; Chambers, Peters and Abbott, 1998; Helen J. Newbery et 
al., 2011; Svobodová et al., 2015), it is tempting to assume that this is also the case in 
the zebrafish. We hypothesised that similar to what was observed in the Xenopus 
(Newbery et al, 2011), this process will occur at the translational level if it does occur 
in the zebrafish. Generation of isoform-specific antibodies will be invaluable for 
testing this hypothesis since any switch will not necessarily be reflected in the 
expression pattern at the RNA level. Determining which tissue type and the point of 
development where this switch occurs could contribute towards providing an answer 
to the question above.  
Further investigation into the expression pattern of the zebrafish eEF1A isoforms at 
the cellular level is also required to shed more light on these ‘moonlighting’ functions. 
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If isoform-specific antibodies could successfully be generated, they could also be used 
for immunohistochemistry (IHC) or immunofluorescence examination of different 
tissues to determine cell type- specific expression and also the subcellular localisation 
of the different isoforms. However, generating specific antibodies for these eEF1A 
isoforms can be a challenging task due to their sequence similarities and there is the 
possibility, they may be specific for Western blotting but not IHC applications from 
experience in our laboratory. Alternatively, individual cell types could be isolated from 
zebrafish transgenic lines expressing different fluorescent protein reporters in any of 
the tissue types using fluorescence-activated cell sorting (FACS) assay. These 
predefined cell populations could then be used for subsequent gene expression analysis 
using techniques such as qRT-PCR or Western blotting if specific antibodies are 
available. More recently, large scale single-cell RNA sequencing (scRNA-seq) is 
being explored with data generated from different embryonic stages in the zebrafish 
currently available (Farrell et al., 2018; Wagner et al., 2018). I examined the datasets 
from these two studies, but none of the eef1a genes was found. Although scRNA-seq 
is more expensive than ISH, it offers the opportunity to generate transcriptome-wide 
data of individual cells and will facilitate the exploration of different developmental 
stages and adult tissues compared to ISH. This may be useful in constructing an atlas 
of the expression patterns and the dynamics of the eEF1A genes in adult fish in future, 
as well as being able to examine other known interacting partners at a single-cell 
resolution.     
Differences in the PTMs between eEF1A1 and eEF1A2 isoforms have been noted and 
could likely contribute to the functional divergence of these proteins. Mapping of these 
PTM sites, both from experimental and predicted studies, to the modelled 3-D 
structures showed they are mostly present on the surfaces with clusters of sequence 
variation between the isoforms suggesting the proteins are differentially regulated 
(Soares and Abbott, 2013). Using the NetPhos 3.1 server (Blom, Gammeltoft and 
Brunak, 1999), I was able to predict likely phosphorylation sites for the zebrafish 
eEF1A isoforms. While these isoforms share some of the predicted sites, likely unique 
sites were also noted for each of them. Bearing in mind the possibility of predicting 
some false-positive sites using this method, it would be ideal to compare predicted 
sites for the zebrafish eEF1A isoforms to that of human to select candidate sites for 
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further investigation in the first instance. One candidate site that may be suitable for 
future studies is the Ser300 predicted to be phosphorylated in the zebrafish eEF1A1A, 
eEF1A1B and eEF1A2. Although these sites have a borderline NetPhos probability 
score of 0.5, these sites are readily accessible by a kinase on the modelled structure 
and Ser300 has been experimentally confirmed in eEF1A1, thus increasing the 
confidence of the prediction. Phosphorylation of Ser300 by type 1 TGF-β receptor 
(TβR-1) has been demonstrated to interfere with the binding activity of aminoacylated-
tRNAs in eEF1A1, thus inhibiting protein synthesis and cell proliferation (Lin et al., 
2010). Although eEF1A1l1 was not predicted to be phosphorylated at this site, it has 
a threonine residue at this position which can also interact with a kinase. To test that 
this is not a false- negative site, it should also be investigated. Another site that might 
have implications for the translation rate is Ser298 (in eEF1A2 and eEF1A1L1) since 
it lies very close to residues involved in eEF1Bα and aminoacyl-tRNA binding. This 
position is also equivalent to Gln296 in yeast, which has been implicated in actin-
related functions (Gross and Kinzy, 2007), therefore phosphorylation could potentially 
affect actin-eEF1A interaction(s) as well. It is interesting that opposite these two sites 
(298 and 300) is an exposed and most likely phosphorylatable eEF1A1L1 specific site 
(>0.84 probability score), Thr303, which could perhaps help with understanding the 
role of both sites and is therefore worth further investigation. Other sites that could 
also be considered and have experimental support include: Ser21 and Thr88, which 
modulate the stability of eEF1A (Sanges et al., 2012) and Ser358, a phosphorylation 
site on eEF1A2 but not eEF1A1 in both zebrafish and human, in which it has been 
shown to have a role in stress-induced quality control of newly synthesized polypetides 
(Gandin et al., 2013). Further studies of these sites could contribute towards 
understanding how eEF1A switches between its main role in protein translation to 
other non-canonical functions. This will be particularly useful in understanding the 
functional difference between eEF1A isoforms in human and perhaps provide insights 
on some disease related to them, for example, the oncogenic ability of eEF1A2.  
Confirmation of the phosphorylation status of these sites can be achieved using mass 
spectrometry. It will also be useful to generate phosphorylation mimics by mutating 
Ser or Thr to either Glu or Asp (phospho-positive) and also to a non-phosphorylatable 
residue such as alanine (phospho-negative) to determine if similar functional 
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significance occurs with the zebrafish. If these sites are validated as true 
phosphorylation sites, in vitro kinase assays should be performed to establish if 
phosphorylation is mediated by the same kinase. If the expected results are observed 
after these experiments, phospho-specific antibodies could be raised and used to 
determine if the eEF1A isoform is phosphorylated in vivo in the zebrafish. It will also 
be interesting to determine if the genes encoding these kinases are expressed at the 
same time as the eEF1A isoforms. Similar experiments as outlined above could also 
be performed for some of the isoform-specific sites predicted with high confidence as 
indicated with the NetPhos score >0.5 (Table 3.3 in chapter 3) with the hope that these 
could contribute to the evolutionary understanding of the eEF1A family in vertebrates. 
6.2.2 Translational validity of the eef1a2 mutant lines for neurological 
diseases 
With the aim of using the zebrafish for drug discovery studies, I generated two lines 
with different deleterious mutations in eef1a2. Since the role of eef1a2 in zebrafish 
was unknown during the course of this project, phenotyping of the mutant zebrafish 
lines was carried out using the wasted mouse model as a guide. However, the severe 
phenotypes such as motor neurodegeneration of the spinal cord in the wasted mouse 
model were absent in both mutant lines which were viable and fertile as adults. Further 
experiments are still required which might elucidate the reason behind the discrepancy 
between these models. I have outlined above three possible factors that could be 
responsible and will require further investigation as understanding the reason for the 
different phenotypes will contribute towards the validation of these models for 
neurological diseases.  
Generation of specific antibodies could help establish whether these models are true 
nulls as they could be used to perform Western blot analysis to detect the presence of 
any residual protein. Alternatively, Del2 and Ins4 could be further characterised to 
confirm that their transcripts are indeed targets of NMD as suggested by the qRT-PCR 
results (see Figure 5.3 in chapter 5). Expression of Del2 and Ins4 alleles could be 
evaluated in vitro by generating constructs for each allele. These constructs should 
then be separately transfected into cell lines and their expression measured using 
Western blotting. Since there is the possibility of the antibody cross-reacting with the 
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endogenous eEF1A, expressing the mutant cDNA with a tag protein would allow the 
effect of the mutation to be easily detected. The wild-type eef1a2 construct generated 
during this project would serve as a useful positive control for this experiment. If the 
protein from cells transfected with the mutant constructs is mostly absent, this will 
confirm the severity of these potential null alleles.    
The presence of multiple eef1a genes in the zebrafish genome encoding separate 
proteins with almost identical amino acid sequence and presumably functional 
equivalence in translation might imply functional redundancy occurring in both mutant 
lines. At the same time, it also poses a challenge to determine which isoform(s) could 
be playing this compensatory role. While the suggested future work described in 
section 6.2.1 could help identify the isoform(s) responsible, a systematic analysis of 
the compensatory effect of the other eef1a genes could also be performed. Loss of 
function mutations should be induced using similar CRISPR/Cas9 technique described 
herein in both Del2 and Ins4 lines and the phenotypes compared to the eef1a2 mutant 
lines. Bearing in mind that eEF1A1L1, which appears to share some features with 
eEF1A2, is the only eEF1A present in the zebrafish during early development, global 
loss of eef1a1l1 could likely be embryonic lethal as observed in the study of 
Amsterdam et al. 2004. To overcome this caveat, the generation of a time-dependent 
conditional knockout (Maddison, Li and Chen, 2014) should be considered. 
The regenerative capacity of the zebrafish CNS imposes a major drawback in 
developing any zebrafish model of neurodegeneration. Since motor neurodegeneration 
in the spinal cord is a benchmark outcome, this phenotype might be subtle in the 
mutant lines if these dead neurons are constantly replaced. For this reason, a good 
positive control is important for the immunohistological assay with GFAP which I 
used in phenotyping these lines. Another alternative to the GFAP-immunostaining 
would be to perform a choline acetyltransferase (ChAT) immunostaining instead on 
spinal cord sections. The total number, as well as the size of ChAT-positive motor 
neurons, could then be quantified and compared between the mutant and wild-type 
fish. Generally, the smaller the motor neuron, the younger it is thought to be, as it gets 
larger with maturation (Da Costa et al., 2014). If a decrease in the number of large 
(mature) ChAT-positive motor neurons are observed in the mutant fish spinal cord, 
this could suggest that neuronal loss occur in them as well. However, if the rate at 
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which neurons are lost is similar to that at which they are replaced, performing these 
immunohistochemical analyses with fish that are more than 24 months, when a decline 
in neurogenesis and regenerative response is expected (Fleisch, Fraser and Allison, 
2011), may be best to make it easier to detect any neuronal death in the mutant lines. 
Alternatively, cell death assays that involve staining with fluorescent markers for 
neuronal death such as TUNEL or Fluoro-Jade can be performed on mutant larval and 
younger adult stages as it is usually difficult to breed fish beyond 24 months without 
a project license. Both of these assays are simple, quick and well-established 
techniques for qualitative and quantitative assessment of neurons undergoing 
apoptosis. If more cells stained with either of these dyes are observed in the mutant 
lines, this would suggest they are undergoing an increased rate of neuronal death than 
that seen in WT fish. Data from the cell-specific expression analysis of the eEF1A 
isoforms in the zebrafish CNS will also be extremely useful in this regard. If a cycle 
of degeneration and regeneration is noted, these mutant lines will be an invaluable 
model to dissect the underlying molecular and cellular pathways involved in replacing 
dead neurons during disease progression, and perhaps identify potential therapeutic 
targets for degenerative diseases.       
Finally, the observation that loss of eEF1A2 in zebrafish might make them susceptible 
to chemical-induced seizures is worth exploring further, especially as it is in line with 
findings in our laboratory with eEF1A2 null mice models (Davies et al., 2017). Since 
I was only able to use the Ins4 lines for this experiment, it will be interesting to follow 
this up using both mutant lines; Del2 and Ins4, to confirm if indeed the seizure 
phenotype is caused by a mutation in eef1a2. Although the set-up I used to carry out 
this assay did not appear to be affected by other external stimuli, it might be worth 
repeating this experiment using the automated larval tracking devices, for example, 
DanioVisionTM (www.noldus.com). This would ensure the testing environment is 
uniform for all rounds of biological replicates performed and an unbiased qualitative 
and quantitative behavioural analysis could be obtained. Using this equipment, Ins4 
and Del2 mutant larvae could also be exposed to other forms of epileptogenic stimuli 
in a controlled manner. For example, an in-built tapping device could be used to 
provide sound/vibration stimulus especially as eEF1A2 null mice were observed to 
show susceptibility to audiogenic seizure in our laboratory (Davies et al., 2017). Visual 
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stimulus can also be employed by varying the lighting conditions providing alternating 
cycles of light and dark conditions. This is similar to flashing light which is the most 
common trigger for reflex seizures. Mutant larvae could be exposed to these stimuli 
alone and/or in combination with PTZ treatment and analysed for any difference in 
seizure behaviour compared to wild-type larvae.  
Depending on the outcome, it might be worth performing other seizure analysis assays 
as the locomotor assay may not be robust enough (Afrikanova et al., 2013; Ingebretson 
and Masino, 2013) even though it served as a useful easy and quick initial screening 
tool for seizure activity. Alternatively, the epileptiform activity can be monitored by 
taking extracellular recordings from the brain of larval fish exposed to PTZ (Baraban 
et al., 2005, 2007; Afrikanova et al., 2013). Electrophysiological recordings obtained 
from larval zebrafish brain is comparable to electroencephalographic (EEG) 
monitoring which is the gold standard for the diagnosis of seizures (Baraban, 2013). 
This provides a more sensitive readout for seizure-like behaviour compared to using 
locomotor activity, however, it cannot be performed in a high-throughput multiwall-
format as the locomotor assay. Abnormal brain activity can also be monitored by 
analysing expression levels of cfos, a robust marker for neuronal activity, using qPCR 
or in situ hybridisation assays in PTZ-treated larvae (Baraban et al., 2005; Baxendale 
et al., 2012). Establishing Del2 and Ins4 lines expressing a genetically encoded 
calcium indicator marker such as GFP-Calmodulin fusion protein (GCaMP) will 
enable the spatiotemporal visualisation of neuronal activity in vivo within the larval 
CNS. A new  GCaMP variant known as NBT:GCaMP3 has recently been developed 
that allows the in vivo visualisation of neural activity in the CNS of larval stages up to 
the age of 21 dpf (Bergmann et al., 2018). Electrophysiological analysis can also be 
performed on both transgenic mutant and wild-type PTZ-treated larvae to obtain a 
quantitative neural activity measurement in vivo. If my initial observation of 
susceptibility of the mutant larvae to PTZ-induced seizure is confirmed using any of 
the approaches described above, the eef1a2 mutant lines will serve as an invaluable 
tool to be used to elucidate the mechanisms of epilepsy and an in vivo platform for 
high-throughput screens for better and safer AEDs for these patients.   
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6.3 Conclusion           
With this work, I have provided an up to date expression profile of the eEF1A genes 
in the zebrafish as well generated two mutant lines for eef1a2. The findings reported 
in this thesis provides groundwork information that can be used in the laboratory to 
further assess the fitness of the zebrafish model for our research. This is particularly 
useful as the success of translating research benefits to the patients depends largely on 





















Appendix figure 1: geNorm analysis for selecting reference genes for qPCR 
experiments. geNorm M graph generated by qbase+ software indicating the average 
expression stability value (M) of the reference genes tested. The stability of the genes 
are ranked with the least stable gene starting from the left and ending with the most 
stable gene on the right. ATPsynth, NADH and 16S are the three most stable genes and 























Appendix figure 2: Analysis of eef1a2 transcripts in Ins4 and confirmation of the 
possibility of Del2 and Ins4 mutations leading to nonsense-mediated decay. A. 
Reduced eef1a2 transcript was noted in F2 Ins4 homozygous (3 months) brain and 
muscle tissues. B. The three different primer sets; eef1a2P, 3’eef1a2 and eef1a2S that 
were used in the molecular characterisation of  Del2 and Ins4 mutant lines did not 
show any significant reduction in eef1a2 mRNA expression when tested with brain 
cDNA from adult fish with a homozygous 12 bps deletion. This is an in-frame mutation 
and theoretically should not cause a truncated protein to be translated. Since the result 
is in agreement, it suggests that the observed decrease in eef1a2 transcript levels in the 
Del2 and Ins4 are likely due to NMD which leads to the increased degradation of the 
mutant mRNA. cDNA samples from age-matched wild-type fish were used as 
controls. eef1a2 mRNA expression was normalised to three reference genes: 
ATPsynth, NADH and 16S. Results are presented as means + S.E.M.; n=3 in each 






Appendix figure 3: Preliminary histological examination of the brain from one 
homozygous Ins4 fish (5 months old) and age-matched wild-type zebrafish. A. 
Representative image from the medulla oblongata showing lower neuronal density in 
Ins4 B. Representative image from the cerebellum with sparsely arranged Purkinje 
cells (indicated with red arrow) noted in Ins4 fish. However, follow-up investigation 
using more number of fish and the Del2 line was carried out and did not support 
preliminary findings, suggesting these were likely artefacts possible from the 
preparation of the sections. Longitudinal sectioning (3µm-thick) and H&E staining 
were carried out by the staffs at Easter Bush Veterinary Centre (EBVC). Histological 
observation and images were provided by Dr. Jorge del Pozo. CCe- Corpus cerebelli. 







Appendix figure 4: Time evolution of a representative larva showing a pattern of 
activity consistent with stage III seizure behaviour. Black arrow shows the larva 
treated with 2.5mM PTZ which was followed in the 96-well plate. Larva remained 
stationary at 13mins 17secs and then loses posture and fell on its side at 13mins 20secs 










Appendix Table 1: Positions with amino acid variation and the respective 
residues in the four zebrafish eEF1A isoforms. 
Position eEF1A1L1 eEF1A1A eEF1A1B eEF1A2 
6 Threonine (T) Leucine (L) Leucine (L) Isoleucine (I) 
76 Alanine (A) Serine (S) Serine (S) Serine (S) 
83 Serine (S) Serine (S) Serine (S) Threonine (T) 
87 Valine (V) Valine (V) Valine (V) Isoleucine (I) 
118 Glycine (G) Alanine (A) Alanine (A) Alanine (A) 
141 Phenylalanine (F) Tyrosine (Y) Tyrosine (Y) Tyrosine (Y) 
151 Glycine (G) Glycine (G) Glycine (G) Alanine (A) 
161 Proline (P) Serine (S) Asparagine (N) Serine (S) 
164 Glutamine (Q) Glutamine (Q) Glutamine (Q) Glutamic acid 
(E) 
165 Alanine (A) Lysine (K) Lysine (K) Lysine (K) 
167 Phenylalanine (F) Tyrosine (Y) Tyrosine (Y) Tyrosine (Y) 
168 Glutamic acid (E) Glutamic acid (E) Glutamic acid (E) Aspartic acid 
(D) 
171 Threonine (T) Valine (V) Valine (V) Valine (V) 
176 Alanine (A) Threonine (T) Threonine (T) Alanine (A) 
184 Asparagine (N) Asparagine (N) Asparagine (N) Serine (S) 
186 Alanine (A) Aspartic acid (D) Aspartic acid (D) Alanine (A) 
187 Serine (S) Threonine (T) Threonine (T) Serine (S) 
189 Alanine (A) Alanine (A) Alanine (A) Proline (P) 
197 Histidine (H) Asparagine (N) Asparagine (N) Histidine (H) 
204 Alanine (A) Alanine (A) Alanine (A) Proline (P) 
206 Serine (S) Proline (P) Proline (P) Serine (S) 
209 Glycine (G) Serine (S) Threonine (T) Proline (P) 
216 Isoleucine (I) Isoleucine (I) Isoleucine (I) Leucine (L) 
217 Glutamic acid (E) Threonine (T) Threonine (T) Aspartic acid 
(D) 




221 Glycine (G) Glycine (G) Glycine (G) Histidine (H) 
222 Asparagine (N) Asparagine (N) Serine (S) Histidine (H) 
223 Alanine (A) Alanine (A) Serine (S) Alanine (A) 
224 Serine (S) Alanine (A) Serine (S) Glycine (G) 
226 Threonine (T) Threonine (T) Threonine (T) Valine (V) 
230 Aspartic acid (D) Glutamic acid (E) Glutamic acid (E) Glutamic acid 
(E) 
234 Alanine (A) Alanine (A) Alanine (A) Threonine (T) 
236 Leucine (L) Glutamine (Q) Glutamine (Q) Methionine (M) 
239 Serine (S) Threonine (T) Threonine (T) Threonine (T) 
271 Valine (V) Leucine (L) Isoleucine (I) Valine (V) 
273 Lysine (K) Lysine (K) Lysine (K) Arginine (R) 
275 Glycine (G) Glycine (G) Glycine (G) Serine (S) 
276 Methionine (M) Methionine (M) Leucine (L) Methionine (M) 
283 Alanine (A) Valine (V) Valine (V) Valine (V) 
285 Valine (V) Valine (V) Valine (V) Isoleucine (I) 
298 Serine (S) Alanine (A) Alanine (A) Serine (S) 
300 Threonine (T) Serine (S) Serine (S) Serine (S) 
303 Threonine (T) Leucine (L) Leucine (L) Leucine (L) 
326 Alanine (A) Alanine (A) Alanine (A) Cysteine (C) 
331 Asparagine (N) Asparagine (N) Asparagine (N) Serine (S) 
335 Methionine (M) Glutamine (Q) Glutamine (Q) Glutamine (Q) 
338 Alanine (A) Alanine (A) Alanine (A) Serine (S) 
339 Asparagine (N) Asparagine (N) Serine (S) Glycine (G) 
341 Asparagine (N) Threonine (T) Threonine (T) Threonine (T) 
355 Glutamine (Q) Alanine (A) Alanine (A) Serine (S) 
358 Alanine (A) Alanine (A) Alanine (A) Serine (S) 
361 Leucine (L) Leucine (L) Leucine (L) Isoleucine (I) 
393 Alanine (A) Serine (S) Serine (S) Serine (S) 




405 Valine (V) Isoleucine (I) Isoleucine (I) Isoleucine (I) 
417 Threonine (T) Glutamic acid (E) Glutamic acid (E) Glutamine (Q) 
440 Serine (S) Glycine (G) Glycine (G) Asparagine (N) 
445 Isoleucine (I) Threonine (T) Threonine (T) Isoleucine (I) 
446 Glycine (G) Alanine (A) Serine (S) Glycine (G) 
447 Glycine (G) Threonine (T) Threonine (T) Glycine (G) 
448 Alanine (A) Serine (S) Serine (S) Serine (S) 
450 Lysine (K) Lysine (K) Lysine (K) Arginine (R) 
459 Alanine (A) Glutamine (Q) Glutamine (Q) Glutamine (Q) 
461 Threonine (T) Alanine (A) Asparagine (N) Serine (S) 
462 Lysine (K) Lysine (K) Lysine (K) Serine (S) 




















Appendix Table 2: Slope, intercept and correlation coefficient (R2) output from 
SDS software to estimate efficiency of primers used for qPCR analyses. 
Primer Slope Y-Intercept Correl. Coeff. (R2 
eef1a1l1 -3.296 11.766 0.997 
eef1a1a -3.223 19.571 0.997 
eef1a1b -3.283 20.197 0.996 
eef1a2P -3.294 21.767 0.994 
eef1a2S -3.495 20.357 0.981 
3’ eef1a2 -3.208 22.445 0.992 
ATPsynth -3.237 14.832 0.999 
NADH -3.227 16.500 0.996 
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